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ABSTRACT 
 
The reaction of specially prepared salicylaldehyde benzyl ethers with the activated 
alkenes, methyl acrylate or acrylonitrile, in the presence of the catalyst, DABCO, has 
afforded Baylis-Hillman products, which have been subjected to conjugate addition 
with either piperidine or benzylamine. Hydrogenolysis of these conjugate addition 
products in the presence of a palladium-on-carbon catalyst has been shown to afford 
the corresponding 3-substituted coumarins, while treatment of O-benzylated Baylis-
Hillman adducts with HCl or HI afforded the corresponding 3-(halomethyl)coumarins 
directly, in up to 94%. The 3-(halomethyl)coumarins have also been obtained in 
excellent yields (up to 98%) and even more conveniently, by treating the unprotected 
Baylis-Hillman products with HCl in a mixture of AcOH and Ac2O, obtained from  
tert-butyl acrylate and various salicylaldehydes. The generality of an established  
route to the synthesis of coumarins via an intramolecular Baylis-Hillman reaction, 
involving the use of salicylaldehyde acrylate esters in the presence of DABCO, has 
also been demonstrated. 
 
Reactions between the 3-(halomethyl)coumarins and various nitrogen and carbon 
nucleophiles have been shown to proceed with a high degree of regioselectivity at the 
exocyclic allylic centre to afford 3-substituted coumarin products. The electron-
impact mass spectra of selected coumarin derivatives have been investigated using 
high-resolution and B/E linked scan data. Fragmentation pathways have been 
proposed and fragmentation modes associated with different coumarin-containing 
analogues have been compared. 
 
A series of coumarin-containing analogues of ritonavir (a clinically useful HIV-1 
protease inhibitor) have been prepared and characterized. The synthetic approach has 
involved the coupling of coumarin derivatives with a hydroxyethylene dipeptide 
isostere to afford ritonavir analogues containing coumarin termini. An interactive 
docking procedure has been used to explore the docking of ritonavir and a coumarin-
containing analogue into the enzyme active site.  
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1. INTRODUCTION 
 
1.1 Distribution, structure and nomenclature of coumarins 
                                                                                                   
Coumarin and many of its derivatives occur naturally. The parent heterocycle, 
coumarin (Figure 1) was first isolated in 1920 by Vogel1 from the fruit of Dipteryx 
odorata Wild. The common name, coumarin, comes from another plant Coumarouna 
odorate, in which it is found; the systematic name is 2H-1-benzopyran-2-one. 2, 3. 
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3
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                        Figure 1. Structure of coumarin and atom numbering  
 
Many compounds, which contain the coumarin moiety, exhibit useful and diverse 
biological activity and, in recent years, there has been a growing interest in their 
synthesis.4 Some of these coumarin derivatives have been found to be useful in 
photochemotherapy, antitumor and anti-HIV therapy,5,6 and as CNS-stimulants,7 
antibacterials,8, 9 anticoagulants10, 11 and dyes.12 
 
Coumarins are widely distributed throughout the plant kingdom, with the vast 
majority carrying an oxygen substituent at the C-7 position. 7-Hydroxycoumarin 
(umbelliferone) is often regarded as the parent (in a structural and biogenetic sense) of 
a large number of structurally more complex coumarins.2 Coumarins occur as 
secondary metabolites in the seeds, roots and leaves of many plant species; their 
function is far from clear, although suggestions include plant growth regulators, 
fungistats, bacteriostats and , even, waste products.13 
 
Synthetic coumarins are widely used as aroma chemicals because of their odour 
strength, tenacity, stability to alkali and relatively cheap price; applications include 
use as a sweetener and fixative (in perfume); fragrance enhancers (for natural 
essential oils); blenders (in soaps and detergents); aroma enhancers (in tobacco); and 
for imparting pleasant odours to industrial products.3 
 1 
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1.2.    Naturally occurring coumarins 
 
Most reviews classify coumarins according to whether particular compounds are 
simple coumarins or derivatives of linear or angular furanocoumarins or 
pyranocoumarins. Murray et al.2  used a biogenetically related approach based upon 
the number of nuclear oxygen atoms in classifying coumarin-containing compounds – 
an approach which will be used in this survey of naturally occurring coumarins. 
Unfortunately, many natural coumarins have been assigned botanically derived 
names, with many ending with the suffixes, “–ol” or “–one”. 
 
1.2.1.    7-Oxygenated coumarins 
 
Two new coumarins have been isolated from the root of Peucedanum ostruthium(L) 
Koch, which has been used since ancient times in folk medicine against various 
diseases. One of these coumarins is the 7-hydroxycoumarin 2; this type of prenylated 
coumarin, containing a free carboxyl group, has only been found in one other species, 
viz., Evodia vitiflora.14   
 
                                            OOH O
HOOC
 
                                   6-(3-carboxybut-2-enyl)-7-hydroxycoumarin    2 
 
The isolation of five coumarins from the root and bark of Pleiospermium alatum, a 
medicinal plant growing in Sri Lanka and India was reported by Bandara et al.15 
These coumarins are all 7-oxygenated systems and exemplify simple coumarins (3) as 
well as linear (4) and angular pyranocoumarin (5) types. Seselin 5 displays significant 
antifungal activity against Cladosporium cladosporioides.15 Numerous 7-alkoxy-
coumarins (e.g. compounds 6a-d) have been isolated from various plants, including:- 
Pamburus missionis,16 Clausena anisata,17 Murraya exotica,18 Pteryxia terebinthina 
(Hook),19 Aster praealtus,20 Coleonema album,21 Musineon divaricatum,22  
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Micomelum minutum,23a, b and Boronia algida.24  
                                                               
O OOH OO O
OO O
Umbelliferone 3 Xanthyletin 4 Seselin 5  
 
O OR1O
5
6
7
6a-d  
                
 
 
                                 R 
 
   Ref. 
    6a  CH2CH2CH=C(CH3)CH2(C5H5O2)   17 
    6b  CH2CH=C(CH3)CH2CH(OH)CH=C(CH3)2   17 
    6c  CH2CH2CH(CH3)C(=CH2)CH2CH2CH(OH)C(OH)(CH3)2   20 
    6d  CH2CH2CH=C(CH3)2   21 
 
 
 
1.2.2.    Dioxygenated coumarins 
 
Common di-oxygenation patterns include the 5,7-; 6,7-; and 7,8-arrangements.  
 
1.2.2.1.   6,7-Dioxygenated coumarins 
 
Ayapin (6,7-methylenedioxycoumarin) 7 and scopoletin (6-methoxy-7-hydroxy- 
coumarin) 8 are simple 6,7-dioxygenated coumarin derivatives; they have been 
described as phytolexins and are known to have inhibitory activity against 
microorganisms. Cabello-Hurtado et al.25 undertook a study of the role and 
biosynthesis of the coumarins in Helianthus spp., and were able to demonstrate the 
presence of scopoletin 8 and ayapin 7 in Helianthus tuberosus, their differential 
accumulation in response to treatment with chemical elicitors like CuCl2 or sucrose.  
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O OOH
MeO
O OO
O
Ayapin 7 Scopoletin 8  
                                                                                                                                          
Highest and earliest accumulation of both coumarins was measured after copper 
treatment. These results contradict the previous data obtained by Tai and Robeson,26a,b 
which suggested that in Helianthus tuberosus, scopoletin 8 is not the precursor of 
ayapin 7 and that both compounds are synthesised by the tuber of Helianthus 
tuberosus after wounding or treatment with a chemical elicitor.  
 
Examples of other types of 6,7-dioxygenated coumarins include compounds 9a-e, 
obtained from the aerial parts of plant species such as:- Pterocaulon 
virgatunm,27Angelica dahurica,28 Diosma acmaeophylla,29 Ruta angustifolia,30 
Ticorea longiflora,31 Chorilaena quercifolia32 and Pterocaulon polystachium.33 
 
               
O O O OO
R1
R2
R3
9a-d 9e
(CH3)2C=CHCH2CH2O
HO(CH3)2C    
  
      
        R1 
 
                   R2 
 
                 R3 
    9a    OCH3  OCH2CHOHC(CH3)=CH2       H 
    9b    OH  OCH3       H 
    9c    OCH3  OCH3       H 
    9d    OCH3  OCH3       CH2CH2CH=C(CH3)2
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1.2.2.2   5,7-Dioxygenated coumarins                     
 
Huang et al. 34 reported the isolation of 5,7-dioxygenated coumarins which include: - 
nordentatin 10, shown to be a strong antibacterial compound; two new pyrano-
coumarins, claucavatin-A 11 and claucavatin-B (as well as carbazole alkaloids) from 
the root bark of Clausena excavata used as a folk medicine in the treatment of snake 
bite and as a detoxification agent.  
 
OO O
OH
OO O
OHO
Nordentatin 10 Claucavatin-A 11  
                                     
Other 5,7-dioxygenated coumarins, such as compounds 12a-d have been found in the 
aerial parts of various plants species, including Eriostemon myoporoides,35 Seseli 
sibiricum,36 Murraya paniculate,37a,b Eriostemon brucei and E.brucei subspecies 
cinereus38 and Dorstenia brasiliensis.39 
 
O O
R1
R2
R3
12a-d          
                                                                                                   
 
     
 
                  R1 
 
    R2 
 
    R3 
   12a CH2C(CH3)2COOH OCH3   OCH3 
   12b CH2C(CH3)2COOCH3 OCH3   OCH3 
   12c (CH2)2CH=C(CH3)(CH2)2CH=C(CH3)2 OH   OH 
   12d H OCH2CH=C(CH3)2   OH 
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1.2.2.3   7,8-Dioxygenated coumarins  
 
Ceska et al.40a reported the isolation of furocoumarins in low yields from the 
cultivated species, Daucus carota, using a combination of ultrasensitive bioassay and 
HPLC techniques. One of these furocoumarins was the 7,8-dioxygenated derivative, 
8-methoxypsoralen 13. Furocoumarins have been shown to be potent 
photosensitizers,40b and to exhibit photomutagenic and photocytotoxic properties. As 
part of the ongoing phytochemical and chemotaxonomic study of members of the 
Cusparieae, Muller et al.41 isolated from the genus, Metrodorea nigra, a number of 
known coumarins, including compound 14. 
 
O OO
OMe OH
O
O OO
8-methoxypsoralen 13 Isogospherol 14
 
Other 7,8-dioxygenated coumarins, such as compounds 15a-c, have been found in the 
aerial parts of various plants species, viz., Zanthoxylum schinifolium,42a,b     
Boenninghausenia albiflora43 and Metodorea flavida.44  
 
                                                      
O OR1
R2
15a-c                                                                               
 
     
 
                               R1  
 
           R2 
   15a OCH2CH=C(CH3)(CH2)2CH(OH)C(CH3)=CH2          OCH3 
   15b OCH2CH=C(CH3)CH2CH=CHC(CH3)2OH          OCH3 
   15c OCH2CH=C(CH3)(CH2)2CH=C(CH3)2          OCH3 
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1.2.3.     Trioxygenated coumarins 
 
Coumarins in this group are classified into three basic categories, viz., 6,7,8-; 5,7,8-; 
and 5,6,7-trioxygenated coumarins.  
 
1.2.3.1.   6,7,8-Trioxygenated coumarins  
 
Del Castillo et al. 30 isolated from the aerial parts of Ruta angustifolia, a new natural 
coumarin, augustifolin, two other coumarins, scoparone and 6,7,8-trimethoxy-
coumarin 16 and the alkaloid, graveolin. Previous studies on Pelargonium reniforme 
Curt revealed the presence of various coumarins and tannins. Pelargonium species,45 
indigenous to certain areas of Southern Africa, are used as an antidiarrhoic and a 
general remedy for the treatment of colds and infection of the lungs in folk medicine, 
and have been shown to  contain a number of highly oxygenated coumarins, including 
compounds 17a-f. Other plant species containing 6,7,8-trioxygenated coumarins 
include:- Imaptiens balsamine root cultures,46 Agathosma pubarula,47 and Metrodorea  
flavida.44 
 
O O
OMe
MeO
MeO
O O
6,7,8-trimethoxycoumarin 16
R1
R2
R3
17a-f  
                                                                                                                                                                        
 
             
 
     R1 
 
      R2 
 
    R3 
    17a     OH      OH    OCH3 
    17b     OH      OH    OH 
    17c     OCH3      OH    OCH3 
    17d     OCH3      OCH2CH=C(CH3)2    OH 
    17e     OCH3      OH    OH 
    17f     OCH3      OCH2CH=C(CH3)2    OCH3 
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1.2.3.2.   5,6,7 Trioxygenated coumarins 
 
Tian-Shung Wu37 obtained from the leaves of Murraya paniculata var. omphalocarpa,  
ten coumarins of which two, murrayanone 18 and murraculatin, were new, the former 
being a 5,6,7-trioxygenated coumarin. Compounds 19a-e are examples of some 
naturally occurring 5,6,7-trioxygenated coumarins, which have been isolated from the 
following plant species (each of which has been shown to contain biologically active 
principles):- Drummondita hassellii and D. calida,48 Pelargonium siddoides,45 Simsia 
cronquistii,49 Pterocaulon balansea and P. lanatum,50 and Pterocaulon polystachium. 
33              
 
OO
O
OMe
MeO
MeO
Murrayanone 18
O O
R1
R2
R3
19a-e          
                                                                                                                                                                        
 
 
 
     R1 
 
   R2 
 
   R3 
     19a     OCH3   OCH3   OH 
     19b     OCH3   OCH3   OCOCH3 
     19c     OCH3   OCH3   OCH3 
     19d     OCH3   OCH2CH=C(CH3)2   OCH2CH=C(CH3)2 
     19e     OCH3   OH   OCH2CH=C(CH3)2 
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1.2.3.3   5,7,8-Trioxygenated coumarins 
 
The structural elucidation and antimicrobial activities of certain 5,7,8-trioxygenated 
coumarins obtained from the dried root of the medicinal plant, Angelica dehurica 
(Umbelliferae), have been reported.28 Nielsen and Lemmich51 have tentatively 
assigned the stereochemistry of  byakangelicine  and byakangelis on the basis of 
optical rotation data; these compounds are among the major constituents of 
Umbelliferum.  
 
The genus Phebalium Vent occurs throughout Australia, including Tasmania, and in 
the northern island of New Zealand. It is divided into four sections, Phebalium (ca 20 
taxa), Eriostemoides (three taxa), Gonioclados (two taxa) and Leionema (ca 20 taxa). 
Phytochemical studies carried out on the aerial parts of 15 taxa (14                              
species and two subspecies) of Phebalium (Rutaceae)  resulted in the isolation of no 
less than 34 coumarins of which twenty-eight were new to the genus and seven 
appeared to be novel natural products. The distribution of these coumarins has been 
reviewed and their chemotaxonomy discussed.52 
 
Compounds 20a-f are examples of the 5,7,8-trioxygenated coumarins isolated from 
Ruta graveolens,53 Phebalium (Rutaceae)52 and Pterocaulon vigatum .L.50 
                                                      
                                                    
OO O
R1
R2
20a-f  
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    R1 
 
   R2 
   20a    OCH2CH(OH)C(CH3)2OH   OCH2CH(OH)C(CH3)2OH 
   20b    OCH3   OCH2CH=C(CH3)2 
   20c    OCH3   OCH2CH(OH)C(CH3)2OH 
   20d    OCH3   OCH3 
   20e    OH   OCH3 
   20f    OCH3   OCH2CHOC(CH3)2 
 
 
 
1.2.4.    Tetraoxygenated coumarins 
 
Coumarins in this class are oxygenated at positions 5,6,7 and 8, but are not as 
common as those in the other classes. Examples of this type of coumarin are the 6,8-
dihydroxy-5,7-dimethoxycoumarin 21a and the 5,6,7,8-tetramethoxycoumarin 21b 
isolated from Pelargonium sidoides by Kolodziej and co-worker in their search for 
biologically active compounds in this species.45 
  
      
O O
OMe
MeO
R1
R2
21a: R1 = R2= OH
21b: R1= R2=  OCH3
 
                                                                               
1.2.5.   3-Substituted coumarins 
 
Most coumarins in this category are furanocoumarins, a great number of which have 
been isolated from plant species, such as Ruta graveolens, Ruta pinnata, Helietta 
longifoliata and Ruta chalepensis L. Joshi and Gawad reported the occurrence of a 
number of coumarins in the root of Clausena indica Oliv, including chalepensin 22a 
and chalepin 22b.54    
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                              OO OR
22a: R = H
22b: R = C(CH3)2OH
 
                                             
Tillequin et al.17 have reported the isolation, structural elucidation and biogenesis of 
some 21 coumarins from the leaves, stem-bark and roots of the plant, Clausena 
anisata, growing in Ngaoundere and Oku in the Cameroon. Two of the compounds 
isolated were the 3-substituted coumarins 23 and 24. 3-substituted coumarins have 
also been isolated from Amyis simplicifolia Karst,55 Ruta graveolens,53 
Boenninghausenia albifola,56 Chloroxylon swietenia DC,57 Clausena excavata34 and 
Amyris balsamifera.58  
 
OO
OH
OH
O OH
O O
CHO
MeO
23 24  
 
1.2.6.   4-Substituted coumarins 
 
Good examples of this type of coumarin are the Mammea coumarins, which have 
been isolated from Mammea americana, M. africana, Mesua ferrea and M. thwaitesii. 
Important members of the group are the 4-(1-acetoxypropyl) coumarins 25a-e all of 
which exhibit insecticidal properties. Another group of coumarins belonging to this 
class are the seshadrins isolated from Dalbergia volubilis and 3’,5-dihydroxy-4’,7-
dimethoxy-4-phenylcoumarin isolated from Exostema caribaeum.59 The synthesis of 
these compounds has been investigated by Bose and Banerji in continuation of their 
work on 4-phenylcoumarins.60 4-Substituted coumarins have also been isolated from 
Mammea longifolia,61 Mesua racemose,62 Kielmeyera reticulata63 and phyllum 
teysmannii.64       
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O O
AcO
OH
O
OH
R1
R2
            R1                         R2
    a      H                          CH2CH2CH3
    b      H                          CH(CH3)CH2CH3
    c      H                          CH2CH2CH2CH3
    d      H                          CH(CH3)2
    e      CH2CH=C(CH3)2   CH(CH3)CH2CH325a-e  
 
 
       
1.3.    Biologically active coumarins 
 
The coumarins have been the subject of extensive studies because of their interesting 
biological activities and have, in fact, been used as therapeutic agents for the 
treatment of various diseases. Coumarins show quite diverse biological activities, 
including anticoagulant, antiallergic, vascodilatory, anthelmintic, diuretic, insecticidal 
and antibiotic properties.1,8 
 
1.3.1.    Anticoagulant compounds 
 
The anticoagulant properties of dicoumarol 26a, [3,3-methylene-bis(4-hydroxy 
coumarin)], isolated from spoiled sweet clover hay, were discovered in 1941.1 This 
discovery led to the synthesis of a series of coumarin derivatives (e.g 26b,c) with 
anticoagulant properties.1 Dicoumarol 26a, which can be readily synthesized by 
condensing 4-hydroxycoumarin with formaldehyde,65a has been identified as the cause 
of sweet clover disease in cattle.65b This compound has also been used in medicine to 
reduce blood-clotting in patients suffering from cardiovascular disease.65b  
 
                                           
O O
OH
OO
OH
R
26a-c  
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             R 
 
                 
      26a              H           Dicoumarol 
      26b             CH3           Pentrombon 
      26c             COOEt           Tromexan 
                                                                                                                                                                         
The anticoagulant properties of such 4-hydroxycoumarins are due to their ability to 
inhibit the synthesis of the coagulant factor, vitamin K1, in the liver. The process of  
clotting involves polymerisation and cross linking of a soluble serum protein, 
prothrombin, into a hard insoluble polypeptide known as fibrin.66 Warfarin, 4-(4-
hydroxycoumarin-3-yl)-4-phenylbutan-2-one, is perhaps the best known anticoa-
gulant. It is widely used as a rodenticide, and for the treatment of various 
thromboembolic diseases.67-68   
 
Coumarin glycosides show significant potential as oral antithrombotic agents. For 
example, iliparcil 27a, a xyloside has been reported to exhibit interesting 
antithrombotic activity, limited, however by its ready hydrolysis in vivo. In order to 
increase the bioavailability of iliparcil, the enantiomeric analogues, (+)-27b and (-)- 
27c, were prepared, the laevorotatory enantiomer being found to be the more active as 
an oral antithrombotic agent in rats.69 
 
O OOz
OH
OH
OH
O OOOH
OH OH
27a (Z = S)
27b (Z = CH2) (-)-27c(+)-  
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1.3.2.   Antibiotic and antibacterial coumarins 
 
Novobiocin 28, chlorobiocin 29 and related synthetic analogues, are coumarin 
derivatives which possess both antibiotic and broad-spectrum, Gram-positive 
antibacterial properties. Musicki et al.70-73 studied the structure-activity relationships 
of a series of coumarin bases as DNA gyrase inhibitors. The results of their work led 
to stereoselective synthesis of 5-monoalkyl- and 5,5-dialkyl-substituted noviose 
derivatives from L-arabinose, and the development of two series of DNA gyrase 
inhibitors, in which the coumarin moiety is replaced by  isothiochroman-2,2-dioxide 
and 1,2-benzooxathiin-2,2-dioxide moieties.  
 
O
OH
O
N
H
O
OH
O
R
O
O OH
MeO
R1 novobiocin   28 (R = CH3; R1 = H2NCO)
chlorobiocin 29 (R = Cl   ; R1 = C6H9N)  
 
Novobiocin and chlorobiocin are naturally occurring antibacterials, which have been 
isolated from certain Streptomyces species.74 However, their toxicity and poor 
pharmacokinetic properties have prevented their use as antibiotics. Chatreaux et al.74 
prepared analogues of the antibiotic novobiocin, containing highly functionalised 
coumarin structures and exhibiting improved pharmacological and pharmacokinetic 
properties. 
 
The coumarin-based antibiotics possess a 3-amino-4-hydroxycoumarin moiety and a 
substituted deoxysugar (noviose), which constitute a common core essential for 
biological activity. Kinetic and structural studies have shown that the coumarin-based 
antibiotics are competitive inhibitors of ATP binding to the gyrase B subunit, while 
labelling studies have established that the substituted coumarin moiety is 
biosynthesised from L-tyrosine and the deoxysugar from D-glucose.75                                                        
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1.3.3.   Biologically active fluorescent and photostable coumarins                                                           
 
3-Substituted 7-hydroxycoumarins have been shown to act as photostable laser dyes 
that emit in the blue-green region of the visible spectrum. The emission range 
increases when the 3-substituent is a heterocyclic moiety,76 and Abdallah et al.77  have 
reported the synthesis 15 new 3-substituted 7-hydroxycoumarins [e.g. compounds 
32(X = S, NH, O)] designed to extend the tunability range and maximise output. This 
work was based on the assumption that the introduction of biologically active 
heterocycles at position-3  could lead to physiologically active fluorescent compounds 
of biological interest.78-79  
 
OHOH
CHO
N
X CH2CN
X
N
OOH O
+
X = S, NH, O
30 31
32  
                                                                                                                                     
The fluorescence properties of coumarin derivatives depend on their substituents, 
which influence the degree of intramolecular charge transfer from 6- and /or 7- 
electron-donating substituents to the electron-accepting coumarin ring. 7-Hydroxy- 
coumarin, for example, is strongly fluorescent and finds use in several 
applications.80,82 Yamana et al. 83 have reported  the introduction of a 2’-coumarin-
labelled nucleoside as a fluorescence energy transfer (FRET) donor in DNA duplexes  
to facilitate the analysis of  DNA structures in solution. Coumarins are also widely 
used as flash-pumpable laser dyes or for photographic purposes because their triplet 
excited state is achieved in high yield. Beley et al.12 combined tridentate ligands, such  
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as 2,2’,6’,2’’-terpyridines or cyclometallating analogues, such as 6-phenyl-2,2’-
bipyridine, with 2,4-diarylchromeno[3,4-c]pyridin-5-ones to obtain new fused-ring 
ligands with enhanced spectral absorption.  
                                                                                                                                               
A new method for the synthesis of furocoumarin via base-catalysed ring cleavage and 
subsequent furan ring closure of 6(8)-(1,2,3-thiadiazol-4-yl)-7-hydroxycoumarin has 
been used to obtained the angelicin and psoralen derivatives 33a-c and 34a-b, 
respectively. Furocoumarin itself has a wide range of applications, such as reaction 
with DNA following excitation with long wavelength UV light, in the treatment of 
skin diseases and in molecular biology as a reagent for the investigation of nucleic 
acid structure and function.84   
 
OO
RS
O
O ORS
33a-c 34a-b  
 
 
 
 
           R 
      a           methyl 
      b           n-hexadecyl 
      c           p-fluorobenzyl 
 
The  7-aminocoumarins comprise an important class of laser dyes, their dipole 
moment in the excited state (e.g 36) is greater than in the ground state (e.g 35) and,  
consequently, they exhibit larger Stokes shifts.67 
 
O ONH2 O OH2N
+ -
35 36  
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1.3.4.    Potential antipsychotic compounds 
 
In an effort to gather further data about the structural factors which determine 
serotonergic and dopaminergic affinity and selectivity, Fall et al.85-86  investigated 
how the substitution-pattern affects the pharmacological profile of 
arylpiperazinecoumarin derivatives which have high affinity for dopamine and 
serotonin. A series of compounds containing a bulky lipophilic group, such as 
cyclohexyl, at position 4 (e.g. compound 37) were prepared. Dopamine (DA) and 
serotonin (5-HT) receptors are implicated in various psychiatric and neurological 
disorders, and research has shown that the N-arylpiperidine fragment is important for 
CNS-activity, especially dopaminergic and serotonergic activity. 
                                                                                                                                                                    
O OO
NNCH3O
 
                                           Arylpiperazinopropyloxycoumarin  37 
 
A series of potential antipsychotic compounds containing a furocoumarin moiety 
linked to various arylpiperazine or piperidine groups have been synthesised, and many 
of them have been shown to exhibit high affinity for the dopamine–D1 and D2, α1-
adrenergic and serotonin 5-HT2 receptors in vitro. Many of the compounds also show 
antipsychotic activity in mice and in rats.87         
 
1.3.5.   Anti-HIV compounds 
 
The human immunodeficiency virus type 1 (HIV-1) belongs to a subfamily of 
retroviruses, Lenti virinae, and is the etiologic agent of the acquired 
immunodeficiency syndrome (AIDS). Among the HIV-enzymes, three have been 
targetted for therapeutic development, viz., reverse transcriptase, protease and 
integrase. HIV-1 is a retrovirus and contains 3 genes, known as the gag, pol and env  
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genes. The integration of HIV-DNA into the genomic DNA of the host cell is carried 
out by the integrases, while the protease acts like a “pair of  molecular scissors” 
cleaving the viral gag-pol precursor proteins. Four HIV-1 protease inhibitors have 
been approved for the treatment of AIDS; these are saquinavir, ritonavir, indinavir  
and nelfinavir.88-90 
 
Takeuchi  et al.91 reported the synthesis of 42 khellactone derivatives by introducing 
additional substituents at positions 3, 4, 5, and 6 of the coumarin nucleus. Their 
investigation was prompted by the isolation of the suksdorfin 38 from Lomatium 
uksdorfii. 3’,4’-Di-O-(-)-camphanoyl-(+)-cis-khellactone (DCK) 39, one of the 
khellactones synthesised, is a potent inhibitor of HIV-1 replication- even more potent 
than AZT. The results indicated that an R-configuration and di-O-(-)-camphanoyl 
substitution at each of the 3’- and 4’-positions are very important for anti-HIV 
activity. Results obtained when this drug was used in combination with other anti-
HIV compounds suggest that its mode of action does not involve inhibition of the 
HIV reverse transcriptase (RT), making it possible to use it in combination with RT 
inhibitors. 
 
O OO
O
O
O O
O
O
O OO
O
O
O
O O
O
OO O
OH
O
O
38 39 40  
 
In an attempt to discover more potent and selective anti-HIV compounds, Kuo-Hsiung 
Lee et al.92 investigated the synthesis and anti-HIV activity of dihydroseselins (e.g.                              
compound 40)  as analogues of DCK 39. In their review of reverse                              
transcriptase inhibitors of natural origin, Konig et al.93  have shown that HIV-1-RT  
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inhibitors have been isolated from many different structural classes, viz., coumarins,94 
flavonoids, tannins, alkaloids, lignans, terpenes, naphtho- and anthraquinones and 
polysaccharides. 
 
Coumarins isolated from Calophyllum genus (Guttiferae) with either an alkyl or a 
phenyl group at the 4-position of the coumarin nucleus possess anti-HIV-1 activity, 
and structural modifications indicated that the stereochemistry of the 2,3-dimethyl-4-
chromanol ring present in such molecules plays an important role in such activity.95  
Calanolides-A 41 and -B 42 are among a series of coumarins recently isolated from 
species of Calophyllum; both compounds strongly inhibited the in vitro replication 
and cytopathicity of HIV-1.96, 97  
                      
OO
O
OH
O OO
O
O
OH
41 42  
                                                
Fuller et al.97 undertook both chemical and biological studies of the latex exuded from 
trees of the genus Calophyllum in an effort to identify an adequate and sustainable 
natural source of calanolide-A, an anti-HIV drug. In their finding, calanolide-A not 
presence in latex, instead a related coumarin, costatolide 43, was abundant in latex of 
Calophyllum teymannii var.inophylloide and is currently being evaluated as a possible 
alternative to calanolide-A for drug development. Cardellina et al.98 reported methods 
for the chiral resolution of  (+)-calanolide-A 41 and (-)-calanolide-A 44 from 
synthetic (±)-calanolide-A, and (+)-calanolide-B 42 and (-)-calanolide-B (43, 
costatolide) from a racemic mixture isolated from Calophyllum lanigerium.  
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OO
O
O
OH
OO
O
O
OH
43 44  
 
Recent reports have shown that the presence of multiple aromatic rings contributes to 
good inhibitory potency  for HIV-1 integrase inhibitors.99a Burke and co-workers,99b 
in an effort to develop new inhibitors, carried out studies on certain coumarin-based                              
analogues using the coumarin derivative 45 as a model. The high HIV-1 integrase 
inhibitory potency of these compounds was attributed to the presence of several 
planes of symmetry which allow multiple orientations. The results show that affinity 
is affected by the position of the central phenylene linker and the points of attachment 
of the coumarin units. 
 
O O
OH
OO
OH
O
OH
OO
OH
O
45  
 
Talele and Kulkarni 100 have reported the design and synthesis of a novel series of 
nonpeptidic HIV-1 protease inhibitors that interact with the  S1, S1′ and S2 binding 
sites of HIV-1 protease; they have also reported X-ray crystal structures of peptide  
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and nonpeptide-derived inhibitors and developed an interactive docking procedure. 
The results obtained from the interactive docking suggest that 4-hydroxycoumarin-3-
yl phenyl ketones 46a-e and their analogues 47a-b should be effective HIV-1 protease 
inhibitors.  
 
O
OH
O
O
R
O
OH
O
R1
46a-e 47a-b
1
 
    
 
 Compound 
 
      R1 
    46a      styryl 
    46b      4-methoxystyryl 
    46c      4-fluorostyryl 
    46d      4-chlorostyryl 
    46e      4-hydroxy-3-methoxystyryl 
    47a      3-(α-ethylbenzyl)- 
    47b      3-phenoxypropyl 
 
Attention has been given to low molecular weight, non-peptidic compounds, in which 
the benzene ring of the coumarin moiety is replaced by conformationally flexible 
cycloalkyl rings of various sizes.101 The resulting products 48 exhibited an increase in 
enzyme binding affinity, with the cycloalkyl ring folding into the S1 pocket of the 
protease. Crystal structures of the cylcoalkyl derivatives have shown that the 
cyclooctyl ring is better able to fill the S1 region than the cycloheptyl ring.101 
                                        
O O
OH O
O O
OH
O
(CH2)n
O
49 5048 (n = 1,2.3,4, and 6)                              
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Thaisrivongs et al. 102, 103 have reported the screening of 5000 dissimilar compounds 
from the Upjohn collection for HIV-1 protease inhibitory activity. The 4-
hydroxycoumarin 49 (warfarin) was identified as a weak inhibitor (IC50 ≈30µM); 
recently, 4-hydroxybenzopyran-2-ones (warfarin and derivatives) and 4-hydroxy- 
pyran-2-one have been reported as competitive inhibitors of HIV protease.102 Based 
on these findings, compounds with similar structures were screened from the Upjohn 
collection and  phenprocoumon 50 was found to have significant inhibitory (Ki =1 
µM) and antiviral activity (ED50= 100-300µM). Both warfarin and phenoprocoumon 
exhibit high bioavailabilty and low clearance in humans and, therefore, are promising 
lead structures for the discovery of new orally bioavailable, non-peptidic HIV 
protease inhibitors. 
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1.4.   Methods of coumarin synthesis  
 
Many synthetic routes to the couumarins have been developed. These include use of 
the Pechmann, Claisen, Perkin, Knoevenagel, Reformatsky and Wittig reactions, to 
mention but a few. 
 
 
1.4.1   Knoevenagel condensation  
  
The Knoevenagel reaction involves the condensation of benzaldehydes with activated 
methylene compounds in the presence of an amine, and is used to overcome the 
inherent difficulties associated with the synthesis of coumarins via the Perkin 
reaction. In order to obtain coumarin rather than the usual cinnamic acid, a 2-hydroxy 
substitutent must be present in the aromatic aldehyde and the conditions for the  
Knoevenagel reaction are less severe than those required for the Perkin reaction. 
Various coumarins have been prepared via Knoevenagel condensation of 
salicylaldehyde with activated methylene compounds as illustrated in Scheme 1.67 
                 
OH
CHO
CH2
X
Y O O
X
+
51 52 53
amine
 
                                                 X =  CO2H, CO2Et, CONH2, CN 
                                                 Y =  CO2H, CO2Et, CN 
 
Scheme 1            
 
Two different mechanisms have been proposed for the above Knoevenagel 
reaction.104 In the first (Scheme 2), formation of an imine or iminium salt 54 with the 
amine (e.g piperidine) is followed by reaction with the enolate of the active methylene 
compound, elimination of the amine and intramolecular ring closure to give the 
coumarin 55. The second proposal involves attack by the carbanion,                              
produced by deprotonation of the active methylene compound by the amine, on the  
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carbonyl group to give the intermediate 56. Proton transfer, ring-closure via acyl 
substitution and dehydration then gives the coumarin 55. 
 
-CH(CO2Et)2
O O
CO2Et
OH
CHO
N
+
OH
Piperidine
-Piperidine
51 54 55  
 
Scheme 2 
 
  
-CH(CO2Et)2
O O
CO2Et
OH
CHO
O
OH
CO2Et
CO2Et
51 56 55
Piperidine
 
 
Scheme 3 
                      
Bogdal.13 has shown that, under microwave irradiation, the Knoevenagel 
condensation can be successfully applied to the synthesis of a number of coumarins 
with yields up of 94%. This reaction involves the condensation of salicylaldehydes 57 
with carboxylic esters in the presence of piperidine under solvent-free conditions 
(Scheme 4).   
 
O O
R
R
R
R
R OH
CHO R
CO2Et
+ Piperidine
2
1
3
1
2
3
57 58 59  
               R1 = H, Et2N               R3 = CO2Et, COMe, CN, p-C6H4NO2 
               R2 = H, OMe 
 
Scheme 4 
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A procedure for preparing coumarin-3-carboxylic acids in up to 80% yield by reacting 
malononitrile with an aldehyde or ketone in the presence of piperidine, has been 
reported.105 An attempt to extend this methodology to the synthesis of 4-phenyl 
derivatives by reacting 2,4-dihydroxybenzophenone with malononitrile, diethyl 
malonate or malonic acid in the presence of piperidine resulted in the formation of the 
decarboxylated analogue.105 
 
1.4.2.   Wittig  reaction 
 
Mali and Yadav106,107 developed a preparation of coumarins via Wittig olefination-
cyclisation of 3-(2-hydroxyaryl)propenoic esters (Scheme 5). Cyclization under 
olefination conditions depends on formation of the Z-alkene intermediate 62, and 
concomitant formation of the E-alkenes is often a problem. This difficulty may be 
addressed by heating the reaction mixture, or by photochemical isomerization, but 
these methods suffer from variable yields, inconvenient work-up, or both.108 In an 
attempt to solve these problems, McNab and co-workers108,109 showed that the 
cyclization takes places in consistently high yield when the isolated 3-(2-
hydroxyaryl)propenoic esters 62 are subjected to flash vacuum pyrolysis (FVP). 
While the E-configuration of the double bond precludes cyclization, the barrier to 
isomerization is overcome by the high-temperature. 
 
OH
R CHO
R
CO2R
OH
R
R
CO2R
O
R
O
R
+ Ph3P
3
2
1 3
2
1
23
60 61 62
63  
          
   R1 = CH3, CH2CH3         R2 =  H, CH3          R3 =  H, Cl, NO2                                  
 
Scheme 5                                                                                                                                                      
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The synthesis of coumarins by condensing o-hydroxybenzaldehydes or o-
hydroxyacetophenones 64 with the stable phosphorane, (ethoxycarbonylmethylene)- 
triphenylphosphorane has also been reported (Scheme 6).106,67,110 Uriarte et al.85 have 
also made use of the Wittig reaction in the synthesis of potential antipsychotic 
compounds containing the coumarin moiety by subjecting keto diphenols  to a Wittig 
reaction with (ethoxycarbonylmethylene)triphenylphosphorane to give the expected 7-
ethoxycoumarin in rather poor yield (24%) and 7-hydroxycoumarin in 70% yield.  
 
OH
COR
R
CO2Et
OH O O
R
Ph3P=CHCO2Et
64 65 66
R = Me, H
 
Scheme 6 
                                                             
A new and efficient route  to the synthesis of 4-carboxymethylcoumarins 69 (Scheme 
7), based on an aromatic electrophilic substitution reaction between the conjugate 
base of a substituted phenol and the betaine formed by the addition of 
triphenylphospine to dimethyl acetylenedicarboxylate (DMAD) has also been 
reported.111 This method complements older established methods and offers 
significant advantages for the synthesis of coumarins having acid-sensitive functional 
groups.  
 
O
R
MeO2C CO2Me
Ph3P
O O
CO2Me
R
+
40-83%
67 68 69
CH2Cl2
R = CH3, t-Bu, OCH3, COCH3, NO2
+
 
 
Scheme 7 
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Highly functionalised heterocycles are key components of many natural and synthetic 
compounds of pharmaceutical or agrochemical relevance. Loffler et al.112 reported a 
one-pot synthesis of coumarins based on the reaction of salicylic esters with a cumu-
lated phosphorus ylide. This reaction is considered to take place via an addition /Witt- 
ig olefination / Claisen rearrangement sequence, and the cascade can be controlled by 
varying the temperature. 
  
1.4.3.   Perkin reaction   
 
Perkin, in the mid-nineteenth century discovered the transformation now known as the 
Perkin reaction,113 a reaction which involves heating an O-hydroxybenzaldehyde with 
acetic anhydride in the presence of sodium acetate at a high temperature (ca. 200oC) 
to afford a trans-cinnamic acid. Optimum yields of coumarins are obtained when a 
1:2 molar ratio of  aldehyde to anhydride is used. Isomerization of the trans-cinnamic 
acid by irradiation or treatment with iodine followed by cyclization affords the 
coumarin 71 (Scheme 8).114 The disadvantage of this approach is the generally poor 
yield of the coumarin obtained, due to the production of tarry materials under the 
severe reaction conditions of the Perkin synthesis. However, the obvious advantages 
is that the formation of isomeric chromones is not possible, as is the case with the 
Pechmann reaction.67 
 
OHOH
CHOMeO
O OOH
MeO
i. NaOAc, Ac2O
ii. H3O+
70 71  
 
Scheme 8 
 
Coumarin is also formed in the reaction of acetic anhydride and salicylaldehyde in the 
presence of trimethylamine as the base catalyst (Scheme 9).115 
                                                                                
 
 
                                                                  
 27 
 
 
 
Introduction              
 
       
OH
CHO
(Me.CO)2O
Et3N
OH
O
OCOMe
+
O O
51 72 73  
              
Scheme 9                     
 
1.4.4.   Pechmann reaction  
 
The Pechmann reaction is a widely used method for preparing coumarins in good 
yield, it involves reacting a phenol with a β-oxo ester in the presence of a catalyst. 
The Pechmann reaction has been carried out using both homogeneous acid catalysts 
[such as sulphuric,116a,b hydrochloric, phosphoric and trifluoroacetic acids,117 and with 
Lewis acids, such as zinc chloride,118 iron (III) chloride, tin(IV) chloride, titanium 
chloride and aluminium chloride119a] and heterogeneous catalysts [such as cation-
exchange resins, Nafion-H, zeolite-HBEA and other solid acids].119b Recently, 
microwave irradiation has also been applied to accelerate this reaction.119c 
 
Zhan-Hui Zhang et al.120 reported the synthesis of coumarins via the Pechmann 
reaction catalysed by montmorilonite K-10 or KSF in yields of up to 96% (Scheme 
10). This procedure is environmentally friendly and inexpensive compared to previous 
methods. They reported that K-10 worked better than KSF in terms of reaction time 
and yield, and that the use of montmorilonite clays as heterogeneous catalysts is a 
viable alternative. Furthermore, this method has the advantages of easy separation of 
the product, minimal environmental effect and recyclability of the catalyst. 
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OH
R +
O
CO2Et
K-10 or KSF,
toluene,  reflux
0-96%
O O
Me
R
74 75 76  
                       
Scheme 10 
 
The use of the cation exchange resins, Zeokarb 225 and Amberlite IR.120, as  
condensing agents in the synthesis of hydroxycoumarins has also been reported.121a 
The main advantages of cation exchange resins are that they simplify the isolation of 
the  product and tend to be relatively inexpensive. In order to obtain a maximum yield 
of the coumarin, between 20 and 40% of the resin by weight of the total reactants is 
used. The reaction is considered to involve the following steps:- (i) addition across the 
double bond of the enolic form of the β-keto ester; (ii) ring closure; and (iii) 
dehydration (Scheme 11).121b 
 
           
OHOH
CH3
OC2H5
O
O
OH OH
O
OC2H5
CH3 OH
O O
CH3 OH2
OH
-C2H5OH
O OOH
CH3
-H2O
+
77 75 78
7980
+
+
     
      
Scheme 11 
             
Bekkum et al.122 have reported the synthesis of 7-hydroxycoumarin in ca 81% yield 
using a solid-acid catalysed reaction of phenols with carboxylic acids (or their esters).  
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Thus, equimolar amounts of resorcinol and acrylic acid, in the presence of zeolite H-
beta [Si/Al =14] or Amberlyst-15, undergo esterification followed by ring closure 
(Scheme 12) to give both 7-hydroxy-3,4-dihydrocoumarin 83 (66%) and 3,4,6,7-
tetrahydrobenzo[1,2-b:5,4-b′]dipyran-2,8-dione 84. Another approach involves the 
reaction of resorcinol and propynoic acid in the presence of zeolite H-beta catalyst, at  
high temperature (150oC) (Scheme 13). In a third approach, ethyl acetoacetate was 
reacted with resorcinol (Scheme 14) (Pechmann reaction) to afford 7-hydroxy-4-
methylcoumarin 80. 
 
 
+
OHOH CO2H O OOH O OOH
Catalyst
OO OO
77 81 82 83
84
                                                                                                        
Scheme 12 
 
 
OHOH
+
O OOH
77 85 86
CO2H
 
                  
Scheme 13 
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OHOH
+
O
CO2Et O O
Me
OH
77 75 80  
 
Scheme 14 
 
Kad et al.123 have reported the use of a microwave–assisted Pechmann reaction in the 
rapid and simple preparation of substituted coumarins, in yields of 72-82%, from 
substituted phenols and methyl acetoacetate in the presence of H2SO4 (Scheme 15). 
Comparison of their results with those obtained by classical methods at room 
temperature show a significient reduction in the reaction time for the microwave-
assisted reaction, from several hours to a few minutes. 
  
             
+
O O
OMe H2SO4
MW, 2-10min
200W
87 88 89
OH
CH3
O O
CH3
CH3
  
                                                      
Scheme 15 
 
1.4.5.   Michael Reaction 
 
The simplest synthetic approach to 4-arylchroman-2-ones (useful precursors for 4-
arylcoumarins) might be expected to involve the condensation of phenols with 
cinnamic acids (or alkyl cinnamates) in strongly acidic media, but this method 
afforded complex mixtures of reaction products.124 Speranza et al.,125 however, have 
reported a novel, mild procedure for the synthesis of 4-arylchroman-2-ones (and 1-
arylbenzo[f]chroman-3-ones) via a Michael-type reaction of dihydric or trihydric 
phenols with p-substituted N-cinnamoylazoles in the presence of DBU (Scheme 16). 
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It was assumed that the mechanism of the reaction involves esterification followed by 
conjugate addition. 
 
+
OHOH
OH
X
COY
+
O O
OH
OH
X
-HY
O O
OH
OH
X
90 91 92 93
Y = NN
N
N
N
,
X = OCH3, CH3, H, F, Cl, Br, NO2
 
                                                        
Scheme 16 
 
Chroman-2-ones have been obtained in moderate to good yields by heating methyl 
(E)-cinnamates and phenols or naphthols in o-xylene under reflux in the absence of 
added catalyst.125 Reaction conditions, such as temperature, solvent and substrate 
concentration proved to be critical in this synthesis which, depending on the 
substituents (R1 and R2), could afford isomeric products (Scheme 17; Table 1). The 
reaction was assumed to involve initial transesterification, followed by protonation of 
the ester function and intramolecular conjugate addition.125 
 
OH
R
R
X
O OMe
OR
R
O
X
+ o-xylene, 142oC, N2
OR
R
O
X
+
1
1
1
2
2
2
94 95 96 97  
Scheme 17  
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Table 1. Selected data for the condensation of phenols with methyl cinnamates.125 
 
 Product 
 
     R1 
 
   R2 
 
    X 
 
 Reaction time
 
   Yield a/ %  
 96a       OH    H     OH          11hrs     52 
 96b     OH    H     OCH3          10hrs     55 
 96c     OH    H     NMe2          5hrs     60 
 96d (97d)b     OH    Me     NMe2          7hrs     75 (2.5:1)c 
 96e     OH    OH     OH          2hrs     90 
 96f     OH    OH     OCH3          3hrs     61 
 96g     OH    OH     NMe2          1hr     70 
 96h (97d)b     OH    OMe     OH          13hrs     76 (2:1)d 
 
a Isolated yield of pure product. b separation of the two isomers was performed by repeated flash      
chromatography. c Yield refers to the isomeric mixture. Regioisomer ratio (96d and 97d) determined by 
1H NMR analysis. d Unresolved mixture of the two isomers (96h and 97h). 
 
 
1.4.6.   Claisen rearrangement  
 
Drewes et al.126 reported the synthesis of 4-methyl-3-methylene-3,4-dihydrocoumarin 
100 via the intramolecular Claisen-rearrangement of the aryl ether 99 in the presence 
of trifluoroacetic acid (Scheme 18). Such compounds had been synthesised previously 
by other routes, but Drewes’ method is more efficient, because the precursor alkyl 3-
acetoxy-2-methylene butanoate is readily prepared via acetylation of a Baylis-Hillman 
product and cyclization may be effected in the presence of trifluoroacetic acid to 
afford the coumarin 100 in 86% yield in a one-pot procedure. 
 
PhOH/NaH
O
CO2R
OAc
CO2R
O O
CF3CO2H / 32oC
[ 3.3]
98 99 100
R = alkyl
                                                                                   
Scheme 18 
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Previously, a similar approach to 3-methylenecoumarin was reported, which involves 
Lewis-acid catalysed Claisen rearrangement of an α-aryloxymethylacrylate ester 101 
(Scheme 19).127 A small amount of a dimer is also produced, which is assumed to 
form via an ene reaction of the highly reactive methylenecoumarin 102. 
                       
Me
O
CO2Me
AlCl3
CH2Cl2 O O
Me
101 102  
 
Scheme 19 
                                                                           
In an attempt to overcome the deficiencies and difficulties encountered with the 
Pechmann synthesis of coumarin derivatives Rapoport et al.116a developed a new 
application of the Claisen rearrangement using allyl or propargyl aryl ethers in which 
the allylic or propargylic α-carbon is oxygenated. This method has been applied in 
cases where formation of the coumarin could not be achieved using the Pechmann 
reaction. The approach is based on the rearrangement of the α-oxygenated allyl aryl 
ether 103 (Scheme 20). The intermediate alkoxychroman 105 is then oxidized to the 
corresponding coumarin.  
 
    
103 104 105
106
O ORR OH ORR O ORR
O OR
R = alkyl
 
         
Scheme 20 
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1.4.7.   Palladium-catalyzed addition 
 
Trost and Toste, 128 in attempting to synthesize aflatoxin via a coumarin intermediate,  
explored a new reaction involving the use of a palladium(0) complex as catalyst 
system. This system is reported to effect:- cycloisomerization of enynes; reductive 
cyclization of enynes and diynes; and semi-hydrogenation of alkynes. Following the 
approach outlined in Scheme 21, they were able to synthesis, in yields of up to 88%, 
various coumarins which had proved inaccessible using methods like the Pechmann 
reaction. The mechanism for this reaction is considered to involve Pd(0) rather than 
Pd(+2). In formic acid palladium(II) acetate is reduced to Pd(0) which then catalyses 
the reaction. Although cis-addition initially affords the (E)-cinnamic ester 109, the 
known ease of E-Z isomerization accounts for the isolation of coumarins rather than 
the (E)-cinnamates. 
 
OR OH
OR
CO2CH2CH3
+
OR
OR
OH
O
OEt
 O O
OR
OR
i
107 108 109 110
R = CH3, H  
 
Scheme 21       Reagents: i) HCOOH, 30% Pd(OAc)2, 50% NaOAc at 50oC 
                                                                                 
Mitra et al. 129 exploited the Heck reaction to synthesize 3-substituted coumarins. 
They reported the palladium-catalysed insertion of 3-bromocoumarin 111 into a 
number of alkenes and alkynes to form the 3-substituted coumarins 112a,b in yields                             
ranging from 48% to 91%. 
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O O
R
O O
Br
111 112a-b
RH
 
                                                                 R 
                                                     a       -C(CH3) =CHCO2Me 
                                                     b       -CH=CH(CH3)2OH 
                                                                                                                                                                         
Scheme 22     Reagents  and conditions:  Palladium(ll) acetate, tri-O-tolyphosphine,  
             Triethylamine, 120oC, 10h. 
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1.5. Previous work in the group and aims of the present investigation 
 
The Baylis-Hillman reaction has attracted the attention of organic chemists in recent 
years as it provides useful multifunctional molecules, which have been successfully 
employed as precursors in various synthetic processes. The application of this reaction 
in the synthesis of substituted indolizines via 1,4-diazabicyclo[2.2.2]octane 
(DABCO)-catalysed coupling of pyridine-2-carboxaldehydes and activated alkenes 
has been demonstrated by researchers in our group (Scheme 23).130   
 
N CHO
DABCO N
OR
O
OMe
..+
CO2Me heat N OR
O
OMe
H
H
+
..-
N
CO2Me
H
H
+
CO2Me
N -H 
+O -RO:
 -
113 114 115; R = H
116; R = Ac
117; R = H
118; R = Ac
119120  
                  
Scheme 23 
    
Initial attempts to extend this methodology to the synthesis of the chromenes 121 
Scheme 24) from salicylaldehyde precursors afforded an insoluble coumarin 
derivative 122 in low yield.131 Subsequent studies aimed at optimising reaction 
conditions afforded the coumarin 122 in 50% yield, although, in general, chromene 
derivatives proved to be the most common products.132a Variation of the reaction                                  
conditions has permitted the chemoselective synthesis of chromenes132b and, in the 
present study, particular attention has been given to the preparation and reactions of 
the coumarin analogues 
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Scheme 24 
                
The Baylis–Hillman approach has also been applied to the synthesis of quinoline 
derivatives 124-128 from o-nitrobenzaldehydes under mild conditions (Scheme 25)133 
and thiochromenes from 2,2-dithiodibenzaldehyde.134 
 
In a continuation of these investigations, the present study focused on the following 
objectives.  
 
i) The use of salicylaldehyde derivatives in developing a chemoselective 
Baylis-Hillman approach to coumarin derivatives.    
ii) An investigation of the reaction of the coumarin products with various 
nucleophiles. 
iii) A study of the electron-impact (EI) mass fragmentation patterns exhibited 
by selected coumarin derivatives. 
iv) The synthesis of coumarin-containing analogues of the HIV-1 protease 
inhibitor, ritonavir.    
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Scheme 25    Reagents and conditions: i)  H2, Pd-C, EtOH; ii) TsOH, toluene, reflux. 
                                            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.  DISCUSSION 
 
 
The discussion will focus mainly on the application of the Baylis-Hillman reaction in 
the synthesis of coumarin derivatives (Section 2.1). Attention will also be given to: - 
the regioselectivity of nucleophilic attack on various coumarin substrates (Section 
2.2), the electron-impact (EI) mass fragmentation of coumarin derivatives (Section 
2.3) and, finally, the synthesis of potential HIV-1 protease inhibitors containing 
coumarin moieties (Section 2.4). 
 
 
2.1. APPLICATION OF THE BAYLIS-HILLMAN REACTION IN THE 
SYNTHESIS OF COUMARIN DERIVATIVES 
  
2.1.1.   The Baylis-Hillman reaction  
 
The reaction involving a tertiary amine catalyst, such as 1,4-diazabicyclo[2.2.2]- 
octane (DABCO), an activated alkene and an aldehyde is widely referred to as the 
Baylis-Hillman or Morita-Baylis-Hillman reaction (Scheme 26). This important 
carbon-carbon bond-forming reaction, which typically affords multifunctional 
hydroxyalkyl derivatives 129,135 serves as a key step in the synthesis of several 
biologically active compounds.135-142 
 
                        
R H
O
+
R
tertiary amine R
OH
R
1 
1 
 
                                                                                                 129 
                                                   R1 = COMe, CN, 
                                                           CO2Et, etc. 
 
Scheme 26 
 
The reaction is considered to involve initial activation of the acrylate system via 
conjugate addition of the catalyst to afford the zwitterionic enolate 130 (Scheme 27).  
Formation of the second zwitterion 131, via nucleophilic attack of the enolate 130 on 
the aldehyde is considered to be the rate determining step of the reaction.143-144
Internal proton transfer may then afford a resonance-stabilized intermediate 132, 
which can undergo E1cB elimination of the catalyst leading to the Baylis-Hillman 
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Scheme 27 
 
product 129. 145  Another possibility involves base-induced anti-E2 elimination of the 
catalyst and the Hα-proton, followed by protonation. An indication that both 
elimination pathways may operate is supported by a study of the solvent and pressure 
dependence of the reaction of benzaldehyde with crotononitrile.146   
 
The Baylis-Hillman reaction, however, is not without drawbacks; prominent among 
these is the slow rate of the reaction.147-148 Aggarwal et al.149 reported the use of 1,8-
diazabicyclo[5.4.0]undecene-7 (DBU) as a superior catalyst to accelerate Baylis-                              
Hillman reactions. Other methods that have been reported to accelerate the Baylis-
Hillman reaction include the following:- α-naphthyl acrylate as a Michael acceptor,150 
use of a Lewis acid as a co-catalyst,151 mild co-operative catalysts152 and indium-
mediated allylation153 to mention but a few. Morita et al.,154 in reports which pre-date 
Baylis and Hillman’s patent,155 described the use of tertiary phosphines as a catalysts, 
while Kataoka et al.156 recently reported the first “Chalcogeno-Baylis-Hillman” 
reaction in which the group 16 elements, sulfur and selenium, are used as catalysts in 
the presence of Lewis acids. Guigen Li et al.157 have reported the use of TiCl4 in 
Baylis-Hillman and Aldol reactions in the absence of a direct Lewis base.       
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In a previous investigation by Robinson,158 the DABCO-catalysed Baylis-Hillman 
reaction between salicylaldehydes and methyl acrylate was observed to afford 
complex mixtures of chromene and coumarin derivatives (Scheme 28). It was 
assumed that the Baylis-Hillman product 133 is, in fact, formed but immediately 
undergoes cyclization via either conjugate addition (pathway Ι) to produce the 
chroman derivative 134, or nucleophilic acyl substitution (pathway II) to afford the 
coumarin derivative 135. Both products, 134 and 135, then appear to undergo further 
reactions to give complex mixtures. 
 
O
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OH
OOH
OH O
OMe
R
R R
O
O
OMe
R
O O
CO2Me
R
OH
CHO O
OMe
Pathway I Pathway II 
..
I II
   134 133
121
   136
   135
+
DABCO
 
 
Scheme 28 
 
The use of O-acetylated and O-silylated salicylaldehydes was expected to inhibit 
cyclization and permit isolation of the Baylis-Hillman products.158 However, the 
protecting groups chosen were not sufficiently stable. Drewes et al.159 reported that  
 
OCH2Ph
CHO
+
O
OMe DABCO
HNMe2
OH O
OCH2Ph
OMe
NMe2 O O
NMe2H2
Pd/C
137 116 138 139
                                                                                                                          
Scheme 29 
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salicylaldehyde benzyl ether 138 could be converted to the novel coumarin derivative 
139 in an overall yield of 86% (Scheme 29). This was achieved by reacting the benzyl 
ether 137 with methyl acrylate 116 in the presence of DABCO, followed by 
conjugation addition of dimethylamine, debenzylation and spontaneous cyclisation.  
 
The obvious stability of the benzyl protecting group under these conditions prompted 
us to use this general approach to prepare the coumarin derivatives required in the 
present investigation (Scheme 30). As will be seen later, however, other amines would 
be substituted for dimethylamine. 
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Scheme 30 
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2.1.2 Preparation of salicylaldehyde benzyl ethers  
 
The value of the benzyl ether protecting group for alcohols has long been recognized, 
and this protecting group has been used in various reactions.160 A protecting group 
needs to be efficiently introduced and later removed under mild conditions. The 
protecting group should also be inert towards reagents used in all the intermediate 
steps. The benzyl ether group was chosen to protect salicylaldehydes owing to its ease 
of formation, inherent stability and the variety of available deprotection methods, viz., 
10% Pd/C in EtOH,161 NaI-BF3.Et2O,162 TMSI,163 SiCl4-NaI,164 AlCl3-PhNMe2 in 
CHCl3,165 Ti (0),166 to mention but a few.  
 
Initial attempts to benzylate salicylaldehyde (using:- benzyl chloride and K2CO3 in 
acetone; benzyl chloride and NaH in toluene; or benzyl chloride and sodium ethoxide 
in ethanol) afforded the 2-benzyloxybenzaldehyde 137a in a maximum yield of only 
(33%). 
 
                             
OH
R
R
CHO
OCH2Ph
R
R CHO
K2CO3,NaI,acetone
PhCH2Br
1
2 2
1
51a-f 137a-f                      
 
   
 
   R1 
 
   R2 
 
 Yield / % 
    137a    H    H     74 
    137b    H    OMe     80 
    137c    H    OEt     70 
    137d    Cl    H     68 
    137e    Br    H     73 
    137f    Br    Br     66 
         
Scheme 31 
                                                                      
An alternative approach using benzyl bromide, K2CO3 and NaI in acetone, as outlined 
by Black,167 was then adopted. The reaction is considered to involve a Finkelstein 
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reaction leading to the formation of sodium bromide and benzyl iodide, followed by 
an SN2 reaction to afford the desired benzyl ether. Using this approach, the required 
benzyl ethers 137a-f were prepared in up to 80% yield, as illustrated in Scheme 31.  
 
The benzyl ethers 137a-f, most of which are known, were fully characterized by 
elemental (high-resolution MS) and spectroscopic (IR and NMR) analysis. The 1H 
NMR spectrum of 2-benzyloxy-5-chlorobenzaldehyde 137d, a new compound, shows 
a two proton singlet at  δ5.18 ppm, corresponding to the benzylic protons, and a one 
proton singlet at δ10.47 ppm, corresponding to the aldehydic proton (Figure 1a). The 
13C NMR spectrum (Figure 1b) reveals the benzylic carbon signal at δ71.0 ppm and 
the aldehydic carbonyl carbon at δ188.3 ppm; the correlations between the 1H and 13C 
NMR spectra were confirmed using the HETCOR data. 
 
 
2.1.3.   Synthesis of Baylis-Hillman products 
 
Careful attention was initially given to optimising the conditions for the Baylis-
Hillman reaction of the salicylaldehyde benzyl ether 137a (Scheme 32). The relative 
concentrations of the reactants, the solvent system and the reaction time were 
examined as indicated in Table 2. After the reaction period indicated, the crude 
reaction mixture was analysed by 1H NMR spectroscopy.  
 
When the Baylis-Hillman reaction was carried out using a vigorously stirred mixture 
of CDCl3 and D2O as the solvent system, no trace of the Baylis-Hillman product 140a 
was observed after six weeks at room temperature (entries 3 and 4). The highest yield 
of the product 140a (95%) was obtained using 26.25 mmol of methyl acrylate to 2.63 
mmol of DABCO in 0.25ml CDCl3 (entry 7). The optimised conditions were then 
used for the reaction of the other benzylated salicylaldehydes 140b-f to afford the 
corresponding Baylis-Hillman products in isolated yields ranging from 66 to 84% 
(Table 3). 
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(a)              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
                                                       
 
 
 
 
 
 
 
 
 
 
 
Figure 1.     a) 400 MHz 1H NMR spectrum; and (b) 100 MHz  p.n.d  13C NMR  
                    spectrum of  2-benzyloxy-5-chlorobenzaldehyde 137d in CDCl3. 
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Scheme 32        
 
Table 2. Yield optimisation data for formation of the Baylis-Hillman product 140a  
 
 
  Entry 
  
Benzyl ether 
137a /mmol 
 
Methyl acrylate   
      /mmol 
 
   DABCO     
     / mmol 
    
    Solvent a 
     / ml             
 
 Time 
  
 
Yield b 
  / %      
      
     1 
       
      5.0 
      
         5.25             
    
          0.25 
          
    0.25 
     
6wks  
       
  22 
      
     2 
        
      5.0 
     
         5.25 
     
          1 
        
    0.25 
     
6wks 
 
  87 
      
     3 
        
      5.0 
      
         5.25 
     
          0.25 
    
    0.25 (0.25c) 
     
6wks 
 
  -- 
      
     4 
        
      5.0 
      
         7.88  
     
          0.2  
    
    1 (1c) 
     
6wks 
 
  -- 
      
     5 
       
      5.0 
      
        10.5 
     
          0.25 
    
    0.25 
     
6wks 
 
  21 
      
     6 
      
      5.0 
      
        10.5 
     
          2.63 
    
    0.25 
     
4wks 
 
  90 
     
     7 
      
      5.0 
      
        26.25 
     
          2.63 
    
    0.25 
     
3wks 
   
  95 
 
aVolume of CDCl3 used. b Yield determined from 1H NMR spectrum of the crude mixture.   
c Volume of D2O used together with CDCl3. 
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The products were readily identified by 1H and 13C NMR spectroscopy, and the 
corresponding spectra for methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2-methylene- 
propanoate 140a is illustrated in Figure 2. The vinylic protons resonate as singlets at 
δ5.68 and δ6.28 ppm, the 3-methine proton as a singlet at δ5.93 ppm, the hydroxyl 
proton as a broad singlet at δ3.37 ppm and the methoxy methyl protons as a singlet at 
δ3.71 ppm (Figure 2a). The 13C NMR spectrum (Figure 2b) reveals the vinylic 
methylene carbon signal at δ125.8 ppm, the HMQC (Figure 3) spectrum confirming 
attachment of the two methylene protons to the same carbon.  
 
Table 3.  Yields obtained for the Baylis-Hillman reactions of the benzyl ethers           
                137a-f methyl acrylate or acrylonitrile.a  
 
 
 
OH
OCH2Ph
R
R
R1
2
3
140a-f ; R3 = CO2Me
144a-e; R3 = CN
 
  
    
       R1  
 
 
     R2 
 
 
        R3 
 
 
Yield b/ % 
     140a        H      H   CO2Me        75 
     140b        H      OCH3   CO2Me        84 
     140c        H      OCH2CH3   CO2Me        80 
     140d        Cl      H   CO2Me        78 
     140e        Br      H   CO2Me        84 
     140f        Br      Br   CO2Me        66 
     144a        H      H   CN        55 
     144b        H      OCH3   CN        61 
     144c        H      OCH2CH3   CN        91c 
     144d        Cl      H   CN        55 
     144e        Br      H   CN        51 
 
a After a reaction time of 21 days. b Isolated yield. c After 7 days 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.     a) 400 MHz 1H NMR spectrum; and (b) 100 MHz p.n.d 13C NMR  
                    spectrum of methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2-methylene-        
                    propanoate 140a in CDCl3 
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Figure 3.    The HMQC spectrum of methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2- 
                   methylenepropanoate 140a in CDCl3 
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Application of the Baylis-Hillman methodology to the reaction of the salicylaldehyde 
benzyl ethers 137a-f with other α,β-unsaturated systems, viz, acrylonitrile and methyl 
vinyl ketone was also explored. The order of reactivity of α,β-unsaturated systems 
(XCH=CH2) has been shown to be: X = CHO > COMe > CN > CO2R > CONH2;168 
the presence of an electron-withdrawing group increases the electrophilicity of the 
alkene thus increasing the rate of formation of the enolate species 130 (Scheme 27). 
 
The use of alternative activated alkenes has been explored by various groups. Thus, 
Basavaiah et al.169 have reported the DABCO-catalysed synthesis of α-methylene-β-
hydroxyalkanones in up to 73% yield by reacting methyl vinyl ketone with selected 
aldehydes in THF for 15 days. Villieras et al.170 have reported the preparation of α-
methylene-β-hydroxynitriles in up to 59% yield by treating selected aldehydes with 
acrylonitrile in the presence of DABCO. Normant et al.171 have reported an extension 
of Baylis-Hillman methodology to include the use of vinyl sulfones as the activated 
alkenes; these reactions, however, were extremely slow, with reaction times extending 
to 11weeks. Perlmutter et al.172 have recently shown that DABCO-catalysed reactions 
of aldehyde with aryl acrylates proceeds at significantly greater rates than with alkyl 
acrylates.  
 
In the present study, treatment of the salicylaldehyde benzyl ether 137a with methyl 
vinyl ketone (MVK) failed to afford the Baylis-Hillman product after 21 days under 
the previously optimised reaction conditions. However, replacement of MVK by 
acrylonitrile afforded the Baylis-Hillman product 144a (Scheme 32) in 55% yield 
within 21 days (Table 3). The procedure was then extended to the preparation of the 
Baylis-Hillman products 144b-e, compound 144c being isolated in 91% yield after 
only 7 days. The acrylonitrile-derived products 144a-e are all new and were fully 
characterized. The 1H NMR spectrum of 3-(2-benzyloxyphenyl)-3-hydroxy-2-
methylenepropanenitrile 144a reveals the 2’-vinylic proton singlets at δ5.93 and 5.96 
ppm, the 3-methine proton singlet at δ5.54 ppm, and the hydroxyl proton singlet at 
δ3.08 ppm (Figure 4a). The 13C NMR spectrum (Figure 4b) confirms the presence of 
the expected fifteen signals, with the 2”-methylene carbon resonating at δ129.7 ppm 
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and the nitrile carbon at δ155.9ppm. These assignments are supported by the HMQC, 
DEPT and COSY NMR data.   
 
(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.     a) 400 MHz 1H NMR spectrum; and (b) 100 MHz  p.n.d 13C NMR  
                     spectrum of 3-(2-benzyloxyphenyl)-3-hydroxy-2-methylenepropane-  
                     nitrile 144a in CDCl3 . 
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2.1.4. Baylis-Hillman reactions between substituted salicylaldehydes and tert-   
            butyl acrylate 
 
In a cognate study directed towards the chemoselective synthesis of chromene 
derivatives, Nocanda134 had observed that the use of tert-butyl acrylate as the 
activated alkene in a DABCO-catalysed reaction with salicylaldehyde afforded tert-
butyl 3-hydroxy-3-(2-hydroxyphenyl)-2-methylenepropanoate 146a in 49% yield 
after 7days. The isolation of the Baylis-Hillman product in this case was attributed to 
the electron-releasing inductive effect and the steric bulk of the tert-butyl group which 
serves to inhibit intramolecular cyclization (via conjugate addition or acyl 
substitution) to either chromene or coumarin derivatives. In the present study, this 
approach was extended to a range of salicylaldehyde precursors 51a-c, e-f to obtain 
the tert-butyl esters 146a-c; e-f (Scheme 33; Table 4), the intention being to explore 
the possibility of intramolecular cyclization via acyl substitution to afford coumarin 
derivatives. 
 
    
OH
R
R CHO1
2
+ OC(CH3)3
O
 CHCl3, rt OH
R
R
OC(CH3)3
OOH
1
2
DABCO
51a-c, e-f 145 146a-c, e-f  
                                                             
                                                                    R1       R2 
                                                            a      H         H 
                                                            b      H         OMe 
                                                            c      H         OEt 
                                                            e      Br        H 
                                                            f      Br        Br 
 
Scheme 33 
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                Table 4.    Yields obtained for the reaction between salicyaldehydes 
                                  51a-c; e-f and tert-butyl acrylate, 145 after 7days 
 
                                                         R1              R2           Yield % 
                                      146a           H              H             40 
                                      146b           H              OMe       57  
                                      146c           H              OEt         58 
                                      146e           Br             H             66 
                                      146f            Br            Br            44 
                                                                                               
The Baylis-Hillman products 146a-c, e-f were fully characterized by both one- and 
two-dimensional NMR spectroscopy, and the 1H NMR spectrum of compound 146e 
(Figure 5a), which is typical of the series, reveals the two, characteristic vinylic 
proton signals at δ5.56 and 6.23 ppm, the 3-methine proton signal at δ5.63 ppm, the 
hydroxyl proton signal at δ4.26 ppm and the nine proton tert-butyl signal at δ1.51 
ppm. In the corresponding 13C NMR spectrum (Figure 5b), the tert-butyl methyl 
carbons resonate at δ28.0 ppm, the carbonyl carbon at δ166.7 ppm and the vinylic 
methylene carbon at δ127.2 ppm. The HMQC spectrum of compound 146e (Figure 6) 
confirms attachment of the two vinylic protons to the same carbon. 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.      a) 400 MHz 1H NMR spectrum; and (b) 100 MHz p.n.d 13C NMR  
                     spectrum of tert-butyl 3-(5-bromo-2-hydroxyphenyl)-3-hydroxy- 
                     2-methylenepropanonate  146e in CDCl3. 
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Figure 6.         The HMQC spectrum of tert-Butyl 3-(5-bromo-2-hydroxyphenyl)-3- 
                         hydroxy-2-methylenepropanonate 146e in CDCl3. 
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2.1.5.   Conjugate addition to protected Baylis-Hillman products 
  
The strategy (summarized in Scheme 30) to achieve the chemoselective synthesis of 
coumarin derivatives has involved :- i) the isolation of protected Baylis-Hillman 
products (discussed in the previous section); ii) conjugate addition to the α,β-
unsaturated system to prevent cyclization to chromene via intramolecular attack at the 
vinylic centre; and iii) deprotection of the phenolic hydroxyl group to ensure 
cyclization via nucleophilic acyl substitution to afford the coumarin derivatives 
(Scheme 30). Having isolated the protected Baylis-Hillman products 140a-f (and the 
non-protected tert-butyl esters 146a-c,e-f), the next challenge was to explore the 
conjugate addition step. 
 
Drewes et al.159 have reported the use of dimethylamine as a nucleophile (Scheme 
29), but we decided to explore conjugate addition using the less volatile nucleophiles, 
piperidine and benzylamine. It is known that both primary and secondary amines may 
attack α,β-unsaturated carbonyl compounds because the carbonyl group lowers the 
electron density at the beta-carbon of the double-bond, thereby permiting nucleophilic 
rather than electrophilic addition.173 Reaction of the benzylated Baylis-Hillman  
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148a-f (Nu = piperidino)        R1      R2
a      H        H
b      H        OMe
c      H        OEt
d      Cl       H
e      Br       H
f       Br      Br        
Scheme 35 
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Table 5.     Yields for conjugate addition of piperidine or benzylamine to the Baylis- 
                   Hillman products 140a-f 
 
O
Ph
OH
Nu
R
R
CO2Me1
2
148a-f (Nu = Piperidino)
147a-f (Nu = PhCH2NH)
 
 
    Compd. 
 
   R1 
 
    R2 
 
 Nucleophile 
 
Isolated Yield / % 
     147a    H     H  Benzylamine          62 
     147b    H     OCH3  Benzylamine          87 
     147c    H     OCH2CH3  Benzylamine          71 
     147d    Cl     H  Benzylamine          69 
     147e    Br     H  Benzylamine          63 
     147f    Br     Br  Benzylamine          71 
     148a    H     H  Piperidine          80 
     148b    H     OCH3  Piperidine          55 
     148c    H     OCH2CH3  Piperidine          58 
     148d    Cl     H  Piperidine          63 
     148e    Br     H  Piperidine          62 
     148f    Br     Br  Piperidine          65 
 
 
products 140a-f when  treated with piperidine or benzylamine as a nucleophile in THF 
at room temperature afforded the diastereomeric products 147a-f and 148a-f in yields 
ranging from 55 to 87% (Scheme 35; Table 5). The conjugate addition products 147a-
f and 148a-f were fully characterized by elemental (high-resolution MS) and 
spectroscopic (MS, IR and NMR) analysis. The 1H NMR spectrum of methyl 2-
(benzylaminomethyl)-3-(2-benzyloxylphenyl)-3-hydroxypropanoate 147a (Figure 7a) 
reveals a singlet at δ5.77 ppm corresponding to the 3-methine proton signal, and a 
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singlet at δ3.75 ppm corresponding to the methoxy protons signal. The pairs of 
benzylic protons resonate at δ5.13 and 3.67 ppm as a double  doublet. The Dept-135 
spectrum (Figure 7b) reveals the benzylic carbon signals at δ46.2 ppm and δ69.6 ppm. 
These assignments are confirmed by both HMQC (Figure 8) and COSY (Figure 9) 
NMR spectrum data. 
   
(a) 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.     a) 400 MHz 1H NMR spectrum; and (b) DEPT-135 spectrum of methyl  
                    2-(benzylaminomethyl)-3-(2-benzyloxylphenyl)-3-hydroxypropanoate  
                    147a in CDCl3.                                                          
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Figure 8.     HMQC spectrum of methyl 2-(benzylaminomethyl)-3-(2-benzyloxy-      
                    phenyl)-3-hydroxypropanoate 147a in CDCl3. 
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Figure 9.       COSY spectrum of methyl 2-(benzylaminomethyl)-3-(2-benzyloxy-     
                       phenyl)-3-hydroxypropanoate 147a in CDCl3. 
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2.1.6.   Synthesis of  3-substituted coumarin derivarives 
 
2.2.6.1. Reductive deprotection and cyclization of conjugate addition products. 
 
In the next phase of our approach to coumarin derivatives, we explored catalytic 
hydrogenation under mild conditions to effect cleavage of the O-benzyl protecting 
group; spontaneous cyclization via intramolecular transesterification was then 
expected to afford the required coumarins. It is known that hydrogenolysis of  
benzylic oxygen bonds occurs readily,174 and many catalysts have been used for this 
purpose. Palladium appears to be the preferred choice combining high hydrogenolysis 
activity with a low tendency to promote reduction of the aromatic ring.175 It was 
therefore decided to use a 10% palladium-on-carbon catalyst. Selected conjugate 
addition products (147a-d and 148a-d) were subjected to catalytic hydrogenoloysis in 
the presence of 10% palladium-on-carbon in ethanol at room temperature for 6 hours 
(Scheme 36). The benzylamino derivatives 147a-d afforded the expected 3-
substituted coumarins 149a-d. The piperidino derivatives 148a-d, however, in  
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Scheme 36 
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addition to the expected 3-substituted coumarins 150a-d, afforded the de-aminated 
products 151a-d. 
 
Table 6.     Yields for the catalytic hydrogenolysis of selected conjugate addition  
                    products (Scheme 36)                                                       
 
O O
Nu
R
R
O O
R
R1
2
1
2
 149a-d (Nu = PhCH2NH) 151a-d
 150a-d (Nu = piperidino)  
 
   Compound 
   
       R1 
 
   R2 
    
   Isolated Yield / % 
      149a        H    H            53 
      149b        H      OCH3            51 
      149c        H    OCH2CH3            66 
      149d        Cl    H            49 
      150a        H    H            51 
      150b        H    OCH3                45 
      150c        H    OCH2CH3            49 
      150d        Cl    H            61 
      151a        H    H            20 
      151b        H    OCH3                9.5 
      151c        H    OCH2CH3            14 
      151d        Cl    H            9 
  
 
It is known that benzylic-oxgyen bonds undergo hydrogenolysis more readily than 
benzylic-nitrogen bonds, thus accounting for the formation of the expected 3-
substituted coumarins 149a-d. In the formation of the piperidino analogues 150a-d, 
the O-benzyl protecting group was cleaved as expected, but the formation of the de-
aminated coumarin derivatives 151a-d was quite unexpected.  
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The 3-substituted coumarins 149a-d, 150a-d and 151a-d were fully characterized by 
elemental (high resolution MS) and spectroscopic (IR and NMR) analysis. The 1H 
NMR spectrum of 8-methoxy-3-(piperidinomethyl)coumarin 150b (Figure 10a) shows 
the piperidino proton signals at δ1.43, 1.65 and 2.24 ppm, and the methoxy proton 
singlet at δ3.93 ppm. The 1’-methylene  protons resonate at δ3.42 ppm as a  doublet 
(J =1.6 Hz) due to long-range allylic coupling with the vinylic 4-H nucleus which 
resonates at δ 7.77 ppm. This coupling relationship was confirmed by the COSY 
spectrum (Figure 11). The 13C NMR spectrum (Figure 10b) reveals the piperidino 
carbon signals  at δ 24.1, 26.0 ppm and 54.7 ppm, the 1’-methylene carbon signal at δ 
56.9 ppm and a signal at δ56.2 ppm corresponding to the methoxy carbon. These 
assignments are supported by the HMQC and DEPT data. The 1H NMR spectrum of 
8-methoxy-3-methylcoumarin 151b (Figure 12a) shows the methyl proton singlet 
resonating at δ 2.20 ppm, the methoxy proton singlet at δ 3.94 ppm and the vinylic 4-
H proton singlet at δ 7.48 ppm. The 13C NMR spectrum (Figure 12b) reveals the 1’-
methyl carbon signal  at δ 17.2 ppm and the methoxy carbon signal at δ 56.2 ppm 
These assignments are supported by the HMQC and DEPT data. 
 
Possible explanations for the formation of  compounds 151a-d are outlined for 
compound 151a in Scheme 37. In pathway I equilibration between the Baylis-Hillman 
product 140a and the conjugate addition product 148a could lead, during 
hydrogenolysis, to the formation of 4-hydroxy-3-methylenecoumarin 135 as a 
reaction intermediate. Further reduction and dehydration would then afford the de-
aminated coumarin 151a. The involvement of compound 135 was proposed by Bode 
et al.176 as an intermediate in the formation of the novel coumarin derivative 122 
(Scheme 24), while Robinson isolated compound 135 in 38% yield from the reaction 
of a disilylated Baylis-Hillman product.158 A second possibility (pathway II) involves 
initial catalytic hydrogenolysis of compound 148a followed by cyclization to the 
substituted coumarin 150a; elimination of piperidine in the presence of the palladium-
on-carbon catalyst then affords compound 151a.  
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.   a) 400 MHz 1H NMR spectrum; and (b) 100 MHz p.n.d 13C NMR  
                    spectrum of  8-methoxy-3-(piperidinomethyl)coumarin 150b in  
                    CDCl3. 
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Figure 11.       COSY spectrum of 8-methoxy-3-(piperidinomethyl)coumarin 150b  
                        in CDCl3. 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.   a) 400 MHz 1H NMR spectrum; and (b) 100 MHz p.n.d 13C NMR  
                    spectrum of  8-methoxy-3-methylcoumarin 151b in CDCl3 
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Scheme 37.     Possible routes to the de-aminated product 151a 
 
In order to explore the possible formation of the de-aminated products 151a-d via 
pathway I, debenzylation of the protected Baylis-Hillman product, methyl 3-(2-
benzyloxyphenyl)-3-hydroxy-2-methylenepropanoate 140a was investigated, using:- 
10% palladium-on-carbon in ethanol;177 a mixture of 10% palladium-on-carbon and 
1,4-cyclohexadiene in ethanol;178 and the combination of a hard acid and a soft 
nucleophile (Et2O-BF3 / EtSH) which has been used for the cleavage of the benzyl 
group.179 Application of these methods, however afforded the respective products 152, 
153 and 154 (Scheme 38) 
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Scheme 38.     Reagents: i) H2, 10% Pd-C, EtOH , 6h;  ii) 10% Pd-C, EtOH, 1,4- 
                        cyclohexadiene, 2h;  iii) EtSH, Et2O-BF3, 40min. 
 
The structures of these reduction products (152-154) were fully elucidated using both 
one- and two-dimensionial NMR spectroscopy. The 1H NMR spectrum of 3-
(ethylsulfanylmethyl)coumarin 154 (Figure 13a), reveals the 1”-CH2 signal as a 
quartet at δ2.61 ppm, and the 2”-CH3 signal as a triplet at δ1.30 ppm. The 13C NMR 
spectrum (Figure 13b) reveals the corresponding 2”-methyl carbon signal at δ14.4  
ppm, and the 1”- and 1’-methylene carbon signals at δ26.3 ppm and δ30.8 ppm  
respectively. These assignments are supported by the HMQC, DEPT and COSY 
NMR data. 
 
Heck et al.180 have reported the catalytic hydrogenolysis of an allylic piperidino 
system using triethylammonium formate and a palladium catalyst. Although an 
attempt to extend this methodology to the synthesis of 3-methylcoumarin 151a via 
hydrogenolysis of 3-(piperidinomethyl)coumarin 150a using 10% palladium-on-
carbon, HCOOH and Et3N proved unsuccessful, elimination of piperidine did occur  
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13.     a)  400 MHz 1H NMR spectrum; b) 100 MHz p.n.d 13C NMR spectrum  
                      of  3-(ethylsulfanylmethyl)coumarin 154 in CDCl3.     
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during hydrogenolysis in the presence of 10% palladium-on-carbon catalyst to afford 
3-methylcoumarin 151a as a sole product in 92% yield (Scheme 39). We therefore 
presume that the de-aminated coumarins 151a-d are, in fact, produced via in situ 
elimination of piperidine from the respective precursors  150a-d (Scheme 36). 
 
              
H2, 10% Pd-C
ethanol, 6h
151a150a
O O
N
O O
 
 
Scheme 39 
 
 
 
2.1.6.2.     Acid-catalysed deprotection and cyclization of the O-benzylated Baylis  
                Hillman products 
 
Ethers are known to be cleaved by heating with concentrated hydriodic acid or 
hydrobromic acid under quite vigorous conditions.181-182 Uriarte et al.85 reported the 
used of hydriodic acid in the demethylation and cyclization of ethyl 3-cyclohexyl-3-
hydroxy-3-(2,5-dimethoxyphenyl)-2-propenoate to afford 4-cyclohexyl-6-hydroxy- 
coumarin in yields of up to 68%. The benzylated Baylis-Hillman products 140a-f 
were therefore treated with hydriodic acid in a mixture of acetic acid and acetic 
anhydride at reflux temperature (Scheme 40), and the 3-(iodomethyl)coumarins 155a-
f were isolated in yields ranging from 61 to 85% (Table 7). Hydriodic acid, however , 
is expensive and difficult to handle and, consequently, it was decided to explore the 
use of concentrated hydrochloric acid as alternative reagent. This, in fact, afforded the 
3-(chloromethyl)coumarins 156a-f in even better yields (up to 94%)! 
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Scheme 40 
 
The formation of the novel 3-(halomethyl)coumarins is presumed to involve 
conjugate addition of the halogen acid to the α,β-unsaturated ester moiety and acid-
catalysed dehydration (or SN′ displacement of OH by X), cleavage of the benzyl ether 
and finally cylization, as outlined in Scheme 41. The advantages of this approach 
compared to the general method outlined in Scheme 28 are as follows :- no need for 
prior conjugate addition of nucleophile, convenient deprotection and cyclization, all in 
one pot and in high yield. 
 
Table 7.  Yields obtained for 3-halomethylcoumarins 155a-f and 156a-f  
 
 
O O
X
R
R
1
2
155a-f (X = I)
156a-f (X = Cl)
 
 
   Substrate 
 
         R1       
 
    R2 
 
155 Yield / %  
 
 156 Yield / %  
       140a              H     H        66         80 
       140b          H     OCH3        62         87 
       140c          H     OCH2CH3         61         94 
       140d          Cl     H        85         94 
       140e          Br     H        61         81 
       140f          Br     Br        61         90 
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Scheme 41.    Proposed steps in the formation of the 3-(halomethyl)coumarins 155a-f  
                        and 156a-f (reflecting SN′ displacement of OH). 
 
It was decided to extend this procedure (Scheme 40) to the protected Baylis-Hillman 
adducts  144, which contain an α,β-unsaturated nitrile moiety. Nitriles are generally 
hydrolysed by acid to either carboxylic acids or amides with the former being the 
more common product. It was hoped that hydrolysis of the nitrile function would be 
followed by intramolecular acyl substitution to afford the coumarin in one pot. The 
Baylis-Hillman adducts 144a-b,d-e were therefore treated with hydrochloric acid in a 
mixture of acetic acid and acetic anhydride at reflux temperature for 45 min, to afford 
the 3-(chloromethyl)coumarin derivatives 156a-b,d-e in up to 87% yield; in one case, 
3-(acetoxymethyl)coumarin 157a was also isolated in 14% yield (Scheme 42; Table 
8).  
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Scheme 42       
 
Table 8.    Data for the reaction of the benzylated Baylis-Hillman nitriles 144a-b,d-e      
                  (Scheme 42). 
                          
 
O O
Cl
R
R
O O
OAc
R
R
157a156a-b,d-e
1
2
1
2
 
 
   Substrate 
 
       R1 
 
       R2 
       156 
  Yield / % 
       157 
  Yield / % 
       144a        H        H       75%     14% 
       144b        H       OCH3       69%     0 
       144d        Cl        H       87%     0 
       144e        Br        H       75%     0 
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The 1H NMR spectrum of 3-(chloromethyl)-8-ethoxycoumarin 156c reveals (on 
expansion) the characteristic 1’-methylene proton signal at δ 4.55 ppm as a doublet (J 
= 0.8 Hz) due to long-range allylic coupling with the vinylic 4-H nucleus (Figure 
14a). Although, the 4-H nucleus appears to resonate as a singlet at δ7.85 ppm, the 
allylic coupling relationship was confirmed by the COSY spectrum (Figure 15). The 
13C NMR spectrum (Figure 14b) shows the 1’-methylene carbon signal at δ 41.0 ppm, 
the ethoxy methylene carbon signal at δ 65.1 ppm and the methyl carbon signal at 
δ14.7 ppm. Assignment of the carbon signals is supported by the DEPT and HMQC 
spectra. The 1H NMR spectrum of the 3-(acetoxymethyl)coumarin 157a reveals the 
characteristic acetyl proton signal at δ 2.15 ppm and the methylene proton singlet at δ 
5.06 ppm (Figure 16a). The 13C NMR specrum (Figure 16b) shows the acetyl carbon 
signal at δ 20.9 ppm and the methylene carbon at δ 61.2 ppm.  
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14.   a) 400 MHz 1H NMR spectrum; b) 100 MHz p.n.d 13C NMR spectrum of  
                    3-(chloromethyl)-8-ethoxycoumarin 156c in CDCl3. 
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Figure 15.     400MHz COSY spectrum of 3-(chloromethyl)-8-ethoxycoumarin 156c  
                      in CDCl3. 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16.   a) 400 MHz 1H NMR spectrum; b) 100 MHz p.n.d 13C NMR spectrum of  
                    3-(acetoxymethyl)coumarin 157a in CDCl3. 
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2.1.6.3.    Synthesis of coumarin derivatives via direct cyclization of unprotected  
                Baylis-Hillman products     
 
In the previous section, treatment of the O-benzylated Baylis-Hillman products 140a-f 
and 144a-e with hydriodic or hydrochloric acid (in acetic acid and acetic anhydride) 
was shown to afford the corresponding 3-(halomethyl)coumarins 155a-f and 156a-f in 
yields of up to 94%, without needing to protect the double bond by conjugate addition 
of an amine. In an approach to the synthesis of coumarins, which was to prove even 
more convenient, attention was given to the cyclization of the completely unprotected 
Baylis-Hillman tert-butyl esters 146. (The electron-releasing inductive effect and 
steric bulk of the tert-butyl group in these compounds appear to inhibit spontaneous 
cyclization via acyl substitution to coumarin derivatives, or  via conjugate addition to 
chromenes.)  
 
Reaction of tert-butyl 3-hydroxy-3-(2-hydroxyphenyl)-2-methylenepropanoate 146a 
with DABCO in CDCl3 might have been expected to permit cyclization to a chroman 
system via intramolecular displacement of DABCO from intermediates, such as 158 
or   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17.    400 MHz 1H NMR spectrum of a crude mixture resulting from the     
                     reaction of tert-butyl 3-hydroxy-3-(2-hydroxyphenyl)-2-methylene  
                     propanoate 146a with DABCO in CDCl3.                                                                                 
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159 (Scheme 43). In the event, the reaction led to the formation of the precursors, tert-
butyl acrylate 145 and salicyaldehyde 51a, as determined by 1H NMR analysis of the 
crude mixture. The 1H NMR spectrum (Figure 17) revealed the tert-butyl and vinylic 
proton signals corresponding to tert-butyl acrylate and a one proton signal at δ 9.89 
ppm, corresponding to the aldehydic proton of salicyaldehyde. This observation is 
consistent with previous reports,183-184 which suggested that the overall Baylis-
Hillman reaction was reversible, and is also in agreement with the result obtained 
from a parallel study in our group directed at the preparation of chromene 
derivatives.132b A tentative mechanistic sequence for the process, outlined in Scheme 
43, involves conjugate addition by DABCO to the Baylis-Hillman ester 146a to afford 
the zwitterionic enolate 158, which undergoes proton transfer to form an enol 159; 
tautomerization to the keto form 160 and, finally, elimination of DABCO to afford 
salicylaldehyde and tert-butyl acrylate. 
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Scheme 43 
  
However, when a solution of the Baylis-Hillman tert-butyl ester 146a  in acetic acid 
was heated under reflux, cyclization occurred to give 3-(acetoxymethyl)coumarin 
157a in 40% yield and the chromene ester 161 in 24% yield (Scheme 44). This result 
clearly supports the assumption that both coumarins and chromenes may be obtained 
 80 
 
 
 
Discussion 
 
 
via cyclization of salicylaldehyde-derived Baylis-Hillman products as outlined in 
Scheme 28.  
 
           161157a
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O
+
146a
 
 
Scheme 44   
                      
In order to ensure regioselective cyclization via intramolecular acyl substitution to the 
coumarins, we decided to explore the use of hydrochloric acid in acetic acid. 
Treatment of tert-butyl 3-hydroxy-3-(2-hydroxyphenyl)-2-methylenepropanoate 146a 
with hydrochloric acid in acetic acid gave the 3-(chloromethyl)coumarin 156a in 98% 
yield after 1 hour (Scheme 45). Surprisingly, use of hydriodic acid instead of 
hydrochloric acid resulted in the formation of the 3-iodomethyl  analogue 155a in 
only 10% yield. The advantages of this method of preparing 3-substituted coumarins 
are clearly evident in that it obviates the need to :- i) protect the salicylaldehyde 
hydroxyl group as the O-benzyl ether; ii) block access to chromenes by conjugate 
addition of an amine to the Baylis-Hillman product; and iii) debenzylate the ether to 
permit cyclization. Moreover, the procedure is simple, rapid and affords the coumarin 
products in excellent yield (Table 9). 
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Scheme 45    
 
              Table 9.     Yields for the acid-catalysed cyclization of the Baylis-Hillman  
                                   tert-butyl esters 146a-c,e,f. 
 
Compound 
 
   R1 
 
   R2 
 
Isolated Yield / % 
    156a    H    H            98 
    156b    H    OMe            97 
    156c    H    OEt            90 
    156e    Br    H            95 
    156f    Br    Br            95 
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2.1.7.    Intramolecular Baylis-Hillman reaction. 
 
The aim in this approach was to synthesize coumarin derivatives via an intramolecular 
Baylis-Hillman reaction, in which both the electrophilic and activated alkene moieties 
are present and suitably located in the same molecule. Recently, Drewes et al.159 
reported an intramolecular Baylis-Hillman reaction of the acrylate ester of 
salicylaldehyde in the presence of DABCO to afford the crystalline quaternary 
ammonium salt 164a in 81% yield, together with 3-(hydroxymethyl)coumarin 165 in 
only 10% yield (Scheme 46). In the present study, the generality of the methodology 
outlined by Drewes et al.159 was investigated as an alternative route to the synthesis of 
substituted coumarins. A range of salicylaldehyde acrylate esters 163a-c,e,g were 
prepared by treating acryloychloride in THF with the phenoxide ions generated from 
the salicylaldehydes 51. Reaction of the resulting acrylate esters 163a-c,e,g with 
DABCO in CH2Cl2 afforded the quaternary salts 164a-c,e,g in moderate to excellent 
yields (Table 10); there was, however, no evidence of the formation of the 
corresponding 3-(hydroxymethyl)coumarins viz., 165.   
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Scheme 46 
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Table 11.        Yields for the salicylaldehyde acrylate esters 163a-c,e,g and 164a-c,e,g     
                         (Scheme 46). 
 
O O
N
+
N
R
R
R
Cl
O O
R
R
R
CHO
3
1
2
3
1
2
164a-c,e,g163a-c,e,g  
 
 Compound 
 
       R1 
 
       R2 
 
      R3 
 
Isolated yield / % 
     163a        H        H       H          83 
     163b        H        H       OMe          87 
     163c        H        H       OEt          89 
     163e        Br        H       H          86 
     163g        H        NO2       H          99 
     164a        H        H       H          61 (78a) 
     164b        H        H       OMe          54 
     164c        H        H       OEt          52 
     164e        Br        H        H          59 
     164g        H        NO2        H          70 
 
                    a Yield reported by Drewes et al. (Ref. 159) 
 
The 1H NMR spectrum of the 7-nitro derivative 164g (Figure 18a) reveals broad 
signals corresponding to the DABCO protons at δ 3.00 and 3.43 ppm, while the 
methylene  protons resonate as a singlet at δ 4.43 ppm. The 13C NMR spectrum 
(Figure 18b) shows the methylene carbon signal at δ 61.0 ppm, the assignment of all 
13C signals being supported by the DEPT spectra (Figure 19). The downfield shifts of 
the methylene proton and carbon signal is due to the ionic charge in the molecule.               
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18.      a) 400 MHz 1H NMR spectrum; and (b) 100 MHz p.n.d 13C NMR  
                        spectrum of  7-nitro derivative 164g in DMSO-d6.     
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Figure 19.       HMQC NMR spectrum of  7-nitro derivative 164g in DMSO-d6. 
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2.2.      REGIOSELECTIVITY OF NUCLEOPHILIC ATTACK ON VARIOUS   
            COUMARIN SUBSTRATES. 
 
Having prepared a range of coumarin substrates, their reaction with various 
nucleophilic reagents could be studied. A number of unusual examples of nucleophilic 
attack on the coumarin systems have been reported. Newman and Dalton185 
rationalized the formation of the 3-alkoxy derivatives 166 from their 3-chloro 
precursors in terms of an internal Michael addition involving the ω-hydroxy group, 
nucleophilic displacement of the chlorine at C-3 and finally, a reverse Michael 
reaction. Livingstone et al.186 have reported the formation of dimeric coumarin 
derivatives 167 following reaction of 2,2-dimethyl-2H-naphtho[1,2-b]pyrans with 
methylmagnesium iodide and treatment with acid. 
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1
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Amino-substituted coumarins have been reported to possess CNS stimulant 
activity,187 and are present in many antimalarial and antimicrobial agents. Research on 
Mannich bases of 7-hydroxy-4-phenylcoumarin188 and 7-ethoxy-4-methylcoumarin189 
has revealed that the biological activity of the coumarin system may be enhanced by 
the presence of an amino group. Raju et al.190 have reported the synthesis of 3-
aminomethyl- and 3-(picolylaminomethyl)coumarins via nucleophilic substitution of  
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of the 3-(chloromethyl)coumarin 170 (Scheme 47) with a view to evaluating their 
antibacterial activity. Patil et al.191 have prepared a range of coumarin sulphonamides 
168 via the corresponding 4-(bromomethyl)coumarin.   
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Scheme 47 
 
In our own group, Robinson158 isolated various coumarin derivatives from Baylis-
Hillman reactions of salicylaldehyde precursors, the formation of which has been 
attributed to in situ attack by nucleophiles present in the reaction mixture on coumarin 
intermediates of type 135 (Scheme 48). 
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Scheme 48 
                
In principle, a nucleophile might be expected to attack a coumarin substrate of the 
type 155, 156 or 164 at any of the electrophilic centres, C-2, C-4 or C-1’, as illustrated 
in Figure 20. Allylic halides commonly undergo nucleophilic displacement with (SN’; 
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path I) or without (SN; path II) rearrangement,192 resulting in the formation of two 
types of product, rearranged and normal, while esters typically undergo nucleophilic 
acyl substitution (path III). 
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In the present study, we have explored the regioselectivity of nucleophilic attack on 
the 3-(halomethyl)coumarins 155 and 156 and the DABCO-derived quaternary 
ammonium compounds 164. Various nucleophilic reagents have been used, viz., 
piperidine, benzylamine, Grignard reagents and the enolates of both malonic ester and 
ethyl acetoacetate.  
 
 
2.2.1. Reaction with nitrogen nucleophiles 
 
The 3-(iodomethyl)coumarins 155a,e were treated with piperidine in THF at room 
temperature for 3days, to afford the corresponding 3-(piperidinomethyl)coumarins, 
149a,e (Scheme 49) in moderate to excellent yield (Table 11). The use of 
benzylamine instead of piperidine afforded the 3-(benzylaminomethyl)coumarin 142a 
in 57% yield. Since none of the rearranged products were detected, it seems that, in 
the cases examined, the reaction proceeds exclusively via direct nucleophilic 
substitution at the allylic centre, C-1/ (Path II; Fig. 20). The quaternary DABCO salt 
164a reacted similarly with piperidine to afford the substituted product 149a (42%). 
The lower yields observed with the DABCO salt 164a, in comparison with the iodo 
analogues, are probably due to its poor solubility in THF.  
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Scheme 49 
 
 Table 11.     Results obtained from the reaction of benzylamine and piperidine with   
                     coumarin substrates. 
 
 
 Substrate 
 
   R1 
 
   X 
 
R2H: Nucleophile 
 
 Product 
 Yield of product 
           / % 
     155a    H    I   Benzylamine    149a           57 
     155a    H    I   Piperidine    150a           82 
     155e    Br    I   Piperidine    150e           55 
     155e    Br    I   Benzylamine    149e           88 
     164a    H    DABCO a   Piperidine    150a           42 
 
a As the quaternary ammonium chloride. 
           
 
2.2.2.   Reaction with enolate nucleophiles 
 
The regioselectivity of attack by the enolate anions derived from ethyl acetoacetate 
and diethyl malonate (172 and 173, respectively) were investigated using 3-
(halomethyl)coumarin substrates (Scheme 50). The enolate anions were generated by 
treating ethyl acetoacetate, or diethyl malonate, with sodium ethoxide in ethanol. The 
3-(halomethyl)coumarins were then added under nitrogen to afford the SN products 
174 and 176 (Table 12).       
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Scheme 50 
 
The coumarin derivatives 174a-e and 176a,c-f were fully characterized by one- and 
two-dimensional NMR and high-resolution mass spectrometric analysis. The 1H NMR 
spectrum of the compound 174a (Figure 21a) reveals the characteristic 4’-vinylic 
signals at δ 7.59 ppm, while the 13C NMR spectrum (Figure 21b) exhibits the 
expected 16 signals (expansion reveals that the signal at ca δ 30.0 ppm is due to two 
overlapping signals). Assignment of the carbon signals is supported by the DEPT, 
HMQC and COSY (Figure 22) spectra. 
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Table 12 :  Results from the reaction of the enolates with 3-(iodomethyl)coumarin    
                   155a and the 3-(chloromethyl)coumarins 156b-f (Scheme 50). 
 
 
 
 
Substract 
 
     
    R1             
 
     
     R2 
  
    Enolate 
     anion 
 
          Products  
  No.          Yield / %  
  155a     H      H      A   174a           41  
  156b     H      OMe      A   174b           42  
  156c     H      OEt      A   174c           42  
  156d     Cl      H      A   174d           41               
  156e     Br      H      A   174e           42  
  155a     H      H      B   176a           47  
  156c     H      OEt      B   176c           50  
  156d     Cl      H      B   176d           61  
  156e     Br      H      B   176e           45  
  156f     Br      Br      B   176f            42  
        
 “A” represents sodium enolate of ethyl acetoacetate.  “B” represents sodium enolate     
  of malonic ester.  
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21    a) 100 MHz 1H NMR spectrum; and (b) 100 MHz p.n.d 13C NMR  
                      spectrum of the SN product 174a  in CDCl3.     
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Figure 22         COSY NMR spectrum of the SN product 174a  in CDCl3. 
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2.2.3. Reaction with Grignard reagents 
 
Coumarins, on treatment with Grignard reagents typically undergo initial addition at 
the carbonyl carbon, C-2. When 3-(iodomethyl)coumarin 155a was treated with 
methyl magnesium bromide in THF, a symmetrical dimer 177 was obtained in 94% 
yield (Scheme 51), but attempts to reproduce this result under the same conditions 
were unsuccessful. The formation of dimer  177 may be rationalized in terms of initial 
metal-halogen exchange between one molecule of compound 155a and CH3MgBr. 
The coumaryl Grignard reagent then displaces the iodine from the second molecule of 
the coumarin 155a.  
 
               
O O
X
OO
O O
O O
155a; (X= I)
156a; (X= CI)
CH3MgBr
THF, 24hr
CH3MgBr
THF, reflux,4hr
177
178  
 
Scheme 51 
 
In an alternative method, reaction of 3-(chloromethyl)coumarin 156 with methyl 
magnesium bromide in refluxing THF (Scheme 51) afforded the 3-ethylcoumarin 178 
(29%), which was fully characterized. The 1H NMR spectrum (Figure 23a) reveals the 
methyl triplet at δ 1.25 ppm, and the methylene quartet at δ 2.60 ppm. The 13C NMR 
spectrum (Figure 23b) reveals the methyl and methylene carbon signals at δ 12.4 and 
δ 23.9 ppm, respectively, and the requisite number of eleven carbon signals. It is thus 
apparent that for all the systems examined (Section 2.2.1-3), substitution occurs at the 
exocyclic 1’-carbon.  
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23    a) 100 MHz 1H NMR spectrum; and (b) 100 MHz p.n.d 13C NMR  
                     spectrum of 3-ethylcoumarin 178  in CDCl3.     
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2.3.    MASS SPECTROMETRIC STUDIES OF 3-SUBSTITUTED  
                COUMARINS 
 
Coumarin, itself generally exhibits a relatively highly abundant molecular ion (m/z 
146) under mass spectral conditions, which loses carbon monoxide to give a 
benzofuran radical cation (m/z 118),193 while 4-hydroxycoumarins favour a retro-
Diels-Alder fragmentation. The mass spectra of many methyl-substituted coumarins 
have been investigated.193 For example, 4-methylcoumarin fragments via the loss of 
carbon monoxide to give a 3-methylbenzofuran radical cation, subsequent loss of a 
hydrogen atom giving a benzopyrylium species (m/z 131).193 Loss of a methyl radical 
from the benzofuran radical cation derived from 7-methoxy-4-methylcoumarin has 
been confirmed by deuterium-labelling experiments,193 while naturally occurring 
coumarins bearing large alkyl side chains typically exhibit cleavage of the side chain 
prior to elimination of carbon monoxide.  
 
Here, we report the results of an electron-impact (EI) mass spectrometric study of 
selected 3-substituted coumarins. The major fragmentation patterns exhibited by 
compounds 149a-e and 150a-e were investigated using high-resolution and B/E 
linked scan data. The EI mass spectra for 3-(benzylaminomethyl)coumarin 149a and 
3-(piperidinomethyl)coumarin 150a are illustrated in Figure 24, and the proposed 
mass fragmentation pathways are outlined in Schemes 52 and 53, respectively.  
 
O O
X
R
R
149a-e; (X = PhCH2NH)
150a-e; (X = piperidino)
1
2
      R1    R2
a    H      H
b    H      OMe
c    H      OEt
d    H      Cl
e    H      Br         
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
Figure 24.   High-resolution EI mass spectra of:- a) 3-(benzylaminomethyl)coumarin  
                    149a; and b) 3-(piperidinomethyl)coumarin 150a.  
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Scheme 52 . Proposed EI mass fragmentation pathways for 3-(benzylaminomethyl)- 
                      coumarin 149a. High-resolution data (m/z) are followed, in parentheses,  
                      by calculated formula masses; an asterisk indicates a pathway supported                         
                      by the B/E linked scan data. The prefix “B” indicates 3-(benzylamino-   
                      methyl)coumarin ion types.  
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The fragmentation of the molecular ion B1 (m/z 265) from compound 149a (Scheme 
52) involves the loss of :- i) a hydrogen atom to give the resonance-stabilized cation 
B2 (m/z 264); ii) a benzyl radical to give the resonance-stabilized cation  B3 (m/z 174) 
; and iii) benzylimine or a benzylamino radical to afford fragments B4 (m/z 160) or 
B5 (m/z 159), respectively. Successive loss of carbon monoxide and a hydrogen atom 
from the odd-electron species B4 then affords the 2-methylbenzofuran radical cation 
B6 (m/z 132) and the resonance-stabilized cation B7 (m/z 131). It is apparent from the 
linked scan data that the benzylamino cation B8, which is responsibile for the base 
peak at m/z 106, is formed by direct fragmentation of the molecular ion B1. 
 
In the case of compound 150a, fragmentation of the molecular ion P1 (m/z 243) 
(Scheme 53) via loss of an ethyl or propyl radical affords ions P2 (m/z 214) or P3 (m/z 
200), respectively, reflecting known fragmentations in the piperidine system.194-195 
Loss of an ethylene radical from the ion P2 accounts for the formation of the odd-
electron species P4 (m/z 187); subsequent elimination of hydrogen cyanide affords ion 
P5 (m/z 160), which then undergoes sequential loss of carbon monoxide and a 
hydrogen radical to afford the benzofuran fragments P7 (m/z 132) and P8 (m/z 131), 
respectively. The cation P6 (m/z 159) is formed via loss of a hydrogen atom from ion 
P5. All of these fragmentations are supported by the linked scan data, which also 
support direct fragmentation of the molecular ion P1 to afford the piperidinyl cation 
P9 responsible for the base peak at m/z 84.  
 
Not surprisingly, the mass fragmentation patterns observed for componds 149a and 
150a (Schemes 52 and 53) are very similar and the common fragmentation modes are 
illustrated in Scheme 54.  
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Scheme 53 . Proposed EI mass fragmentation pathways for 3-(piperidinomethyl)- 
                     coumarin 150a. High-resolution data (m/z) are followed, in parentheses,  
                     by calculated formula masses; an asterisk indicates a pathway supported 
                     by linked scan data. The prefix “P” indicates 3-(piperidinomethyl)-    
                     coumarin ion types. 
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Scheme 54.  Fragmentations common to the 3-substituted coumarins  149a and  150a.   
 
M/z values and relative intensities of peaks observed in the mass spectra of the 3-
(benzylaminomethyl)coumarins 149a-e, sorted according to ion types B1-B8 (Scheme 
52), are summarized in Table 13. Table 14 similarily summarises the peaks observed 
in the mass spectra of the 3-(piperidinomethyl)coumarins 150a-e which correspond to 
ion types P1-P9 (Scheme 53). The mass spectra and high-resolution data for 
compounds 149b-e and 150b-e are detailed in the experimental section. 
 
Table 13.  Ion Types B1-B8 observed in the mass spectra of the 149a-e. 
 
 
Compd 
 
   B1 
 
   B2 
 
 B3 
 
  B4 
 
 B5 
 
 B6 
 
 B7 
 
 B8 
   149a    265 
  (0.3) 
   264 
   (0.8) 
 174 
 (37) 
 160 
 (7) 
159 
(10) 
 132 
 (0.3) 
131 
(7) 
106 
(100) 
   149b    295 
  (0.3) 
   294 
   (0.7) 
 204 
 (36) 
 190 
 (8) 
189 
(9) 
 162 
 (1.7) 
161 
(0.3) 
106 
(100) 
   149c    309 
  (0.6) 
   308 
   (14) 
 218 
 (59) 
 204 
 (6) 
203 
(12) 
 176 
 (13) 
175 
(3) 
106 
(100) 
   149d    299 
  (0.4) 
   298 
   (0.8) 
 208 
 (32) 
 195 
 (3.3) 
 196 
 (2.3) 
 166 
 (3.1) 
165 
(8) 
106 
(100) 
   149e    344 
  (2) 
   343 
  (42) 
 252 
 (72) 
 238 237 
(19) 
 210 
 (7.2) 
209 
(17) 
106 
(100)  (17) 
 
 
 
 
 
 102 
 
 
 
Discussion 
 
 
Table 14.   Ion Types P1-P9 observed in the mass spectra of the 150a-e.  
 
 
Compd 
 
  P1 
 
   P2 
 
 P3 
 
  P4 
 
 P 5 
 
 P6 
 
 P7 
 
 P8 
 
 P9 
   150a   243 
  (7) 
   214 
   (4.5) 
 200 
 (8) 
  187 
  (2) 
 160 
 (11) 
 159 
 (8) 
 132 
 (3) 
 131 
 (5) 
 84 
 (100) 
   150b   273 
  (17) 
   244 
   (3) 
 230 
 (20) 
  217 
  (4) 
 190 
 (34) 
 189 
 (17) 
 162 
 (4) 
 131 
 (0.2) 
 84 
 (100) 
   150c   287 
  (19) 
   258 
   (3) 
 244 
 (2) 
  231 
  (3) 
 204 
 (18) 
 203 
 (13) 
 176 
 (21) 
 175 
 (3.5) 
 84 
 (100) 
   150d   277 
  (11) 
   248 
   (3) 
 234 
 (15) 
  221 
  (3) 
 160 
 (2.5) 
 159 
 (2.2) 
 166 
 (4.6) 
 165 
 (11) 
 84 
 (100) 
   150e   321 
  (8) 
   292 
   (2) 
 278 
 (11) 
  265 
  (2) 
 238 
 (14) 
 237 
 (9) 
 ----  209 
 (7) 
 84 
 (100) 
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2.4.    HIV-1 PROTEASE INHIBITORS  
                           
HIV-1 protease is an enzyme, which cleaves peptides. It is a symmetrical dimer 
consisting of two 99 amino acid monomers, each of which contributes an aspartic acid 
residue at the active site.196-197 HIV-1 protease functions as a “pair of molecular 
scissors” which cleave gag and pol precursor proteins to produce viral structural 
proteins as shown in Scheme 55. Numerous HIV-1 protease inhibitors have been 
designed with the incorporation of non-hydrolysable groups which mimic the natural, 
polypeptide substrates.198 
 
                    HIV-1 protease                                        aspartic acid residues 
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Scheme 55 
 
The cleavage mechanism (Scheme 55) is considered to involve the delivery of a water 
molecule to the substrate cleavage site by the two aspartic acid residues. The resulting 
“tetrahedral transition-state intermediate” 179 collapses to give C-terminal acid (180) 
and N-terminal amine (181) fragments, which can then be used by the virus for 
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structural purposes.199 Inhibition of this cycle affords virions which  are immature and 
non-infectious.200-201 The protease enzyme has been an attractive target for antiviral 
therapy, and there are currently four approved HIV-1 protease inhibitors for the 
treatment of AIDS, viz., saquinavir 182, indinavir 183, ritonavir 184 and nelfinavir 
185. 
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In our study, the aim has been to synthesise ritonavir analogues 186, which contain 
coumarin moieties at the termini of a common “backbone”. Ritonavir and its clinically 
useful analogues contain a hydroxyethylene dipeptide “backbone”, and our strategy, 
therefore, was to synthesise the diamine 188, which could then be coupled to 3-
halomethylcoumarins to afford the required ritonavir analogues as illustrated in the 
retrosynthetic analysis (Scheme 56).  
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Scheme  56 
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2.4.1.   Synthesis of the diamine “backbone”. 
 
The diamine 188, required as the “backbone” for the novel ritonavir analogues, was 
synthesized using the methodology reported by Stuk et al.202 (Scheme 57). This 
approach required the protection of the amino group of the precursor, L-phenylalanine 
189, as the N,N-dibenzyl derivative. Reaction of L-phenylalanine with benzyl chloride 
under basic conditions gave the tribenzylated derivative 190, which was then treated 
with the acetonitrile-derived anion in THF at   -40oC to afford the cyanomethylketone 
product 191; the temperature and the addition of the reagent have to be carefully 
controlled to minimize racemization. Reaction of intermediate 191 with 3 equivalents 
of benzyl magnesium chloride gave the enaminone 192 which, on reduction with 
sodium borohydride in the presence of methanesulphonic acid, afforded the 
intermediate ketone 193. Further reduction using NaBH3(OTFA), followed by 
debenzylation (with 5% palladium-on-carbon catalyst in the presence of ammonium 
formate) and treatment with concentrated HCl gave the hydrochloride salt 195. 
Conversion to the required free diamine 188 was achieved by neutralising with 
saturated aqueous sodium carbonate. Compounds 188-195 were all fully characterized 
and  the 1H NMR and 13C NMR spectroscopic data were shown to be consistent with 
those reported by Stuk et al.202  
 
 
2.4.2.     Synthesis of coumarin-containing ritonavir analogues . 
 
We had previously explored the reaction of 3-(halomethyl)coumarins with nitrogen 
nucleophiles, viz., benzylamine and piperidine (Scheme 49), with success and an 
extension of this methodology to the diamine 188 was expected to afford the ritonavir 
analogue 186a (Scheme 58). Treatment of the diamine 188 with 3-(iodomethyl)-
coumarin 155a in THF for ca 8h, in fact, afforded the required product 186 in 25% 
yield (Scheme 58). Purification of compound 186a using preparative layer 
chromatography, however, proved to be difficult. Nevertheless, purified material was 
obtained and fully characterized.  
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Scheme 57 
 
An alternative method was then explored, which involved boiling a mixture of 3-
(iodomethyl)coumarin 155a,  diamine 188  and NaHCO3 in acetone, under reflux for 
ca 2h, to give the required product 186a in only 13% yield. In a third approach, a 
mixture of 3-(chloromethyl)coumarin 156a, the diamine 188 and Na2CO3 in ethanol 
was stirred for ca 76h; work-up afforded the required product 186a  in 50% yield, and 
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this method was then used to prepare the substituted analogues 186b,d and e in yields 
ranging from 53to 71% (Scheme 59; Table 15). 
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In a final attempt to optimise the yield further, the quaternary ammonium salt 164a 
was used as the substrate instead of a 3-(halomethyl)coumarin. Remarkably, when the 
salt 164a was stirred together with the diamine 188 in ethanol at room temperature, 
the ritonavir analogue 186a was isolated in 85% yield! 
 
Table 15.    Yield of the novel analogues of ritonavir containing coumarin moieties  
                    186a,b,d,e (Scheme 59). 
 
 
 
        R1 
 
      R2 
   Isolated 
    Yield / % 
      186a         H       H        50 (85) a 
      186b         OCH3       H        53 
      186d         H       Br        71 
      186e         H       Cl        63 
                                  a Using the coumaryl quaternary ammonium salt 164a 
 
The novel ritonavir analogues 186a,b,d,e were all characterized using high-resolution 
MS and one- and two-dimensional NMR analysis. The 1H NMR spectrum of 
compound 186d (illustrated in Figure 25) reveals the 3-methine proton multiplet  at ca 
3.95 ppm, the 5-methine signal at 3.10 ppm, the 4-methylene multiplet at 1.64 ppm 
and the diastereotopic amino methylene signals at 3.65 and 3.71 ppm. The 13C NMR 
spectrum (Figure 26a) shows the three methine carbons resonating at 72.9 ppm (C-3), 
63.5 ppm (C-2) and 59.7 (C-5), while the five methylene carbons resonate at 36.6 and  
37.1 (2x NHCH2), 40.7 (C-1), 45.8 (C-4) and 46.7 (C-8). The methylene and the 
methine carbon signal assignments were confirmed using the DEPT spectrum (Figure 
26b).   
 
 
2.4.3.   Molecular modelling studies of a ritonavir analogue  
 
The application of molecular modelling and X-ray crystallographic techniques has led 
to the synthesis of several highly potent HIV-1 protease inhibitors.202 In this study, 
docking of the coumarin-containing ritonavir analogue 186a into the active site of the 
HIV-1 protease enzyme203 was explored using an interactive docking procedure.100   
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Figure 25.      400 MHz 1H NMR spectrum of   (2S,3S,5S)-3-hydroxy-2,5-bis[(6- 
                       bromo-2-oxo-2H-chromen-3-yl)methylamino]-1,6-diphenylhexane                       
                       186d in CDCl3.     
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26.    a)100 MHz 13C NMR spectrum; and (b) DEPT spectrum of  spectrum 
                     of (2S,3S,5S)-3-hydroxy-2,5-bis[(6-bromo-2-oxo-2H-chromen-3-yl)-    
                     methylamino]-1,6-diphenylhexane 186d in CDCl3.     
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It was hoped that the hydroxyl group and lactone oxygens of compound 186a might 
be suitably located to hydrogen bond with structural water molecules or amino acid 
residues in the receptor cavity, thereby enhancing its binding to HIV-1 protease. A 
three-dimensional model of  the synthetic ritonavir analogue 186a was built using the 
MSI Cerius2 platform on an SG-O2 computer. The X-ray structure of the HIV-1 
protease enzyme containing ritonavir (Figure 27), as determined by Kempf et al.,204 
was down-loaded from the Cambridge Crystallographic Data Base. Energy 
minimization of compound 186a was achieved using the Universial Force Field; the 
resulting structure was then used for the docking procedure. Removal of ritonavir 
from the enzyme structure exposed the receptor cavity of the enzyme (Figure 28). 
Using the LIGAND-FIT module, the synthetic analogue 186a was docked 
interactively into the enzyme active site. The conformer exhibiting the best fit (as 
shown in Figure 29) was examined for possible hydrogen-bonding interactions with 
the enzyme active site.  The potential hydrogen-bonding interactions between the 
compound 186a and the enzyme receptor in the presence of structural water 
molecules is illustrated in Figure 30. It is apparent that hydrogen-bonding interaction 
may be possible between:- i) a structural water molecule and both the 3-hydroxyl 
group and an amine nitrogen atom (inter-atomic separations of 3.484 and 2.377 Ǻ, 
respectively); and ii) the isoleucine 50B residue and the second amino nitogen of 
compound 186a (2.630Ǻ) 
 
Having successfully synthesised the ritonavir analogues 186a,b,d and e, and having 
demonstrated the ability of the parent system 186a  to fit within the receptor cavity, 
the next phase of the programme is to submit the synthetic analogues for biological 
testing. 
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Figure 27.      X-Ray Diffraction structure of HIV-1 protease showing  ritonavir in the  
                       enzyme binding cavity, as determined by Kempf.204                      
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Figure 28.    Active Site of the HIV-I protease enzyme from the X-ray structure 
reported by Kempf et al. 204 
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Figure 29.      The “bestfit” conformation of the synthetic inhibitor 186a (R, R’, R”=  
                        H) in the active site of the HIV-1 protease enzyme. 
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Figure 30.      The possible hydrogen-bnding interactions between the synthetic   
                        inhibitor 186a and HIV-1 protease enzyme receptor.                      
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2.5 Conclusions 
 
An earlier investigation had revealed that the Baylis-Hillman reaction between 
salicylaldehyde and methyl acrylate resulted in the formation of complex mixtures of 
chromene and coumarin derivatives, and no less than eight distinct product types, 
including both coumarins and chromenes, had been isolated. 
 
The present study was aimed at developing the Baylis-Hillman methodology to ensure 
regioselective intramolecular acyl substitution to afford coumarins chemoselectively. 
Initally, the synthesis of coumarins was achieved using protecting group strategies. 
Specially prepared O-benzylated salicylaldehydes were reacted with activated alkenes 
to give the corresponding Baylis-Hillman products in 51-91% yield. Subsequent 
conjugate addition reactions of the Baylis-Hillman products with the amines,  
benzylamine and piperidine, afforded diastereomeric adducts which, following 
catalytic hydrogenolysis, cyclized spontaneously to give the 3-substituted coumarins 
in up to 67% yield; 3-methylcoumarins were also isolated as minor products. The 
formation of the 3-methylcoumarins under these conditions was examined and found 
to be due to cleavage of the conjugate addition products during catalytic 
hydrogenolysis.  
 
The O-benzylated Baylis-Hillman products were successfully cyclized, under acid-
catalysed conditions using HI or HCl, to give the 3-(halomethyl)coumarins in up to 
94% yield, thus eliminating the amine conjugate addition step. This process appears to 
involve removal of the benzyl ester protecting group, conjugate addition of the halo 
acid to the α,β-unsatuarated ester moiety and spontaneous cyclization. It was found 
that use of HCl gave better yields then HI. The use of completely unprotected Baylis-
Hillman products, prepared from tert-butyl acrylate and various salicylaldehydes 
afforded the 3-(chloromethyl)coumarins in even better yields (up to 98%), the 
advantage of this method being the elimination of protecting groups altogether. An 
alternative approach to 3-substituted coumarins via intramolecular DABCO-catalysed 
Baylis-Hillman reactions of salicylaldehyde acrylate esters was also explored, 
affording coumarin-derived quaternary salts in up to 70% yield. An electron-impact 
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(EI) mass spectrometric study of selected 3-substituted coumarins, using high-
resolution and B/E linked scan data, has revealed certain common fragmentation 
modes. 
 
Regioselectivity studies involving substitution reactions of 3-(halomethyl)coumarins 
with various carbon and nitrogen nucleophiles and the enolate-derived anions of ethyl 
acetoacetate and diethyl malonate have been undertaken. The results indicated the 
exclusive formation of SN-type (rather than SN/) products in up to 61% yield, with   
substitution occuring at the exocyclic allylic centre in each case.  
 
Four ritonavir analogues containing coumarin moieties have been synthesized by 
treating a specially prepared, hydroxyethylene dipeptide isostere with several 
coumarin derivatives in the presence of base. Use of a DABCO-derived quaternary 
ammonium salt instead of a (halomethyl)coumarin gave the required product under 
mild conditions in 85% yield – an approach which clearly provides convenient and 
efficient access to these complex  systems. 
 
It is apparent that the various aims of the project have been successfully addressed. 
Future research in this area is expected to include the following 
 
1) Use of carbon nucleophiles, such as butyllithium and Grignard reagents, to 
further  explore the regioselectivity of nucleophilic attack on the coumarin 
system.  
2) Biological testing of the ritonavir analogues. 
3) Further work on the interactive docking procedure, as a means of investigating 
the hydrogen-bonding interactions between the synthetic ritonavir analogues and 
the HIV1-protease enzyme receptor. 
 
3.  EXPERIMENTAL 
 
 
3.1.   General 
 
Melting points were determined using a Kofler hot-stage apparatus and are 
uncorrected. NMR spectra were run on Bruker AMX400 or AVANCE 400mHz 
spectrometers at 303oK. Spectra recorded in CDCl3 were calibrated using the solvent 
signals at 7.25 ppm for 1H and 77.0 for 13C, while 1H NMR spectra run in CD3OD 
were calibrated using the solvent signal at 3.31 ppm. IR spectra were recorded on a 
Perkin-Elmer FT-IR Spectrum 2000 spectrometer. Low-resolution mass spectra were 
obtained on a Finnegan Mat GCQ mass spectrometer using the electron impact (EI) 
ionisation mode, and high-resolution mass spectra on a VG 70-SEQ double focusing 
magnetic sector spectrometer (Cape Technikon Mass Spectrometry Unit). 
 
Flash chromatography was carried out using Merck Silica gel 60 [particle size 0.040-
0.063 mm (230-400 mesh)], while preparative layer chromatography was effected on 
glass plates coated with Merck silica gel 60 PF254. Thin layer chromatography (TLC) 
was performed using precoated Merck silica gel F254 plates, with visualization of the 
components by inspection under UV light (254/365 nm) and /or by exposure to iodine 
vapour. 
 
Solvents were dried under dry N2 using the procedures described by Perrin and 
Armarego.205 Thus, THF was dried over sodium wire and distilled using 
benzophenone as an indicator, dichloromethane was distilled from CaH2, methanol 
was distilled from magnesium methoxide (generated in situ by reacting methanol with 
magnesium turnings in the presence of iodine) and acetone was distilled from and 
stored over 3A molecular sieves. 
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3.2.     Preparative procedures 
 
3.2.1. Preparation of salicylaldehyde benzyl ethers 
 
2-Benzyloxybenzaldehyde 137a 
 
To a mixture of salicylaldehyde (6.3g, 52mmol), benzyl bromide (6.2ml, 52mmol), 
anhydrous K2CO3 (42.8g, 0.31mol) and NaI (46.5g, 0.31mol) was added distilled 
acetone (100ml), and the mixture was boiled under reflux for 12h. Water (50ml) was 
then added and the aqueous layer extracted with CHCl3 (2x100ml). The combined 
extracts were washed with brine and dried (anhyd. Na2SO4), filtered and concentrated 
in vacuo to give a dark brown oil. Crystallization from hexane afforded, as yellow 
crystals, 2-benzyloxybenzaldehyde 137a (8.63g, 79%), m.p. 42-44oC (lit.,206 cites as 
oil) (Found: M+, 212.08396. Calc. for C14H12O2 M, 212.08373); γmax(KBr)/cm-1 1685 
(C=O); δH (400 MHz; CDCl3) 5.19 (2H, s, OCH2Ph), 7.06 (2H, d, J 8.0Hz, ArH), 
7.33-7.55 (6H, series of multiplets, Ar-H), 7.86 (1H, d, J 8.0Hz, Ar-H) and 10.57 (1H, 
s, CHO); δC (100 MHz; CDCl3) 70.5 (OCH2Ph), 113.0, 121.0, 125.2, 127.3, 128.3, 
128.4, 128.7, 135.8, 136.1 and 161.0 (Ar-C) and 189.7 (C=O); m/z 212 (M+, 6.1%) 
and 91 (100). 
 
2-Benzyloxy-3-methoxybenzaldehyde 137b 
 
The procedure described for the synthesis of 2-benzyloxybenzaldehyde 137a was 
followed, using 3-methoxysalicylaldehyde (4.76g, 31mmol), benzyl bromide (3.72ml, 
31.3mmol), anhydrous K2CO3 (26g, 0.19mol) and NaI (28.2g, 0.19mol) in distilled 
acetone (100ml). Work-up afforded, as a white solid, 2-benzyloxy-3-
methoxybenzaldehyde 137b (6.80g, 89%), m.p. 38-40oC (from hexane) (lit.,207 45oC) 
(Found: M+, 242.09476. Calc. for C15H14O3 M, 242.09429); γmax (KBr)/cm-1 1695 
(C=O); δH (400 MHz; CDCl3) 3.94 (3H, s, OCH3), 5.17 (2H, s, OCH2Ph), 7.10-7.18 
(2H, series of multiplets, Ar-H), 7.32-7.39 (6H, series of overlapping signals, Ar-H) 
and 10.24 (1H, s, CHO); δC (100 MHz; CDCl3) 56.1 (OCH3), 76.3 (OCH2Ph), 118.1,  
119.1, 124.2, 128.5, 128.6, 128.7, 130.4, 136.4, 151.1 and 153.1 (Ar-C) and 190.2 
 
 
 121 
 
 
 
Experimental 
 
 
(C=O); m/z 242 (M+, 7.2%) and 213 (100). 
 
2-Benzyloxy-3-ethoxybenzaldehyde 137c  
    
The procedure described for the synthesis of 2-benzyloxybenzaldehyde 137a was 
followed, using 3-ethoxysalicylaldehyde (5.2g, 31mmol), benzyl bromide (3.72ml, 
31.3mmol), anhydrous K2CO3 (26g, 0.19mol) and NaI (28.2g, 0.19mol) in distilled 
acetone (100ml). Work-up afforded, as a pale orange powder, 2-benzyloxy-3-
ethoxybenzaldehyde 137c (6.84g, 85%), m.p. 36-38oC (from hexane) (lit.,208 39-40oC) 
(Found: M+, 256.10841. Calc. for C16H16O3 M, 256.10994); γmax (KBr)/cm-1 1688 
(C=O); δH (400 MHz; CDCl3) 1.51 (3H, t, J 7.2Hz, CH3), 4.15 (2H, q, J 7.2Hz, 
OCH2CH3), 5.19 (2H, s, OCH2Ph), 7.09-7.40 (8H, series of overlapping signals, Ar-
H) and 10.26 (1H, s, CHO); δC (100 MHz; CDCl3) 14.9 (CH3), 64.7 (OCH2CH3), 76.2 
(OCH2Ph), 119.0, 119.1, 124.2 128.5, 128.6, 128.7, 130.3, 136.5, 151.3 and 152.3 
(Ar-C) and 190.3 (C=O); m/z 256 (M+, 11.1%) and 227 (100). 
 
2-Benzyloxy-5-chlorobenzaldehyde 137d 
     
The procedure described for the synthesis of 2-benzyloxybenzaldehyde 137a was 
followed, using 5-chlorosalicylaldehyde (4.9g, 31mmol), benzyl bromide (3.72ml,                              
31.3mmol), anhydrous K2CO3 (26g, 0.19mol) and NaI (28.2g, 0.19mol) in distilled 
acetone (100ml). Work-up afforded, as pale yellow crystals, 2-benzyloxy-5-
chlorobenzaldehyde 137d (5.15g, 67%), m.p. 70-72oC (from hexane) (Found: M+, 
246.04567. C14H11O235Cl requires M, 246.04476); γmax (KBr)/cm-1 1680 (C=O); δH 
(400 MHz; CDCl3) 5.18 (2H, s, OCH2Ph), 7.00 (1H, d, J 8.8Hz, Ar-H), 7.34-7.42 
(5H, series of multiplets, Ar-H), 7.45 (1H, dd, J 2.4Hz and J 8.8Hz, Ar-H), 7.79 (1H, 
d, J 2.4Hz, ArH) and 10.47 (1H, s, CHO); δC (100 MHz; CDCl3) 71.0 (OCH2Ph), 
114.8, 126.2, 126.8, 127.3, 128.0, 128.5, 128.8, 135.3, 135.6 and 159.4 (Ar-C) and 
188.3 (C=O); m/z 246 [M+ (35Cl), 9.6%] and 91 (100). 
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2-Benzyloxy-5-bromobenzaldehyde 137e 
 
The procedure described for the synthesis of 2-benzyloxybenzaldehyde 137a was 
followed, using 5-bromosalicylaldehyde (9.14g, 31mmol), benzyl bromide (3.72ml, 
31.3mmol), anhydrous K2CO3 (26g, 0.19mol) and NaI (28.2g, 0.19mol) in distilled 
acetone (100ml). Work-up afforded, as light yellow crystals, 2-benzyloxy-5-
bromobenzaldehyde 137e (6.43g, 71%), m.p. 72-74oC (from hexane) (lit.,209 73-74oC) 
(Found: M+, 289.99356. Calc. for C14H11O279Br M, 289.99424); γmax (KBr)/cm-1 1682 
(C=O); δH (400 MHz; CDCl3) 5.18 (2H, s, OCH2Ph), 6.95 (1H, d, J 8.8Hz, Ar-H), 
7.32-7.43 (5H, series of multiplets, Ar-H), 7.59 (1H, dd, J 2.8Hz and J 8.8Hz, Ar-H), 
7.94 (1H, d, J 2.8Hz, Ar-H) and 10.45 (1H, s ,CHO); δC (100 MHz: CDCl3) 70.9 
(OCH2Ph), 113.9, 115.2, 126.5, 127.3, 128.5, 128.8, 131.1, 135.5, 138.2 and 159.9 
(ArC) and 188.2 (C=O); m/z 290 [M+ (79Br), 11.6%] and 91 (100). 
 
2-Benzyloxy-3,5-dibromobenzaldehyde 137f     
 
The procedure described for the synthesis of 2-benzyloxybenzaldehyde 137a was 
followed, using 3,5-dibromosalicylaldehyde (8.76g, 31.3mmol), benzyl bromide 
(3.72ml, 31.3mmol), anhydrous K2CO3 (26g, 0.19mol) and NaI (28.2g, 0.19mol) in 
distilled acetone (100ml). Work-up afforded, as white crystals, 2-benzyloxy-3,5-
dibromobenzaldehyde 137f (7.6, 66%), m.p. 100-102oC (from hexane) (lit.,209 109.5-
110oC) (Found: M+, 367.90452. Calc. for C14H10O279Br2 M, 367.90475); γmax (KBr)/ 
cm-1 1695 (C=O); δH (400 MHz; CDCl3) 5.12 (2H, s, OCH2Ph), 7.38 (5H, s, Ar-H), 
7.85 (1H, d, J 2.4Hz, Ar-H), 7.97 (1H, d, J 2.4Hz, Ar-H) and  9.96 (1H, s, CHO); δC 
(100 MHz; CDCl3) 78.0 (OCH2Ph), 118.3, 119.5, 128.8, 128.9, 129.2, 132.8, 134.7, 
134.9, 157.4 and 141.4 (Ar-C) and 187.5 (C=O); m/z 368 [M+ (79Br2), 5.5%] and 91 
(100). 
 
 
 
 
 
 
 
 
 123 
 
 
 
Experimental 
 
 
3.2.2.   Preparation of Baylis-Hillman products 
 
The reaction between 2-benzyloxybenzaldehyde 137a and methyl acrylate in the 
presence of DABCO to give the Baylis-Hillman product 140a was studied in detail by 
varying the experimental parameters in order to determine the optimum conditions. 
The reaction was monitored using 1H NMR spectroscopy and the results are discussed 
in Section 2.1.3 (p. 47).  
 
 
3.2.2.1.    Optimisation Studies of Baylis-Hillman reaction 
 
Experiment 1 
 
A mixture of 2-benzyloxybenzaldehyde 137a (1.06g, 5mmol), methyl acrylate 
(0.50ml, 5.3mmol) and DABCO (28mg, 0.25mmol) in CDCl3 (0.25ml) was stirred in 
a stoppered reaction flask for five weeks to give the Baylis-Hillman product, methyl 
3-(2-benzyloxyphenyl)-3-hydroxy-2-methylenepropanoate 140a (ca 22%), as determ -
ined by 1H NMR analysis of the crude reaction mixture. 
 
Experiment 2 
 
A mixture of 2-benzyloxybenzaldehyde 137a (1.06g, 5mmol), methyl acrylate 
(0.50ml, 5.3mmol) and DABCO (112mg, 1mmol) in CDCl3 (0.25ml) was stirred in a 
stoppered reaction flask for six weeks to give the Baylis-Hillman product, methyl 3-
(2-benzyloxyphenyl)-3-hydroxy-2-methylenepropanoate 140a (ca 87%), as determin- 
ed by 1H NMR analysis of the crude reaction mixture. 
 
Experiment 3 
 
A mixture of 2-benzyloxybenzaldehyde 137a (1.06g, 5mmol), methyl acrylate 
(0.50ml, 5.3mmol) and DABCO (28mg, 0.25mmol) in CDCl3 (0.25ml) and D2O 
(0.25ml) was stirred in a stoppered reaction flask for six weeks with no evidence of 
the formation of the expected Baylis-Hillman product, methyl 3-(2-benzyloxyphenyl)-
3-hydroxy-2-methylenepropanoate 140a, as determined by 1H NMR analysis of the 
crude reaction mixture. 
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Experiment 4 
 
A mixture of 2-benzyloxybenzaldehyde 137a (1.06g, 5mmol), methyl acrylate 
(0.71ml, 7.9mmol) and DABCO (22.4mg, 0.2mmol) in CDCl3 (1ml) and D2O (1ml) 
was stirred in a stoppered reaction flask for six weeks  with no evidence of the 
formation of the expected Baylis-Hillman product, methyl 3-(2-benzyloxyphenyl)-3-
hydroxy-2-methylenepropanoate 140a, as determined by 1H NMR analysis of the 
crude reaction mixture. 
 
Experiment 5 
 
A mixture of 2-benzyloxybenzaldehyde 137a (1.06g, 5mmol), methyl acrylate (ca 
1.0ml, 10mmol) and DABCO (28mg, 0.25mmol) in CDCl3 (0.25ml) was stirred in a 
stoppered reaction flask for six weeks to give the Baylis-Hillman product, methyl 3-
(2-benzyloxyphenyl)-3-hydroxy-2-methylenepropanoate 140a (ca 21%), as 
determined by 1H NMR analysis of the crude reaction mixture. 
 
Experiment 6 
 
A mixture of 2-benzyloxybenzaldehyde 137a (1.06g, 5mmol), methyl acrylate (ca 
1.0ml, 10.5mmol) and DABCO (294mg, 2.63mmol) in CDCl3 (0.25ml) was stirred in 
a stoppered reaction flask for four weeks to give the Baylis-Hillman product, methyl 
3-(2-benzyloxyphenyl)-3-hydroxy-2-methylenepropanoate 140a (ca 90%), as 
determined by 1H NMR analysis of the crude reaction mixture. 
 
Experiment 7 
 
A mixture of 2-benzyloxybenzaldehyde 137a (1.06g, 5mmol), methyl acrylate 
(2.37ml, 26.3mmol) and DABCO (294mg, 2.63mmol) in CDCl3 (0.25ml) was stirred 
in a stoppered reaction flask for three weeks to give the Baylis-Hillman product, 
methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2-methylenepropanoate 140a (ca 95%), as 
determined by 1H NMR analysis of the crude reaction mixture. 
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3.2.2.2.   Preparation of O-benzylated Baylis-Hillman products 
 
Methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2-methylenepropanoate 140a  
 
A mixture of 2-benzyloxybenzaldehyde 137a (1.06g, 5.0mmol), methyl acrylate 
(1.0ml, 11mmol) and DABCO (294mg, 2.63mmol) in CDCl3 (0.25ml) was stirred in a 
stoppered reaction flask for three weeks. The mixture was concentrated in vacuo to 
give a brown oil, which was purified by flash column chromatography [elution with 
hexane-EtOAc (3:1)] to afford starting material 2-benzyloxybenzaldehyde 137a 
(0.16g, 11%) and, as a pale yellow oil,159 methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2-
methylenepropanoate 140a (1.12g, 75%) (Found, M+ 298.12046. Calc. for C18H1804 
M, 298.12051); γmax (thin film)/cm-1 3501 (OH) and 1728 (C=O); δH (400 MHz; 
CDCl3) 3.37 (1H, br s, OH), 3.71 (3H, s, OCH3), 5.08 (2H, s, OCH2Ph), 5.68 and 6.28 
(2H, 2xs, C=CH2), 5.93 (1H, s, CHOH), 6.92-7.38 (9H, series of overlapping 
multiplets, Ar-H); δC (100  MHz; CDCl3) 51.9 (OCH3), 68.6 (CHOH), 70.3 (OCH2), 
111.9, 121.1, 125.8, 127.4, 127.8, 128.0, 128.6 128.9, 129.6, 136.7, 141.4 and 155.8 
(C=CH2 and Ar-C) and 167.0 (C=O); m/z 298 (M+, 1.5%) and 175 (100). 
 
Methyl 3-(2-benzyloxy-3-methoxyphenyl)-3-hydroxy-2-methylenepropanoate  
140b 
 
The procedure described for the synthesis of methyl 3-(2-benzyloxy-5-bromophenyl)-
3-hydroxy-2-methylenepropanonate 140e was followed, using 2-benzyloxy-3-
methoxybenzaldehyde 137b (1.21g, 5.0mmol), methyl acrylate (2.37ml, 26.3mmol) 
and DABCO (294mg, 2.63mmol) in CDCl3 (0.25ml). Work-up afforded the starting 
material, 2-benzyloxy-3-methoxybenzaldehyde 137b (0.24g, 15%) and, as a pale 
yellow oil, methyl 3-(2-benzyloxy-3-methoxyphenyl)-3-hydroxy-2-methylene-
propanoate 140b (1.34g, 84%) (Found: M+, 328.13079. C19H20O5 requires M, 
328.13107); γmax (thin film)/cm-1 3501(OH) and 1728 (C=O); δH (400 MHz; CDCl3) 
2.88 (1H, d, J 5.2Hz, OH), 3.69 and 3.89 (6H, 2xs, 2xOCH3), 5.07 (2H, s, OCH2), 
5.71 and 6.27 (2H, 2xs, C=CH2), 5.86 (1H, d, J 5.2Hz, CHOH), 6.89-7.45 (8H, series 
of multiplets, Ar-H); δC (100 MHz; CDCl3) 51.8 and 55.8 (2xOCH3), 67.7 (CHOH), 
74.7 (OCH2), 112.1, 119.4, 124.1, 125.8, 128.0, 128.2, 128.4, 135.1, 137.6, 141.7,  
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145.3 and 152.5 (C=CH2 and Ar-C) and 166.8 (C=O); m/z 328 (M+, 9.7%) and 205 
(100). 
 
Methyl 3-(2-benzyloxy-3-ethoxyphenyl)-3-hydroxy-2-methylenepropanoate 140c 
 
The procedure described for the synthesis of methyl 3-(2-benzyloxy-5-bromophenyl)-
3-hydroxy-2-methylenepropanonate 140e was followed, using 2-benzyloxy-3-ethoxy 
benzaldehyde 137c (1.28g, 5.0mmol), methyl acrylate (2.37ml, 26.3mmol) and 
DABCO (294mg, 2.63mmol) in CDCl3 (0.25ml). Work-up afforded the starting 
material, 2-benzyloxy-3-ethoxybenzaldehyde 137c (10mg, 0.6%) and, as a pale 
yellow oil, methyl 3-(2-benzyloxy-3-ethoxyphenyl)-3-hydroxy-2-methylenepropanoate 
140c (1.37g, 80%) (Found: M+, 342.14677. C20H22O5 requires M, 342.14672);  γmax 
(thin film)/cm-1 3484 (OH) and 1719 (C=O); δH (400 MHz; CDCl3)  1.47 (3H, t, J 
7Hz, CH3), 2.93 (1H, d, J 5.2Hz, OH), 3.69 (3H, s, OCH3), 4.10 (2H, q, J 6.8Hz, 
OCH2CH3), 5.10 (2H, s, OCH2Ph), 5.72 and 6.28 (2H, 2xs, C=CH2) 5.87 (1H, d, J 
5.2Hz, CHOH), 6.89-7.46 (8H, series of multiplets, Ar-H); δC (100 MHz; CDCl3) 
15.0 (OCH2CH3), 51.8 (OCH3), 64.3 (OCH2CH3), 68.0 (CHOH), 74.7 (OCH2Ph), 
125.8 (C=CH2), 113.2, 119.4, 124.1,0 128.0, 128.42, 128.35, 135.2, 137.7, 141.7, 
145.5 and 151.9 (C=CH2 and Ar-C) and 166.9 (C=O); m/z 342 (M+, 15.6%) and 219 
(100).  
 
Methyl 3-(2-benzyloxy-3-chlorophenyl)-3-hydroxy-2-methylenepropanoate 140d 
 
The procedure described for the synthesis of methyl 3-(2-benzyloxy-5-bromophenyl)-
3-hydroxy-2-methylenepropanonate 140e was followed, using 2-benzyloxy-5-
chlorobenzaldehyde 137d (1.23g, 5.0mmol), methyl acrylate (2.37ml, 26.3mmol) and 
DABCO (294mg, 2.63mmol) in CDCl3 (0.25ml). Work-up afforded the starting 
material, 2-benzyloxy-5-chlorobenzaldehyde 137d (60mg, 3.6%) and, as pale a 
yellow oil, methyl 3-(2-benzyloxy-3-chlorophenyl)-3-hydroxy-2-methylenepropanoate 
140d (1.29g, 78%) (Found: M+, 332.08243. C18H17O435Cl requires M, 332.08154); 
γmax (thin film)/cm-1 3479 (OH) and 1715 (C=O); δH (400 MHz; CDCl3) 3.32 (1H, br  
s, OH), 3.73 (3H, s, OCH3), 5.05 (2H, s, OCH2Ph), 5.66 and 6.29 (2H, 2xs, C=CH2),  
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5.88 (1H, s, CHOH), 6.84 (1H, d, J 8.8Hz, Ar-H), 7.17-7.40 (7H, series of multiplets,  
Ar-H); δC (100 MHz; CDCl3) 52.0 (OCH3), 67.8 (CHOH), 70.5 (OCH2Ph), 126.4 
(C=CH2), 113.1, 126.2, 127.3, 127.8, 128.2, 128.5, 128.6, 131.5, 136.3, 140.7 and 
154.2 (C=CH2 and Ar-C) and 166.9 (C=O); m/z 332 [M+(35Cl), 5.7%] and 209 (100).  
 
Methyl 3-(2-benzyloxy-5-bromophenyl)-3-hydroxy-2-methylenepropanoate 140e 
 
A mixture of 2-benzyloxy-5-bromobenzaldehyde 137e (1.46g, 5.0mmol), methyl 
acrylate (2.37ml, 26.3mmol) and DABCO (294mg, 2.63mmol) in CDCl3 (0.25ml) was 
stirred in a stoppered reaction flask for three weeks. Work-up afforded the starting 
material, 2-benzyloxy-5-bromobenzaldehyde 137e (80mg, 4.2%) and, as pale yellow 
crystals, methyl 3-(2-benzyloxy-5-bromophenyl)-3-hydroxy-2-methylenepropanonate 
140e (1.58g, 84%), m.p. 114-116oC (Found: M+, 376.02870. C18H17O479Br requires 
M, 376.03102); γmax (KBr)/cm-1 3217 (OH) and 1716 (C=O); δH (400 MHz; CDCl3) 
3.32 (1H, br s, OH), 3.72 (3H, s, OCH3), 5.04 (2H, s, OCH2Ph), 5.65 and 6.28 (2H, 
2xs, C=CH2), 5.88 (1H, s, CHOH), 6.78 (1H, d, J 8.4Hz, Ar-H), 7.30-7.39 (6H, series 
of multiplets, Ar-H) and 7.54 (1H, d, J 2.4Hz, ArH); δC (100 MHz; CDCl3) 52.0 
(OCH3), 67.7 (CHOH), 70.5 (OCH2Ph), 113.5, 113.7, 126.4, 127.3, 128.2 128.6, 
130.6, 131.5, 131.9, 136.2, 140.8 and 154.7 (C=CH2 and Ar-C) and 166.9 (C=O); m/z 
376 [M+(79Br), 11.5%) and 255 (100).  
 
Methyl 3-(2-benzyloxy-3,5-dibromophenyl)-3-hydroxy-2-methylenepropanoate 
140f 
 
The procedure described for the synthesis of methyl 3-(2-benzyloxy-5-bromophenyl)- 
3-hydroxy-2-methylenepropanonate 140e was followed, using 2-benzyloxy-3,5-
dibromobenzaldehyde 137f (1.85g, 5.0mmol), methyl acrylate (2.37ml, 26.3mmol) 
and DABCO (294mg, 2.63mmol) in CDCl3 (0.25ml). Work-up afforded the starting    
material, 2-benzyloxy-3,5-dibromobenzaldehyde 137f (50mg, 2.2%) and, as a pale 
yellow oil, methyl 3-(2-benzyloxy-3,5-dibromophenyl)-3-hydroxy-2-methylene- 
propanoate 140f (1.50g, 66%) (Found: M+, 453.94193. C18H16O479Br2 requires M, 
453.94153); γmax (thin film)/cm-1 3501 (OH) and 1732 (C=O); δH (400 MHz; CDCl3)  
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2.84 (1H, br s, OH) 3.69 (3H, s, OCH3), 5.05 and 5.09 (2H, 2xd, J 10.8Hz, OCH2Ph), 
5.76 and 6.35 (2H, 2xs, C=CH2), 5.81 (1H, d, J 3.2Hz, CHOH), 7.35-7.48 (6H, series 
of multiplets, ArH); δC (100 MHz; CDCl3) 52.1 (OCH3), 67.3 (CHOH), 75.5 
(OCH2Ph), 126.6 (C=CH2), 117.7, 118.3, 128.2, 128.5, 128.6, 130.2, 135.6, 136.3, 
138.5, 140.5 and 152.5 (C=CH2 and Ar-C) and 166.4 (C=O); m/z 454 [M+(79Br2), 
1.9%] and 333 (100). 
 
3-(2-Benzyloxyphenyl)-3-hydroxy-2-methylenepropanenitrile 144a 
 
A mixture of 2-benzyloxybenzaldehyde 137a (1.06g, 5.0mmol), acrylonitrile (1.72ml, 
26.3mmol) and DABCO (294mg, 2.63mmol) in CDCl3 (0.25ml) was stirred in a 
stoppered reaction flask for 21 days.The mixture was concentrated in vacuo to give a 
dark brown oil (1.67g), which was purified using flash chromatography [elution with 
hexane-EtOAc (3:1)] to afford, as a pale yellow oil, 3-(2-benzyloxyphenyl)-3-hydroxy-
2-methylenepropanenitrile 144a (0.73g, 55%) (Found: M+, 265.11071. C17H15NO2 
requires M, 265.11028); γmax (thin film)/cm-1 3432 (OH) and 2217(CN); δH (400 
MHz; CDCl3) 3.08 (1H, br s, OH), 5.08 and 5.10 (2H, t, J 12Hz, OCH2Ph), 5.54 (1H, 
s, CHOH), 5.93 and 5.96 (2H, 2xd, J 1.6Hz and J 0.4Hz, C=CH2), 6.97-7.42 (9H, 
series of overlapping signals, ArH); δC (100 MHz; CDCl3) 70.5 (OCH2Ph), 70.6 
(CHOH), 129.7 (C=CH2), 112.2, 117.1, 121.5, 125.8, 127.4, 127.6, 128.0, 128.3, 
128.7, 130.0 and 136.2 (C=CH2 and Ar-C) and 155.9 (CN); m/z 265 (M+, 27.6%) and 
91 (100).  
 
3-(2-Benzyloxy-3-methoxyphenyl)-3-hydroxy-2-methylenepropanenitrile 144b 
 
The procedure described for the synthesis of 3-(2-benzyloxyphenyl)-3-hydroxy-2-
methylenepropanenitrile 144a was followed, using 2-benzyloxy-3-methoxy- 
benzaldehyde (1.21g, 5.0mmol), acrylonitrile (1.72ml, 26.3mmol) and DABCO 
(294mg, 2.63mmol) in CDCl3 (0.25ml). Work-up afforded, as a pale yellow oil, 3-(2-
benzyloxy-3-methoxyphenyl)-3-hydroxy-2-methylenepropanenitrile 144b (0.90g, 61%) 
(Found: M+, 295.12122. C18H17NO3 requires M, 295.12084); γmax (thin film)/cm-1 
3432 (OH) and 2227(CN); δH (400 MHz; CDCl3) 2.77 (1H, d, J 5.6Hz, OH), 3.90  
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(3H, s, OCH3), 5.06 and 5.14 (2H, 2xd, J 11.2Hz, OCH2Ph), 5.43 (1H, d, J 5.6Hz, 
CHOH), 5.89 and 5.92 (2H, 2xd,  J1.6Hz, C=CH2), 6.93-7.42 (8H, series of 
overlapping signals, ArH); δC (100 MHz, CDCl3) 55.8 (OCH3), 69.6 (CHOH) 74.9 
(OCH2Ph), 128.9 (C=CH2), 113.0, 117.1, 119.4, 124.6, 125.8, 128.2, 128.3, 128.5, 
133.0, 137.2 and 145.2 (C=CH2 and Ar-C) and 152.5 (CN); m/z 295 (M+, 35.2%) and 
187 (100).  
 
3-(2-Benzyloxy-3-ethoxyphenyl)-3-hydroxy-2-methylenepropanenitrile 144c 
 
The procedure described for the synthesis of 3-(2-benzyloxyphenyl)-3-hydroxy-2-
methylenepropanenitrile 144a was followed, using 2-benzyloxy-3-ethoxy- 
benzaldehyde (1.28g, 5.0mmol), acrylonitrile (1.72ml, 26.3mmol) and DABCO 
(294mg, 2.63mmol) in CDCl3 (0.25ml). Work-up afforded, as a pale yellow oil, 3-(2-
benzyloxy-3-ethoxyphenyl)-3-hydroxy-2-methylenepropanenitrile 144c (1.40g, 91%) 
(Found: M+, 309.13738. C19H19NO3 requires M, 309.13649); γmax (thin film)/cm-1 
3443 (OH) and 2228 (CN); δH (400 MHz; CDCl3) 1.47 (3H, t, J 7Hz, CH3), 2.80 (1H, 
br s, OH), 4.12 (2H, q, J 6.8Hz, OCH2CH3), 5.08 and 5.17 (2H, 2xd, J 10.8Hz, 
OCH2Ph), 5.43 (1H, br s, CHOH), 5.90 and 5.93 (2H, 2xd, J1.2Hz, C=CH2), 6.91-
7.42 (8H, series of overlapping signals, ArH); δC (100 MHz; CDCl3) 14.9 (CH3), 64.2 
(OCH2CH3), 74.9 (OCH2Ph), 69.8 (CHOH), 129.8 (C=CH2), 114.1, 117.1, 119.4, 
124.6, 125.8, 128.3, 128.5, 131.2, 133.0, 137.2 and 145.2 (C=CH2 and Ar-C) and 
152.5 (CN); m/z 309 (M+, 5.9%) and 201 (100).  
 
3-(2-Benzyloxy-3-chlorophenyl)-3-hydroxy-2-methylenepropanenitrile 144d 
 
The procedure described for the synthesis of 3-(2-benzyloxyphenyl)-3-hydroxy-2-
methylenepropanenitrile 144a was followed, using 2-benzyloxy-5-chlorobenz-
aldehyde (1.23g, 5.0mmol), acrylonitrile (1.72ml, 26.3mmol) and DABCO              
(294mg, 2.63mmol) in CDCl3 (0.25ml). Work-up afforded, as a pale yellow oil, 3-(2-
benzyloxy-3-chlorophenyl)-3-hydroxy-2-methylenepropanenitrile 144d (0.82g, 55%) 
(Found: M+, 299.07235. C17H14NO235Cl requires M, 299.07131); γmax (thin film)/cm-1 
3397 (OH) and 2220 (CN); δH (400 MHz; CDCl3) 2.88 (1H, d, J 6.0Hz, OH), 5.05  
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and 5.08 (2H, 2xd, J 11.6Hz, OCH2Ph), 5.54 (1H, d, J 6.0Hz, CHOH), 5.94 and 5.98 
(2H, 2xd, J1.6Hz, C=CH2), 6.84 (1H, d, J 8.8Hz, ArH), 7.24-7.40 (7H, series of 
multiplets, ArH); δC (100 MHz; CDCl3) 69.6 (CHOH), 70.9 (OCH2Ph), 130.3 
(C=CH2), 113.5, 116.8, 125.2, 126.6, 127.6, 127.8, 128.5, 128.8, 129.2, 129.6 and 
135.8 (C=CH2 and Ar-C) and 154.3 (CN); m/z 299 [M+(35Cl), 18.1%] and 91 (100).  
 
3-(2-Benzyloxy-5-bromophenyl)-3-hydroxy-2-methylenepropanenitrile 144e 
 
The procedure described for the synthesis of 3-(2-benzyloxyphenyl)-3-hydroxy-2-
methylenepropanenitrile 144a was followed, using 2-benzyloxy-5-bromo-
benzaldehyde (1.46g, 5.0mmol), acrylonitrile (1.72ml, 26.3mmol) and DABCO 
(294mg, 2.63mmol) in CDCl3 (0.25ml). Work-up afforded, as pale yellow crystals, 3-
(2-benzyloxy-5-bromophenyl)-3-hydroxy-2-methylenepropanenitrile 144e (0.88g,  
51%), m.p. 80-82oC (Found: M+, 343.01884. C17H14NO279Br requires M, 343.02079); 
γmax (KBr)/cm-1 3413 (OH) and 2231 (CN); δH (400 MHz; CDCl3) 2.83 (1H, d, J 
6.0Hz, OH), 5.05 and 5.08 (2H, 2xd, J 11.6Hz, OCH2Ph), 5.54 (1H, d, J 4.8Hz, 
CHOH), 5.96 and 5.98 (2H, 2xd, J 1.2Hz, C=CH2), 6.86 (1H, d, J 8.8Hz, ArH), 7.35-
7.42 (6H, series of overlapping signals, ArH) and 7.52 (1H, d, J 2.4Hz, ArH); δC (100 
MHz; CDCl3) 69.5 (CHOH), 70.8 (OCH2Ph), 130.3 (C=CH2), 113.8, 113.9, 116.8, 
125.2, 127.6, 128.5, 128.8, 129.6, 130.7, 132.6 and 135.7 (C=CH2 and Ar-C) and 
154.8 (CN); m/z 342 [M+(79Br), 13.2%) and 92 (100).  
 
 
3.2.2.3.    Baylis-Hillman reactions of salicylaldehyde and tert-butyl acrylate 
 
tert-Butyl 3-hydroxy-3-(2-hydroxyphenyl)-2-methylenepropanoate 146a  
 
A mixture of salicylaldehyde (1.0ml, 9.6mmol), tert-butyl acrylate (2.1ml, 14mmol) 
and DABCO (0.86g, 7.7mmol) in CDCl3 (3ml) was stirred in a stoppered reaction 
flask for 14 days. The mixture was concentrated in vacuo to give dark brown oil, 
which was purified using flash chromatography [elution with hexane-EtOAc (4:1)] to 
afford, tert-butyl 3-hydroxy-3-(2-hydroxyphenyl)-2-methylenepropanoate 146a 
(0.95g, 40%) as a colorless oil which later crystalised, m.p.108-110oC (lit.,134 104- 
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106oC) (Found: M+, 250.11914. Calc. for C14H18O4 M, 250.12051); γmax (KBr)/cm-1 
3361 (OH) and 1693 (C=O); δH (400 MHz; CDCl3) 1.51 [9H, s, C(CH3)3], 4.29 (1H, 
d, J 3.6Hz, OH), 5.48 and 6.23 (2H, 2xs, C=CH2), 5.69 (1H, d, J 2.4Hz, CHOH), 
6.85-7.20 (4H, series of multiplets, ArH), 8.09 (1H, s, ArOH); δC (100 MHz, CDCl3) 
28.1 [C(CH3)3], 74.0 (CHOH), 82.7 [C(CH3)3],  127.0 (C=CH2), 117.6, 119.8, 125.8, 
124.1, 127.8, 129.6 and 140.8 (C=CH2 and Ar-C) and 156.1 (C=O); m/z 250 (M+, 
1.2%) and 131 (100).  
 
tert-Butyl 3-hydroxy- 3-(2-hydroxy-3-methoxyphenyl)-2-methylenepropanoate 
146b 
 
The procedure described for the synthesis of tert-butyl 3-hydroxy-3-(2-
hydroxyphenyl)-2-methylenepropanoate 146a was followed, using 3-methoxy 
salicylaldehyde (1.52g, 9.6mmol), tert-butyl acrylate (2.1ml, 14mmol) and DABCO 
(0.86mg, 7.7mmol) in CDCl3 (3ml). Work-up afforded, as a pale yellow oil, tert-butyl 
3-hydroxy-3-(2-hydroxy-3-methoxyphenyl)-2-methylenepropanoate 146b (1.53g, 
57%) (Found: M+, 280.13073. C15H20O5 requires M, 280.13107); γmax (thin film)/cm-1 
3412 (OH) and 1714 (C=O); δH (400 MHz; CDCl3) 1.45 [9H, s, C(CH3)3], 3.68 (1H, 
d, J 4.0Hz, OH), 3.91 (3H, s, OCH3), 5.64 and 6.22 (2H, 2xs, C=CH2), 5.81 (1H, d, J 
2.8Hz, CHOH), 6.61 (1H, s, ArOH) and 6.82 (3H, s, ArH); δC (100 MHz; CDCl3) 
28.0 [C(CH3)3], 56.0 (OCH3), 69.9 (CHOH), 81.7 [C(CH3)3], 125.4 (C=CH2), 110.5, 
119.6, 119.7, 126.3, 142.0, 143.8, and 147.1(C=CH2 and Ar-C) and 166.2 (C=O); m/z 
280 (M+, 8.2%) and 161 (100).   
 
tert-Butyl 3-hydroxy-3-(3-ethoxy-2-hydroxyphenyl)-2-methylenepropanoate 146c 
 
The procedure described for the synthesis of tert-butyl 3-hydroxy-3-(2-hydroxy-
phenyl)-2-methylenepropanoate 146a was followed, using 3-ethoxy salicylaldehyde 
(1.66g, 9.6mmol), tert-butyl acrylate (2.1ml, 14mmol) and DABCO (0.86g, 7.7mmol) 
in CDCl3 (3ml). Work-up afforded, as a pale yellow oil, tert-butyl 3-hydroxy-3-(3-
ethoxy-2-hydroxyphenyl)-2-methylenepropanoate 146c (1.65g, 58%) (Found: M+, 
294.14688. C16H22O5 requires M, 294.14672); γmax (thin film)/cm-1 3383 (OH) and  
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1714 (C=O); δH (400 MHz; CDCl3) 1.43 [12H, overlapping s and t, C(CH3)3 and 
OCH2CH3], 3.63 (1H, d, J 5.2Hz, CHOH), 4.09 (2H, q, J 7.2Hz, OCH2CH3), 5.66 and 
6.21 (2H, 2xs, C=CH2), 5.82 (1H, d, J 4.0Hz, CHOH), 6.45 (1H, s, ArOH) and 6.83 
(3H, series of overlapping signals, ArH); δC (100 MHz; CDCl3) 14.8 (CH2CH3), 28.0 
[C(CH3)3], 64.5 (OCH2CH3), 69.4 (CHOH), 81.5 [C(CH3)3], 111.3, 119.5, 119.6, 
125.1, 126.6, 142.2, 143.6 and 146.1(C=CH2 and Ar-C) and 166.1 (C=O); m/z 294 
(M+, 18.2%) and 220 (100).   
 
tert-Butyl 3-(5-bromo-2-hydroxyphenyl)-3-hydroxy-2-methylenepropanoate 146e 
 
The procedure described for the synthesis of tert-butyl 3-hydroxy-3-(2-
hydroxyphenyl)-2-methylenepropanoate 146a was followed, using 5-
bromosalicylaldehyde (1.93g, 9.6mmol), tert-butyl acrylate (2.1ml, 14mmol) and 
DABCO (0.86g, 7.7mmol) in CDCl3 (3ml) and stirring for 3 days. The reaction 
mixture was filtered through a layer of silica gel. Crystallization from CHCl3 
afforded, as white crystals, tert-butyl 3-(5-bromo-2-hydroxyphenyl)-3-hydroxy-2-
methylenepropanoate 146e (2.07g, 66%), m.p. 186-188oC (Found: M+, 328.03063. 
C14H17O479Br require M, 328.03102); γmax (KBr)/cm-1 3298 (OH), and 1686 (C=O); 
δH (400 MHz, CDCl3) 1.51 [9H, s, C(CH3)3], 4.26 (1H, br s, OH), 5.56 and 6.23 (2H, 
2xs, C=CH2), 5.63 (1H, s, CHOH), 6.80 (1H, d, J 8.8Hz, ArH), 7.09 (1H, d, J 8.4Hz, 
ArH), 7.29 (1H, dd, J 8.8 and J 2.0Hz, ArH) and 8.18 (1H, br s, ArOH); δC (100 
MHz, CDCl3) 28.0 [C(CH3)3], 72.9 (CHOH), 83.0 [C(CH3)3], 111.8, 119.5, 126.5, 
127.2, 130.3, 132.2, 140.3 and 155.1 (C=CH2 and Ar-C) and 166.7 (C=O); m/z 328 
[M+(79Br), 3.7%] and 211 (100).  
 
tert-Butyl 3-(3,5-dibromo-2-hydroxyphenyl)-3-hydroxy-2-methylenepropanoate 
146f 
 
The procedure described for the synthesis of tert-butyl 3-hydroxy-3-(2-
hydroxyphenyl)-2-methylenepropanoate 146a was followed, using 3,5-dibromo- 
salicylaldehyde (2.69g, 9.6mmol), tert-butyl acrylate (7.68ml, 52.5mmol) and 
DABCO (0.86g, 7.7mmol) in CDCl3 (3ml) and stirring for 3 days. The reaction 
mixture was filtered through a layer of silica gel. Crystallization from CHCl3  
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afforded, as white crystals, tert-butyl 3-(3,5-dibromo-2-hydroxyphenyl)-3-hydroxy-2-
methylenepropanoate  146f (1.70g, 44%) m.p. 186-188oC; (Found: M+, 405.94240. 
C14H16O479Br2 require M, 405.94153); δH (400 MHz, CDCl3) 1.48 [9H, s, C(CH3)3], 
4.24 (1H, br s, OH), 5.62 and 6.26 (2H, 2xs, C=CH2), 5.67 (1H, s, CHOH), 7.16 (1H, 
d, J 2.0Hz, ArH), 7.56 (1H, d, J 2.0Hz, ArH) and 8.12 (1H, br s, ArOH); δC (100 
MHz, CDCl3) 28.0 [C(CH3)3], 71.5 (CHOH), 82.9 [C(CH3)3], 112.0, 112.1, 127.0, 
128.4, 129.7, 134.4, 140.3 and 151.0 (C=CH2 and Ar-C) and 166.3 (C=O).  
 
 
3.2.3.        Reaction of nitrogen nucleophiles with Baylis-Hillman    
                  products 
 
3.2.3.1.   Conjugate addition reactions with benzylamine 
 
Methyl 2-(benzylaminomethyl)-3-(2-benzyloxyphenyl)-3-hydroxypropanoate 
147a 
 
A mixture of methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2-methylenepropanoate 140a 
(0.6g, 2mmol), benzylamine (0.22ml, 2mmol) in methanol (4ml) was stirred in a 
stoppered reaction flask for 3 days. Excess benzylamine was evaporated in vacuo to 
give a yellow oil (0.80g), which was purified by preparative layer chromatography 
[elution with hexane-MeOH-EtOAc (2:0.1:1)] to afford methyl 3-(2-benzylamino-
methyl)-3-(2-benzyloxyphenyl)-3-hydroxypropanoate 147a (0.50g, 62%) as pale 
yellow crystals, m.p. 94-960C (Found: MH+, 406.201633. C25H28NO4 requires M+1, 
406.201834); γmax (KBr)/cm-1 3308 (OH) and 1720 (C=O); δH (400 MHz; CDCl3) 2.54 
(1H, dd, J 12Hz and J 3.2Hz, CHANHCH2Ph), 3.06-3.13 (2H, series of overlapping 
signals, CHCHBNHCH2Ph), 3.64 and 3.69 (2H, 2xd, J 12.8Hz, NHCH2Ph), 3.75 (3H, 
s, OCH3), 5.13 (2H, 2xd, J 12.2Hz, OCH2Ph), 5.77 (1H, m, CHOH), 6.91 and 6.95 
(2H, 2xd, J 8.4Hz and J 7.6Hz, ArH) and 7.20-7.47 (12H, series of overlapping 
signals, Ar-H); δC (100 MHz; CDCl3) 46.2 (CH2NHCH2Ph), 47.4 (CHCO2CH3), 51.9 
(OCH3), 54.2 (CH2NH2CH2Ph), 69.6 (OCH2Ph), 71.8 (CHOH), 111.3, 120.9, 126.8, 
127.0, 127.2, 127.7, 128.1, 128.37, 128.42, 128.5, 131.7, 137.0, 139.1 and 154.5 (Ar-
C) and 174.2 (C=O); m/z 405 (M+, 0.1%) and 91 (100).  
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Methyl 2-(benzylaminomethyl)-3-(2-benzyloxy-3-methoxyphenyl)-3-hydroxy-
propanoate 147b 
 
The procedure described for the synthesis of methyl 2-(benzylaminomethyl)-3-(2-
benzyloxyphenyl)-3-hydroxypropanoate 147a was followed, using 3-(2-benzyloxy-3-
methoxyphenyl)-3-hydroxy-2-methylenepropanoate 140a (0.66g, 2mmol), benzyl- 
amine (0.22ml, 2mmol) in methanol (4ml). Work-up and chromatography afforded 
methyl 2-(benzylaminomethyl)-3-(2-benzyloxy-3-methoxyphenyl)-3-hydroxypropan-
oate 147b (0.76g, 87%) as a pale yellow oil, (Found: MH+, 436.212314. C26H30O5N 
requires M+1, 436.212398); γmax (thin film)/cm-1 3325 (OH) and 1732 (C=O); δH (400 
MHz; CDCl3) 2.48 (1H, dd, J 12.4 and J 3.2Hz, CHANHCH2Ph), 3.04-3.12 (2H, 
series of overlapping signals, CHCHBNHCH2Ph), 3.65 (2H, s, CH2NHCH2Ph), 3.73 
and 3.90 (6H, 2xs, OCH3), 4.89 and 5.22 (2H, 2xd, J 10.8Hz, OCH2Ph), 5.65 (1H, m, 
CHOH) and 6.89-7.53 (13H, series of multiplets, ArH); δC (100 MHz; CDCl3) 46.1 
(CH2NHCH2Ph), 48.1 (CHCO2CH3), 51.8 and 55.7 (2xOCH3), 54.1 (CH2NH2CH2Ph), 
72.1 (CHOH), 74.5 (OCH2Ph), 111.2, 118.8, 123.9, 127.1, 127.9, 128.19, 128.24, 
128.3, 128.4, 137.1, 137.5, 139.0, 143.8 and 152.3 (Ar-C) and 173.8 (C=O); m/z  436 
(MH+, 17.3%) and 120 (100).  
 
Methyl 2-(benzylaminomethyl)-3-(2-benzyloxy-3-ethoxyphenyl)-3-hydroxyprop- 
anoate 147c 
 
The procedure described for the synthesis of methyl 2-(benzylaminomethyl)-3-(2-
benzyloxyphenyl)-3-hydroxypropanoate 147a was followed, using 3-(2-benzyloxy-3-
ethoxyphenyl)-3-hydroxy-2-methylenepropanoate 140c (0.68g, 2mmol), benzylamine 
(0.22ml, 2mmol) in methanol (4ml). Work-up and chromatography afforded methyl 2-
(benzylaminomethyl)-3-(2-benzyloxy-3-ethoxyphenyl)-3-hydroxypropanoate 147c 
(0.64g, 71%) as a pale yellow oil, (Found: MH+, 450.228102. C27H32O5N. requires 
M+1, 450.228048); γmax (thin film)/cm-1 3323 (OH) and 1733 (C=O); δH (400 MHz; 
CDCl3) 1.49 (3H, t, J 7.0Hz, OCH2CH3), 2.47 (1H, m, CHANHCH2Ph), 3.06-3.10 
(2H, m, CHCHBNHCH2Ph), 3.64 (2H, s, CH2NHCH2Ph), 3.72 (3H, s, OCH3), 4.10 
(2H, q, J 6.8Hz, OCH2CH3), 4.89 and 5.24 (2H, 2xd, J 10.4Hz, OCH2Ph), 5.64 (1H, s, 
CHOH) and 6.87-7.52 (13H, series of multiplets, ArH); δC (100 MHz; CDCl3) 15.0  
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(OCH2CH3), 46.1 (CH2NH2CH2Ph), 48.1 (CHCO2CH3), 51.9 (OCH3), 54.1 
(NH2CH2Ph), 64.1 (OCH2CH3), 72.2 (CHOH), 74.5 (OCH2Ph), 112.2, 118.7, 123.9, 
127.2, 128.0, 128.28, 128.31, 128.46, 128.50, 137.2, 137.7, 139.1, 143.9 and 151.7 
(Ar-C) and 174.0 (C=O); m/z  450 (MH+, 6.9%) and 91 (100).  
 
Methyl 2-(benzylaminomethyl)-3-(2-benzyloxy-5-chlorophenyl)-3-hydroxyprop-
anoate 147d 
 
The procedure described for the synthesis of methyl 2-(benzylaminomethyl)-3-(2-
benzyloxyphenyl)-3-hydroxypropanoate 147a was followed, using 3-(2-benzyloxy-3-
chlorophenyl)-3-hydroxy-2-methylenepropanoate 140d (0.67g, 2mmol), benzylamine 
(0.22ml, 2mmol) in methanol (4ml). Work-up and chromatography afforded, as a 
yellow solid, methyl 2-(benzylaminomethyl)-3-(2-benzyloxy-5-chlorophenyl)-3-
hydroxypropanoate 147d (0.61g, 69%), m.p. 68-70oC (Found: MH+, 440.162907. 
C25H27NO435Cl, requires: M+1, 440.162861); γmax (KBr)/cm-1 3298 (OH) and 1732 
(C=O); δH (400 MHz; CDCl3) 2.51 (1H, m, CHANHCH2Ph), 3.05 (1H, m, 
CHCH2NH), 3.14 (1H, m, CHBNHCH2Ph), 3.68 (2H, s, CH2NHCH2Ph), 3.74 (3H, s, 
OCH3), 5.06 (2H, 2xd, J 12.0Hz, OCH2Ph), 5.72 (1H, d, J 2.4Hz, CHOH) and 6.83-
7.51 (13H, series of multiplets, ArH); δC (100 MHz; CDCl3) 46.3 (CH2NHCH2Ph), 
47.0 (CHCO2CH3), 52.0 (OCH3), 54.2 (CH2NH2CH2Ph), 70.0 (OCH2Ph), 71.5 
(CHOH), 112.7, 126.3, 126.8, 127.3, 127.4, 127.8, 127.9, 128.2, 128.5, 128.6, 133.8, 
136.5, 138.7 and 153.0 (Ar-C) and 173.8 (C=O); m/z 440 [MH+(35Cl), 1.8%] and 91 
(100).  
 
Methyl 2-(benzylaminomethyl)-3-(2-benzyloxy-5-bromophenyl)-3-hydroxy 
propanoate 147e 
 
The procedure described for the synthesis of methyl 2-(benzylaminomethyl)-3-(2-
benzyloxyphenyl)-3-hydroxypropanoate 147a was followed, using 3-(2-benzyloxy-5-
bromophenyl)-3-hydroxy-2-methylenepropanoate 140e (0.60g, 2mmol),  benzylamine 
(0.22ml, 2mmol) in methanol (4ml). Work-up and chromatography afforded methyl 2- 
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(benzylaminomethyl)-3-(2-benzyloxy-5-bromophenyl)-3-hydroxypropanoate 147e 
(0.61g, 63%) as a yellow oil, (Found: MH+, 484.112392. C25H26NO479Br requires 
M+1, 484.112345); γmax (thin film)/cm-1 3324 (OH) and 1732.3 (C=O); δH (400 MHz; 
CDCl3) 2.53 (1H, m, CHANHCH2Ph), 3.07 (1H, m, CHCH2NHCH2Ph), 3.16 (1H, 
ddd, J 1.6Hz, J 2.0Hz and J 8.0Hz, CHBNHCH2Ph), 3.69 (2H, 2xd, J 13.4, 
CH2NHCH2Ph), 3.75 (3H, s, OCH3), 5.08 (2H, 2xd, J 11.8, OCH2Ph), 5.74 (1H, s, 
CHOH), 6.80 (1H, d, J 8.8Hz, ArH), 7.27-7.44 (11H, series of multiplets, ArH) and 
7.69 (1H, d, J 2.0Hz, ArH); δC (100 MHz; CDCl3) 46.3 (CH2NHCH2Ph), 47.0 
(CHCO2CH3), 52.0 (OCH3), 54.2 (CH2NH2CH2Ph), 69.9 (OCH2Ph), 71.3 (CHOH), 
113.2, 113.6, 126.9, 127.3, 127.9, 128.1, 128.4, 128.5, 130.1, 130.8, 134.1, 136.3, 
138.7 and 153.5 (Ar-C) and 173.7 (C=O); m/z 484 [MH+(79Br), 3.0%] and 121 (100).  
 
Methyl 2-(benzylaminomethyl)-3-(2-benzyloxy-3,5-dibromophenyl)-3-hydroxy 
propanoate 147f 
 
The procedure described for the synthesis of methyl 2-(benzylaminomethyl)-3-(2-
benzyloxyphenyl)-3-hydroxypropanoate 147a was followed, using 3-(2-benzyloxy-
3,5-dibromophenyl)-3-hydroxy-2-methylenepropanoate 140f (0.91g, 2mmol),  benzyl- 
amine (0.22ml, 2mmol) in methanol (4ml). Work-up and chromatography afforded 
methyl 2-(benzylaminomethyl)-3-(2-benzyloxy-3,5-dibromophenyl)-3-hydroxy propan- 
oate, 147f (0.80g, 71%) as a yellow oil, (Found: MH+, 562.122773. C25H26NO479Br2, 
requires: M+1, 562.022856); γmax (thin film)/cm-1 3419 (OH) and 1747 (C=O); δH 
(400 MHz; CDCl3) 2.43 (1H, dd, J 12.4Hz, CHANHCH2Ph), 3.02 (1H, m, 
CHCH2NH), 3.14 (1H, dd, J 12.4Hz and J 12.8Hz, CHBNHCH2Ph), 3.60 (2H, s, 
CH2NHCH2Ph), 3.70 (3H, s, OCH3), 4.81 and 5.15 (2H, 2xd, J 10.0Hz, OCH2Ph), 
5.59 (1H, d, J 2.8Hz, CHOH) and 7.27-7.57 (12H, series of multiplets, ArH); δC (100 
MHz; CDCl3) 46.3 (CH2NHCH2Ph), 47.7 (CHCO2CH3), 52.1 (OCH3), 54.2 
(CH2NH2CH2Ph), 72.1 (CHOH), 75.2 (OCH2Ph), 117.9, 118.3, 127.6, 128.3, 128.48, 
128.54, 128.6, 128.7, 130.0, 134.8, 136.1, 138.2, 140.6 and 151.3 (Ar-C) and 173.1 
(C=O); m/z 562 [M+(79Br2), 1.2%] and 91 (100).  
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3.2.3.2.   Conjugate addition reactions with piperidine 
 
Methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2-(piperidinomethyl)propanoate 148a 
 
A mixture of methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2-methylenepropanoate 140a 
(0.56g, 2mmol) and piperidine (0.50ml) in THF (5ml) was stirred in a stoppered 
reaction flask for 3 days. Excess piperidine was evaporated in vacuo to give a yellow 
oil (0.77g), which was purified by preparative layer chromatography [elution with 
CHCl3-EtOAc (3:1)] to afford methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2-
(piperidinomethyl)propanoate 148a (0.61g, 80%) as pale yellow crystals, m.p. 102-
104oC (Found: M+, 383.21036. C23H29NO4 requires M, 383.20966); γmax (KBr)/CM-1 
3145 (OH) and  1722 (C=O); δH (400 MHz; CDCl3) 1.43 (2H, m, CH2CH2CH2N), 
1.58 (4H, m, CH2CH2N), 2.41 and 2.51 (4H, 2x br s, CH2CH2N), 2.69 (1H, d, J 
9.2Hz, CHANHCH2Ph), 3.00 (1H, t, J 11.2Hz, CHCH2NH ), 3.26 (1H, m, 
CHBNHCH2Ph), 3.40 (3H, s, OCH3), 5.05 and 5.10 (2H, 2xd, J 12.0Hz, OCH2Ph), 
5.38 (1H, d, J 8.0Hz, CHOH), 6.90 (1H, d, J 8.4Hz, ArH), 6.94 (1H, t, J 7.2Hz, ArH) 
and 7.18-7.37 (7H, series of multiplets, ArH); δC (100 MHz; CDCl3) 23.9, 25.8 and 
54.8 (CH2CH2CH2N), 47.3 (CHCO2CH3), 51.5 (OCH3), 60.0 (CH2NCH2), 70.3 
(OCH2Ph), 72.9 (CHOH), 112.1, 121.0, 127.3, 127.7, 128.41, 128.43, 128.7, 130.7, 
137.2 and 155.9 (Ar-C) and 172.6 ( C=O); m/z 383 (M+, 1.0%) and 91 (100).  
 
Methyl 3-(2-benzyloxy-3-methoxyphenyl)-3-hydroxy-2(piperidinomethyl)propa-
noate 148b 
 
The procedure described for the synthesis of methyl 3-(2-benzyloxyphenyl)-3-
hydroxy-2-(piperidinomethyl)propanoate 148a was followed, using 3-(2-benzyloxy-3-
methoxyphenyl)-3-hydroxy-2-methylenepropanoate 140b (0.66g, 2mmol) and 
piperidine (0.50ml) in THF (5ml). Work-up and chromatography afforded, as a pale 
yellow oil, methyl 3-(2-benzyloxy-3-methoxyphenyl)-3-hydroxy-2-(piperidinomethyl)-
propanoate 148b (0.46g, 55%) (Found: M+, 413.22071. C24H31NO5 requires M, 
413.22022); γmax (thin film)/cm-1 3366 (OH) and 1732 (C=O); δH (400 MHz; CDCl3) 
1.42 (2H, m, CH2CH2CH2N), 1.57 (4H, m, CH2CH2N), 2.37 and 2.53 (4H, 2x br s,  
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CH2CH2N), 2.64 (1H, d, J 12Hz, CHCHANCH2), 2.96 (1H, t, J 10.8, CHCHBNCH2), 
3.21 (1H, m, CHCO2CH3), 3.40 and 3.88 (6H, 2xs, OCH3), 4.97 and 5.13 (2H, 2xd, J 
10.8Hz, OCH2Ph), 5.31 (1H, d, J 8.4Hz, CHOH), 6.85 (1H, dd, J 7.2Hz and J 7.2Hz, 
Ar-H), 7.02-7.38 (5H, series of multiplets, Ar-H) and 7.52 (2H, d, J 7.2Hz, Ar-H); δC 
(100 MHz; CDCl3) 23.9, 25.9 and 54.7 (CH2CH2CH2N), 47.5 (CHCO2CH3), 51.5 and 
55.8 (2xOCH3), 60.4 (CHCH2N), 73.3 (CHOH), 74.8 (OCH2Ph), 111.8, 120.2, 124.0, 
127.6, 127.9, 128.2, 136.0, 138.2, 145.7 and 152.7 (Ar-C) and 172.4 ( C=O); m/z 413 
(M+, 1.3%) and 99 (100).  
 
Methyl 3-(2-benzyloxy-3-ethoxyphenyl)-3-hydroxy-2-(piperidinomethyl)prop -
anoate 148c 
 
The procedure described for the synthesis of methyl 3-(2-benzyloxyphenyl)-3-
hydroxy-2-(piperidinomethyl)propanoate 148a was followed, using 3-(2-benzyloxy-3-
ethoxyphenyl)-3-hydroxy-2-methylenepropanoate 140c (0.69g, 2mmol) and 
piperidine (0.50ml) in THF (5ml). Work-up and chromatography afforded, as a pale 
yellow oil, methyl 3-(2-benzyloxy-3-ethoxyphenyl)-3-hydroxy-2-(piperidinomethyl)- 
propanoate 148c (0.50g , 58%) (Found: M+, 427.23545. C25H33NO5 requires M, 
427.23587); γmax (thin film)/cm-1 3419 (OH) and 1731 (C=O); δH (400 MHz; CDCl3) 
1.47 (5H, overlapping signals, OCH2CH3 and CH2CH2CH2N), 1.54 (4H, m, 
CH2CH2CH2N), 2.37 (2H, br s, CH2CH2CH2N), 2.53 (2H, m, CH2CH2NCH2), 2.64 
and 2.99 (2H, dd, J 3.6Hz and J 9.6Hz, CHCH2N), 3.21 (1H, m, CHCO2CH3), 3.40 
(3H, s, OCH3), 4.06 (2H, q, J 7.2Hz, OCH2CH3), 4.98 and 5.13 (2H, 2xd, J 10.8Hz, 
OCH2Ph), 5.30 (1H, d, J 8.0Hz, CHOH) and 6.84-7.53 (8H, series of multiplets, Ar-
H); δC (100 MHz; CDCl3) 15.0 (OCH2CH3), 23.9, 25.9 and 54.7 (CH2CH2CH2N), 
47.4 (CHCO2CH3), 51.5 (OCH3), 60.3 (CH2N), 64.2 (OCH2CH3), 73.4 (CHOH), 74.8 
(OCH2Ph), 113.0, 120.1, 123.9, 127.6, 128.1, 128.2, 136.1, 138.3, 146.0 and 152.0 
(Ar-C) and 172.5 ( C=O); m/z 427 (M+, 1.2%) and 99 (100).  
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Methyl 3-(2-benzyloxy-5-chlorophenyl)-3-hydroxy-2-(piperidinomethyl)propan -
oate 148d 
 
The procedure described for the synthesis of methyl 3-(2-benzyloxyphenyl)-3-
hydroxy-2-(piperidinomethyl)propanoate 148a was followed, using 3-(2-benzyloxy-5-
chlorophenyl)-3-hydroxy-2-methylenepropanoate 140d (0.67g, 2mmol) and piperid- 
ine (0.50ml) in THF (5ml). Work-up and chromatography afforded, as a pale yellow 
oil, methyl 3-(2-benzyloxy-5-chlorophenyl)-3-hydroxy-2-(piperidinomethyl)propan- 
oate 148d (0,67g, 63%) (Found: M+, 417.17090. C23H28NO435Cl requires M, 
417.17069); γmax (thin film)/cm-1 3347 (OH) and 1714 (C=O); δH (400 MHz; CDCl3) 
1.43 (2H, m, CH2CH2CH2N), 1.58 (4H, m, CH2CH2N), 2.40 and 2.52 (4H, 2x br s, 
CH2CH2N), 2.64 and 2.99 (2H, 2xdd, J 12.8Hz and J 12.6Hz, CHCH2N), 3.11 (1H, 
m, CHCO2CH3), 3.42 (3H, s, OCH3), 5.04 (2H, 2x d, J 11.8Hz , OCH2Ph), 5.41 (1H, 
d, J 7.6Hz, CHOH), 6.81(1H, d, J 8.8Hz, Ar-H) and 7.13-7.46 (7H, series of 
multiplets, Ar-H); δC (100 MHz; CDCl3) 23.9, 25.9 and 54.8 (CH2CH2CH2N), 47.3 
(CHCO2CH3), 51.5 (OCH3), 59.9 (CHCH2N), 70.5 (OCH2Ph), 71.9 (CHOH), 113.2, 
126.1, 127.2, 127.9, 128.2, 128.4, 128.5, 132.8, 136.7 and 154.3 (Ar-C) and 172.2 ( 
C=O); m/z 417 [M+(Cl35), 1.2%] and 98 (100). 
 
Methyl 3-(2-benzyloxy-5-bromophenyl)-3-hydroxy-2-(piperidinomethyl)propan- 
oate 148e 
 
The procedure described for the synthesis of methyl 3-(2-benzyloxyphenyl)-3-
hydroxy-2-(piperidinomethyl)propanoate 148a was followed, using methyl 3-(2-
benzyloxy-5-bromophenyl)-3-hydroxy-2-methylenepropanoate 140e (0.75g,2mmol) 
and piperidine (0.50ml) in THF (5ml). Work-up and chromatography afforded, as a 
pale yellow oil, methyl 3-(2-benzyloxy-5-bromophenyl)-3-hydroxy-2-(piperidino- 
methyl) propanoate 148e (0.60g, 62%) (Found: M+, 461.12015. C23H28NO479Br 
requires M, 461.12017); γmax (thin film)/cm-1 3419 (OH) and 1732 (C=O); δH (400 
MHz; CDCl3) 1.43 (2H, m, CH2CH2CH2N), 1.57 (4H, m, CH2CH2N), 2.39-2.51 (4H, 
2x br s, CH2CH2N), 2.64 (1H, m, CHCHAN), 2.99 (1H, t, J 10.8Hz, CHCHBN), 3.10 
(1H, m, CHCO2CH3), 3.42 (3H, s, OCH3), 5.03 (2H, 2xd, J 11.8Hz, OCH2Ph),  5.41 
(1H, d, J 7.6Hz, CHOH), 6.75 (1H, d, J 8.4Hz, Ar-H), 7.27-7.42 (6H,  
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series of overlapping signals, Ar-H) and 7.53 (1H, s, Ar-H); δC (100 MHz; CDCl3) 
23.9, 25.8 and 54.7 (CH2CH2CH2N), 47.3 (CHCO2CH3), 51.5 (OCH3), 59.8 
(CHCH2N), 70.4 (OCH2Ph), 71.8 (CHOH), 113.4, 113.6, 127.1, 127.9, 128.5, 131.15, 
131.17, 133.2, 136.6 and 154.7 (Ar-C) and 172.1 (C=O); m/z 461 [M+(79Br), 3.4%] 
and 99 (100).  
 
Methyl 3-(2-benzyloxy-3,5-dibromophenyl)-3-hydroxy-2-(piperidinomethyl)- 
propanoate 148f 
 
The procedure described for the synthesis of methyl 3-(2-benzyloxyphenyl)-3-
hydroxy-2-(piperidinomethyl)propanoate 148a was followed, using 3-(2-benzyloxy-
3,5-dibromophenyl)-3-hydroxy-2-methylenepropanoate 140f (0.91g, 2mmol) and 
piperidine (0.50ml) in THF (5ml). Work-up and chromatography afforded, as a pale 
yellow oil, methyl 3-(2-benzyloxy-3,5-dibromophenyl)-3-hydroxy-2-(piperidino- 
methyl)propanoate 148f (0.73g, 65%) (Found: M+, 539.02614. C23H27NO479Br2 
requires M, 539.03068); γmax (thin film)/cm-1 3412 (OH) and 1732 (C=O); δH (400 
MHz; CDCl3) 1.44 (2H, m, CH2CH2CH2N), 1.56 (4H, m, CH2CH2N), 2.38 and 2.56 
(4H, 2x br s, CH2CH2N), 2.63 (1H, d, J 10.8Hz, CHCHAN), 3.02 (2H, series of 
multiplets, CHCHBN and CHCO2CH3), 3.42 (3H, s, OCH3), 4.91 and 5.12 (2H, 2xd, J 
10.4Hz, OCH2Ph), 5.24 (1H, d, J 8.0Hz, CHOH), 7.33-7.53 (5H, series of multiplets, 
Ar-H), 7.59 (1H, d, J 2.0Hz, Ar-H) and 7.65 (1H, d, J 2.4Hz, Ar-H); δC (100 MHz; 
CDCl3) 23.8, 25.8 and 54.8 (CH2CH2CH2N), 47.3 (CHCO2CH3), 51.8 (OCH3), 60.4 
(CHCH2N), 73.1 (CHOH), 75.5 (OCH2Ph), 117.6, 118.4, 127.9, 128.1, 128.4, 130.9, 
135.1, 136.9, 139.6 and 152.8 (Ar-C) and 171.5 ( C=O); m/z 539 [M+(79Br2), 0.4%] 
and 99 (100). 
 
 
 
 
 
 
 
 
 
 
 
 141 
 
 
 
Experimental 
 
 
3.2.4.   Synthesis of coumarins via conjugate addition  products          
 
3-(Benzylaminomethyl)coumarin 149a 
 
A mixture of methyl 2-(benzylaminomethyl)-3-(2-benzyloxyphenyl)-3-hydroxy-
propanoate 147a (490mg, 1.21mmol) and pre-equilibriated 10% Pd-C catalyst (84mg) 
in 95% EtOH (6.7ml) was hydrogenated at room temperature and atmospheric 
pressure. Hydrogen absorption ceased after the uptake of one equivalent of hydrogen. 
The mixture was filtered and the solvent removed in vacuo to give the crude mixture 
(360mg), as a pale yellow oil, which was purified using preparative layer  
chromatography [elution with CHCl3-EtOAc (3:1)] to afford,  as a pale yellow solid, 
3-(benzylaminomethyl)coumarin 149a (170mg, 53%), m.p. 70-74oC (Found: M+, 
265.10796. C17H15O2N requires M, 265.11028); γmax (KBr)/cm-1 3323 (N-H) and  
1713 (C=O); δH (400 MHz; CDCl3) 1.98 (1H, br s, NH), 3.76 (2H, d, J 1.2Hz, 1’-
CH2), 3.86 (2H, s, CH2Ph), 7.23-7.51 (9H, series of overlapping signals, Ar-H) and 
7.72 (1H, s, 4-H);† δC (100 MHz; CDCl3) 48.3 and 53.2 (2xCH2), 116.4, 119.2, 124.3, 
127.0, 127.4, 127.5, 128.1, 128.4, 130.9, 139.1, 139.7 and 153.1 (ArC) and 161.4 
(C=O); m/z 265 (M+, 0.9%) and 174 (100). 
 
3-(Benzylaminomethyl)-8-methoxycoumarin  149b 
 
The procedure described for the synthesis of 3-(benzylaminomethyl)coumarin 149a 
was followed, using methyl 2-(benzylaminomethyl)-3-(2-benzyloxy-3-methoxy-
phenyl)-3-hydroxypropanoate 147b (550mg, 1.26mmol) and pre-equilibriated 10% 
Pd-C catalyst (84mg) in absolute EtOH (6.7ml). Work-up and chromatography  
afforded, as a pale yellow oil, 3-(benzylaminomethyl)-8-methoxycoumarin 149b 
(0.19g, 51%) (Found: M+, 295.11855. C18H17O3N requires M, 295.12084); γmax 
(KBr)/cm-1 3394 (N-H) and 1714 (C=O); δH (400 MHz; CDCl3) 1.88 (1H, br s, NH), 
3.76 ( 2H, d, J 1.2Hz, 1’-CH2), 3.84 (2H, s, CH2Ph), 3.95 (3H, s, OCH3), 7.04 (2H, d,  
J 8.0Hz, Ar-H), 7.17-7.36 (6H, series of multiplets, Ar-H) and 7.69 (1H, s, 4-H);† 
 
 
†coupling to the 1’CH2 group is evident in the COSY spectrum. 
 142 
 
 
 
Experimental 
 
 
δC (100 MHz; CDCl3) 48.4 and 53.2 (2xCH2), 56.3 (OCH3), 113.0, 119.1, 120.0, 
124.3, 127.1, 127.7, 128.2, 128.5, 139.3, 139.7, 142.9 and 147.1 (Ar-C) and  160.9 
(C=O); m/z (FAB) 296 (MH+, 100%). 
 
3-(Benzylaminomethyl)-8-ethoxycoumarin  149c 
 
The procedure described for the synthesis of 3-(benzylaminomethyl)coumarin 149a 
was followed, using methyl 2-(benzylaminomethyl)-3-(2-benzyloxy-3-ethoxy-
phenyl)-3-hydroxypropanoate 147c (550mg, 1.22mmol) and pre-equilibriated 10% 
Pd-C catalyst (84mg) in absolute EtOH (6.7ml). Work-up and chromatography 
afforded, as a pale yellow solid  3-(benzylaminomethyl)-8-ethoxycoumarin 149c 
(250mg, 66%), m.p. 98-102oC (Found: M+, 309.13649. C19H19NO3 requires M, 
309.13649); γmax(KBr)/cm-1 3300 (N-H) and 1712 (C=O); δH (400MHz; CDCl3) 1.49 
(3H, t, J 6.8Hz, OCH2CH3), 2.00 (1H, br s, NH), 3.76 (2H, d, J 0.8Hz, 1’-CH2), 3.84 
(2H, s, CH2Ph), 4.20 (2H, q, J 6.8Hz, OCH2CH3), 7.01-7.36 (8H, series of multiplets, 
Ar-H) and 7.68 (1H, d, J 0.8Hz, 4-H);† δC (100 MHz; CDCl3) 14.7 (OCH2CH3), 48.4 
and 53.2 (2xCH2N), 64.9 (OCH2CH3), 114.3, 119.0, 120.0, 124.2, 127.0, 127.5, 
128.1, 128.4, 139.3, 139.8, 143.1 and 146.4 (Ar-C) and 161.0 (C=O); m/z (FAB) 310 
(MH+, 100%). 
 
3-(Benzylaminomethyl)-6-chlorocoumarin   149d 
 
The procedure described for the synthesis of 3-(benzylaminomethyl)coumarin 149a 
was followed, using methyl 2-(benzylaminomethyl)-3-(2-benzyloxy-5-chloro-
phenyl)-3-hydroxypropanoate 147d (540mg, 1.23mmol) and pre-equilibriated 10% 
Pd-C catalyst (84mg) in absolute EtOH (6.7ml). Work-up and chromatography 
afforded, as a yellow solid, 3-(benzylaminomethyl)-6-chlorocoumarin 149d (180mg, 
49%), m.p. 106-110oC (Found: M+, 298.06348. C17H13O3NCl35 requires M-1, 
298.06348); γmax (KBr)/cm-1 3322 (N-H) and 1719 (C=O); δH (400 MHz; CDCl3) 1.82 
(1H, br s, NH), 3.75 (2H, d, J 0.6Hz, 1’-CH2), 3.85 (2H, s, CH2Ph), 7.23-7.45 (8H, 
series of multiplets, Ar-H) and 7.69 (1H, s, 4-H);†  δC (100 MHz; CDCl3) 48.1 and  
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53.7 (2xCH2N), 117.8, 120.3, 126.7, 127.1, 128.0, 128.4, 128.8, 129.5, 130.8, 137.7, 
139.6 and 151.4 (Ar-C) and 160.7 (C=O); m/z 298 [MH+ (Cl35), 96.1%] and 91 (100). 
  
3-(Piperidinomethyl)coumarin  150a and 3-methylcoumarin 151a  
 
A mixture of methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2-(piperidinomethyl)-
propanoate 148a (466mg, 1.22mmol)  and pre-equilibriated 10% Pd-C catalyst 
(84mg) in absolute EtOH (6.7ml) was hydrogenated at room temperature and 
atmospheric pressure for 6h. The resulting mixture was filtered and the solvent 
removed in vacuo to give a pale yellow oil (380mg), which was purified by 
preparative layer  chromatography [elution with CHCl3-EtOAc (3:1)] to afford the 
following two products:- 
i)   3-(piperidinomethyl)coumarin 150a, as a brown solid (150mg, 51%), m.p.  66-
68oC (Found: M+, 243.12588. C15H17O2N requires M, 243.12593); γmax (KBr)/ cm-1  
1723 (C=O); δH (400 MHz; CDCl3) 1.46 (2H, m, CH2CH2CH2N), 1.59 (4H, m, 
CH2CH2N), 2.48 (4H, br s, CH2CH2N), 3.42 (2H, d, J 0.4Hz, 1’-CH2), 7.23-7.49 (4H, 
series of multiplets, ArH) and 7.78 (1H, s, 4-H); δC (100 MHz; CDCl3) 24.1, 25.9 and 
54.7 (CH2CH2CH2N), 56.9 (1’-CH2), 116.3, 119.3, 124.2, 126.0, 127.5, 130.7, 139.4 
and 152.9 (Ar-C) and 161.6 (C=O); m/z 243 (M+, 62.9%) and 200 (100); and  
 ii)  3-methylcoumarin 151a, as a pale yellow solid (40mg, 20%), m.p. 92-94oC 
(lit.,210 90-92oC) (Found: M+, 160.05272. C10H8O2 requires: M, 160.05243); γmax 
(KBr)/cm-1 1707 (C=O); δH (400 MHz; CDCl3) 2.22 (3H, s, CH3), 7.23-7.48 (4H, 
multiplets, Ar-H) and 7.52 (1H, s, 4-H); δC (100 MHz; CDCl3) 17.1 (CH3), 116.4, 
119.5, 124.2, 125.7, 126.9, 130.4, 139.2, 153.2 and 162.2 (Ar-C); m/z 160 (M+, 
82.1%) and 131(100). 
 
8-Methoxy-3-(piperidinomethyl)coumarin 150b and 8-methoxy-3-methyl 
coumarin 151b   
 
The procedure described for the synthesis of 3-(piperidinomethyl)coumarin 150a and 
3-methylcoumarin 151a was followed, using methyl 3-(2-benzyloxy-3-methoxy- 
phenyl)-3-hydroxy-2-(piperidinomethyl)propanoate 148b (503mg, 1.22mmol) and  
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pre-equilibriated 10% Pd-C catalyst (84mg) in absolute EtOH (6.7ml). Work-up and 
chromatography afforded:-  
 
i)   8-methoxy-3-(piperidinomethyl)coumarin 150b, as a pale yellow oil  (150mg, 
45%) (Found: M+, 273.13684. C16H19O3N requires M, 273.13649); γmax (thin 
film)/cm-1 1714 (C=O); δH (400 MHz; CDCl3) 1.45 (2H, m, CH2CH2CH2N), 1.60 
(4H, m, CH2CH2N), 2.47 (4H, t. J 7.2Hz, CH2CH2N), 3.42 (2H, d, J 1.6Hz, 1’-CH2), 
3.93 (3H, s, OCH3), 7.02 (1H, d, J 8.8Hz, ArH), 7.06 (1H, d, J 7.6Hz, ArH), 7.18 (1H, 
t, J 7.8Hz, ArH) and 7.77 (1H, s, 4-H); δC (100 MHz; CDCl3) 24.1, 26.0 and 54.7 
(CH2CH2CH2N), 56.2 (OCH3), 56.9 (1’-CH2), 112.7, 119.1, 120.1, 124.1, 126.3, 
139.7, 142.7 and 147.0 (Ar-C) and 161.1 (C=O); m/z 273 (M+, 91.2%) and 230 (100); 
and  
ii)   8-methoxy-3-methylcoumarin 151b, as a grey solid (22mg, 9.5%), m.p. 68- 72oC 
(Found: M+, 190.06299. C11H10O3 requires M, 190.06299); γmax (KBr)/cm-1 1716 
(C=O); δH (400 MHz; CDCl3) 2.20 (3H, s, CH3), 3.94 (3H, s, OCH3), 7.01 (2H, t, J 
8.4Hz, ArH), 7.18 (1H, t, J 8.0Hz, ArH) and 7.48 (1H, s, 4-H); δC (100 MHz; CDCl3) 
17.2 (CH3), 56.2 (OCH3), 112.4, 118.4, 120.2, 124.1, 126.1, 139.3, 142.9 and 147.0 
(ArC) and 161.6 (C=O); m/z 190 (M+, 100%). 
 
8-Ethoxy-3-(piperidinomethyl)coumarin 150c and 8-ethoxy-3-methylcoumarin 
151c 
 
The procedure described for the synthesis of 3-(piperidinomethyl)coumarin 150a and 
3-methylcoumarin 151a was followed, using methyl 3-(2-benzyloxy-3-ethoxyphenyl)-
3-hydroxy-2-(piperidinomethyl)propanoate 148c (520mg, 1.22 mmol) and pre-
equilibriated 10% Pd-C catalyst (84mg) in absolute EtOH (6.7ml). Work-up and 
chromatography afforded:-  
i)   8-ethoxy-3-(piperidinomethyl)coumarin 150c, as a pale yellow oil (170mg, 49%) 
(Found: M+, 287.15293. C17H21O3N requires M, 287.15214); γmax (thin film)/cm-1 
1731 (C=O); δH (400 MHz; CDCl3) 1.47 (5H, m, OCH2CH3 and CH2CH2CH2N), 1.62 
(4H, m, CH2CH2N), 2.49 (4H, t, J 4.8Hz, CH2CH2N), 3.45 ( 2H, s, 1’-CH2), 4.17 (2H, 
q, J 7.0Hz, OCH2CH3), 7.02 and 7.05 (2H, 2x d, J 8Hz and J 7.6Hz, ArH), 7.17 (1H,  
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t, J 8Hz, ArH) and 7.77 (1H, s, 4-H); δC (100 MHz, CDCl3) 14.8 (OCH2CH3), 24.2, 
26.0 and 54.7 (CH2CH2CH2N), 56.9 (1’-CH2), 65.0 (OCH2CH3), 114.3, 119.1, 120.3,  
124.1, 126.3, 139.8, 143.1 and 146.4 (Ar-C) and 161.3 (C=O); m/z 287 (74.4%) and 
176 (100); and  
ii)   8-ethoxy-3-methylcoumarin 151c, as a pale yellow oil (35mg, 14%) (Found: M+, 
204.07884. C12H12O3 requires M, 204.07864); γmax (thin film)/cm-1 1714 (C=O); δH 
(400 MHz; CDCl3) 1.47 (3H, t, J 7.0Hz, CH2CH3), 2.19 (3H, d, J 1.2Hz, 3-CH3), 4.16 
(2H, q, J 6.8Hz, OCH2CH3), 6.95 and 6.98 (2H, 2xdd, J 1.2Hz and J 8.0Hz, ArH),  
7.15 (1H, t, J 8.0Hz, ArH) and 7.47 (1H, d, J 1.2Hz, ArH); δC (100 MHz; CDCl3) 14.7 
(OCH2CH3), 17.1 (3-CH3), 64.8 (OCH2CH3), 113.7, 118.4, 120.3, 124.0, 125.9, 
139.4, 143.1 and 146.3 (Ar-C) and 161.8 (C=O); m/z 204 (M+, 59.1%) and 176 (100 ). 
 
6-Chloro-3-(piperidinomethyl)coumarin 150d and 6-chloro-3-methylcoumarin 
151d   
 
The procedure described for the synthesis of 3-(piperidinomethyl)coumarin 150a and 
3-methylcoumarin 151a was followed, using methyl 3-(2-benzyloxy-5-chlorophenyl)-
3-hydroxy-2-(piperidinomethyl)propanoate 148d (508mg, 1.22mmol) and pre-
equilibriated 10% Pd-C catalyst (84mg) in absolute EtOH (6.7ml). Work-up and 
chromatography afforded:-  
i)  6-chloro-3-(piperidinomethyl)coumarin 150d, as a pale yellow solid (205mg, 
61%), m.p. 116-118oC (Found: M+, 277.08708. C15H16O2N35Cl requires M, 
277.08696); γmax(KBr)/cm-1 1724 (C=O); δH (400 MHz; CDCl3) 1.47 (2H, m, 
CH2CH2CH2N), 1.63 (4H, m, CH2CH2N), 2.48 (4H, t, J 4.8Hz, CH2CH2N), 3.42 (2H, 
d, J 1.6Hz, 1’-CH2), 7.26 (1H, t, J 4.6Hz, ArH), 7.40 and 7.42 (1H, 2x d, J 2.4 Hz and 
J 2.8Hz, ArH), 7.48 (1H, d, J 2.4Hz, ArH) and 7.72 (1H, s, 4-H); δC (100 MHz; 
CDCl3) 24.2, 26.1 and 54.8 (CH2CH2CH2N), 57.0 (1’-CH2), 117.8, 120.6, 126.9, 
127.8, 129.5, 130.7, 138.0 and 151.4 (ArC) and 161.0 (C=O); m/z 277 [M+ (35Cl), 
52.3%) and 234 (100); and  
ii)   6-chloro-3-methylcoumarin 151d, as a pale yellow solid (22mg, 9%), m.p. 70-
72oC (lit.,210 158-160oC) (Found: M+, 194.01329. Calc. for C10H7O235Cl  M, 
194.01346); γmax (KBr)/cm-1 1707 (C=O); δH (400 MHz; CDCl3) 2.21 (3H, s, CH3)  
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and  7.22-7.42 (4H, series of multiplets, Ar-H); δC (100 MHz; CDCl3) 17.3 (CH3), 
117.9, 120.6, 126.2, 127.3, 126.5, 130.4, 137.9 and 151.6 (Ar-C) and 161.6 (C=O); 
m/z 194 [M+ (35Cl), 100%]. 
 
 
Investigation of the preparation of 3-methylcoumarin 151a from 3-(piperidino- 
methyl)coumarin 150a 
 
Method 1 
 
A solution of 3-(piperidinomethyl)coumarin 150a (20mg, 0.08mmol) in CD3OD 
(0.5ml) in an NMR tube was examined regularly by 1H NMR analysis over a period 
of 43 days, with no evidence of the formation of the 3-methylcoumarin.. Evaporation 
of the solvent afforded a crude product, which was purified by preparative layer 
chromatography [elution with CHCl3-EtOAc (3:1)] to give the starting material, 3-
(piperidinomethyl)coumarin 150a. 
 
Method 2 
 
Conc. HCl (1drop) was added to a solution of 3-(piperidinomethyl)coumarin 150a 
(20mg, 0.08mmol) in CD3OD (0.5ml) in an NMR tube and the solution was analysed 
regularly for several days by 1H NMR spectroscopy, with no evidence of the 
formation of 3-methylcoumarin 151a. Evaporation of the solvent afforded a crude 
product, which was purified by preparative layer chromatography [elution with 
CHCl3-EtOAc (3:1)] to give the starting material, 3-(piperidinomethyl)coumarin 
150a. 
 
Method 3 
 
To a mixture of 3-(piperidinomethyl)coumarin 150a (260mg, 0.5mmol), formic acid 
(0.12ml) and Et3N (0.6ml) was added pre-equilibriated 10% Pd-C catalyst (1.2mg), 
and the resulting mixture was stirred under a reflux condenser for 72h at 25oC. The 
mixture was filtered and the solvent removed in vacuo to give a crude product 
(70mg), which was purified by preparative layer chromatography [elution with 
CHCl3-EtOAc (3:1)] to afford the starting material, 3-(piperidinomethyl)coumarin 
150a. 
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Method 4 
 
A mixture of 3-(piperidinomethyl)coumarin 150a (150mg, 0.61mmol) and pre-
equilibriated 10% Pd-C catalyst (42mg) in absolute EtOH (4ml) was hydrogenated at 
room temperature and atmospheric pressure for 6h. The resulting mixture was filtered 
and the solvent removed in vacuo to give 3-methylcoumarin 151a (90mg, 92%), as a 
pale yellow solid.  
 
3.2.5.  Miscellaneous reactions   
 
6-Bromo-3-methylcoumarin 151e 
 
The procedure (method 1) described for the synthesis of 3-(iodomethyl)coumarin 
155a was followed, using conc. HI (10ml)  and methyl 3-(2-benzyloxy-5-
bromophenyl)-3-hydroxy-2-methylenepropanoate 140e (0.46g, 1.0mmol) in a mixture 
of AcOH  (5ml) and Ac2O (5ml). Work-up afforded, as a yellow solid, 6-bromo-3-
methylcoumarin 150e (0.16g, 65%), m.p. 152-154oC (Found: M+, 237.96430. 
C10H70279Br require M, 237.96294); γmax (KBr)/cm-1 1728 (C=O); δH (400 MHz; 
CDCl3)  2.21 (3H, d, J 1.2Hz, CH3), 7.19 (1H, dd, J 2.2Hz and J 7.2Hz, Ar-H), 7.42 
(1H, d, J 0.8Hz, Ar-H) and 7.53 (2H, dd, J 2.4Hz and J 2.0Hz, Ar-H); δC (100 MHz; 
CDCl3) 17.2 (CH3), 116.8, 118.17, 118.2, 121.1, 127.3, 129.2, 133.2, 137.7 (Ar-C) 
and 152.1 (C=O); m/z 238 [M+(79Br), 0.3%] and 92 (100). 
 
Methyl 3-(2-benzyloxyphenyl)-2-methylpropenoate 152  
 
A solution of methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2-methylenepropanoate 140a 
(0.30g, 1mmol ) in ethanol (4ml) was stirred under N2, in a two-necked round -
bottomed flask, immersed in a water bath at 25oC. Pre-equilibrated 10% Pd/ C catalyst 
(84mg) was then added, followed by 1,4–cyclohexadiene (0.94ml, 10mmol). The 
mixture boiled under reflux for 2h and then filtered through celite. The solid residue 
was washed with ethanol (ca 5ml), and the filtrate and the washings were combined 
and evaporated in vacuo to afford a crude residue (0.25g), which was purified using 
preparative layer chromatography [elution with hexane-EtOAc (3:1)] to afford, as a  
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yellow oil, methyl 3-(2-benzyloxyphenyl)-2-methylpropenoate 152 (50mg, 18%) 
(Found: M+, 282.12610. C18H18O3 requires M,  282.12559); γmax (thin film)/cm-1 1711 
(C=O); δH (400 MHz; CDCl3) 2.08/2.12‡(3H, 2xd, J 1.6Hz and J 1.6Hz, CH3C=C), 
3.59/3.82‡(3H, 2xs, OCH3), 5.10/5.14‡ (2H, 2xs, OCH2Ph), 6.90-7.44 (9H, series of 
multiplets, Ar-H ) and 7.95 (1H, br s, Ar-H); δC (100 MHz; CDCl3) 14.2/21.3‡ (CH3), 
51.3/51.9†(OCH3), 70.2 (OCH2Ph), 112.5, 120.5, 127.0, 127.8, 128.5, 129.0, 129.7, 
130.3, 131.5, 135.0, 136.9 and  156.7 (Ar-C) and 169.1 (C=O); m/z 282 (M+, 15%) 
and 92 (100). 
 
Methyl 3-(2-hydroxyphenyl)-2-methylpropanoate 153  
 
A mixture of methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2-methylenepropanoate 140a 
(0.36g, 1.2mmol) and pre-equilibriated 10% Pd-C catalyst (84mg) in absolute EtOH 
(6.7ml) was hydrogenated at room temperature and atmospheric pressure for 6h. The 
mixture was filtered and the solvent removed in vacuo to give a yellow oil (204mg), 
which was purified by flash chromatography [elution with hexane-EtOAc (3:1.5)], 
followed by extraction with acetone to afford, as a pale yellow oil, methyl 3-(2-
hydroxyphenyl)-2-methylpropanoate 153 (186mg, 80%) (Found: M+, 194.09567. 
C11H14O3 requires M, 194.09429); γmax (thin films)/cm-1 3396 (0H) and 1709 (C=O); 
δH (400 MHz; CDCl3) 1.26 (3H, d, J 7.2Hz, 2-CH3), 2.70 (1H, dd, J 4.8 and 13.6Hz, 
CHAH), 2.86 (1H, m, CHCH3), 3.01 (1H, dd, J 8.8 and J 13.6 Hz, CHBH), 3.65 (3H, s, 
OCH3), 6.84 (2H, m, ArH), 6.92 (1H, br s, ArOH) and 7.05-7.11 (2H, m, ArH); δC 
(100 MHz; CDCl3) 17.9 (CHCH3), 33.5 (CH2), 40.7 (CHCH3), 52.1 (OCH3), 116.8, 
120.5, 125.8, 127.9, 131.2, 154.2 (Ar-C) and 178.7 (C=O); m/z 194 (M+, 11.5%) and 
162 (100). 
 
 
 
 
 
‡  Chemical shift data reported in this format reflect the presence of geometric   
    isomers. 
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3-(Ethylsulfanylmethyl)coumarin 154 
 
To a solution of methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2-methylenepropanoate 
140a (0.22g, 0.72mmol) in EtSH (2ml) was added BF3.Et2O (1ml, 8mmol), and the 
resulting mixture was stirred at room temperature for 40min. The reaction mixture 
was then poured into water and extracted with diethyl ether. The combined organic 
fractions  were washed with satd. brine, dried (Na2SO4), filtered and concentrated in 
vacuo to afford an oil (0.54g), which was purified using preparative layer 
chromatography [elution with hexane-EtOAc (3:1)] to afford, as a yellow solid, 3-
(ethylsulfanylmethyl)coumarin 154 (15mg, 10%), m.p. 68-72oC (Found: M+, 
220.05715. C12H12O2S requires M, 220.05580); γmax (KBr)/cm-1 1720 (C=O); δH ( 400 
MHz; CDCl3) 1.29 (3H, t, J 7.4Hz, SCH2CH3), 2.58 ( 2H, q, J 7.4Hz, SCH2CH3), 3.66 
( 2H, s, CH2S), 7.27 ( 1H, d, J 7.6Hz, Ar-H), 7.33 (1H, d, J 8Hz, Ar-H), 7.48 (2H, t, J 
8.0 Hz, Ar-H) and 7.71 (1H, s, 4-H);  δC (100 MHz; CDCl3) 14.4 (SCH2CH3), 26.3 
and 30.8 (CH2SCH2CH3) 116.6, 119.2, 124.4, 126.4, 127.5, 131.2, 139.4, 153.3 (Ar-
C) and 161.0 (C=O); m/z (FAB) 220 (MH+, 37%) and 160 (100). 
 
 
 
3.2.5.    Synthesis of coumarins via acid-catalysed reactions of O-   
              benzylated Baylis-Hillman products 
 
3-(Iodomethyl)coumarin 155a 
 
Method 1 
 
Conc. HI (10ml) was added to a solution of methyl 3-(2-benzyloxyphenyl)-3-
hydroxy-2-methylenepropanoate 140a (0.31g, 1.0mmol) in a mixture of AcOH (5ml) 
and Ac2O (5ml). The mixture was boiled under reflux for 2h, allowed to cool to room 
temperature and then poured into ice-cooled water (10ml). Stirring for 30min (or 
more) gave a precipitate, which was filtered off and washed with hexane to afford, as 
a grey solid, 3-(iodomethyl)coumarin 155a (0.20g, 66%), m.p. 150-152oC (Found: 
M+, 286.9554. C10H802I requires M, 286.9569); γmax (KBr)/cm-1 1709 (C=O); δH (400  
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MHz; CDCl3) 4.34 (2H, s, CH2I), 7.22-7.52 (4H, series of doublets, Ar-H) and 7.81 
(1H, s, 4-H); δC (100 MHz; CDCl3) –1.6 (CH2I), 116.7, 119.1, 124.7, 127.2, 127.6, 
131.9, 140.4 and 153.5 (Ar-C) and 159.7 (C=O); m/z 287 (M+, 0.21%) and 159 (100).  
 
Method 2 
 
Conc. HI (2ml) was added to a solution of tert-butyl 3-hydroxy-3-(2-hydroxyphenyl)-
2-methylenepropanoate 146a (52mg, 0.21mmol) in a mixture of AcOH (1ml) and 
Ac2O (1ml). The mixture was boiled under reflux for 2h, allowed to cool to room 
temperature and then poured into ice-cooled water (5ml). Stirring for 30min (or more) 
gave a precipitate, which was filtered off and washed with hexane to afford, as a pink 
solid, 3-iodomethylcoumarin 155a (10mg, 17%). 
 
3-(Iodomethyl)-8-methoxycoumarin 155b 
 
The procedure (method 1) described for the synthesis of 3-(iodomethyl)coumarin 
155a was followed, using conc. HI (10ml) and methyl 3-(2-benzyloxy-3-
methoxyphenyl)-3-hydroxy-2-methylenepropanoate 140b (0.34g, 1.0mmol) in a 
mixture of AcOH (5ml) and Ac2O (5ml). Work-up afforded, as a light yellow solid, 3-
(iodomethyl)-8-methoxycoumarin 155b (0.20g, 62%), m.p. 184-186oC (Found: M+, 
315.95968. C11H903I requires M, 315.95965); γmax (KBr)/cm-1 1718 (C=O); δH (400 
MHz; CDCl3) 3.94 (3H, s, OCH3), 4.34 (2H, s, CH2I), 7.06 (2H, overlapping doublets, 
Ar-H), 7.18 (1H, t, J 8Hz, Ar-H) and 7.78 (1H, s, 4-H). δC (100 MHz; CDCl3) –1.7 
(CH21), 56.3 (OCH3), 113.8, 119.1, 119.8, 124.6, 127.6, 134.6, 140.6 and 143.0 (Ar-
C) and 159.2 (C=O); m/z 316 (M+, 0.1%) and 189 (100).  
 
8-Ethoxy-3-(iodomethyl)coumarin 155c 
 
The procedure (method 1) described for the synthesis of 3-(iodomethyl)coumarin 
155a was followed, using conc. HI (10ml) and methyl 3-(2-benzyloxy-3-
ethoxyphenyl)-3-hydroxy-2-methylenepropanoate 140c (0.35g, 1.0mmol) in a mixture 
of AcOH (5ml) and Ac2O (5ml). Work-up afforded, as a brown solid, 8-ethoxy-3-
(iodomethyl)coumarin 155c (0.21g, 61%), m.p. 120-122oC (Found: M+, 329.97490.  
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C12H1103I requires M, 329.97530); γmax (KBr)/cm-1 1714 (C=O); δH (400 MHz; 
CDCl3) 1.49 (3H, t, J 7.0Hz, CH3 ), 4.20 (2H, q, J 6.8Hz, OCH2CH3), 4.37 (2H, s, 
CH2I), 7.07 (2H, overlapping doublets, Ar-H), 7.18 (1H, t, J 7.8Hz, ArH) and 7.80 
(1H, s, 4-H); δC (100 MHz; CDCl3) –1.5 (CH2I), 14.7 (OCH2CH3), 65.0 (OCH2CH3), 
115.0, 119.1, 119.9, 124.6, 127.4, 140.7, 143.4 and 146.26 (Ar-C) and 159.4 (C=O); 
m/z 329 (M+, 0.2%) and 203 (100). 
 
6-Chloro-3-(iodomethyl)coumarin 155d 
 
The procedure (method 1) described for the synthesis of 3-(iodomethyl)coumarin 
155a was followed, using conc. HI (10ml) and methyl 3-(2-benzyloxy-5-
chlorophenyl)-3-hydroxy-2-methylenepropanoate 140d (0.34g, 1.0mmol) in a mixture 
of AcOH (5ml) and Ac2O (5ml). Work-up afforded, as a yellow solid, 6-chloro-3-
(iodomethyl)coumarin 155d (0.28g, 85%), m.p. 188-190oC (Found: (M+Na)+, 
342.8979. C10H602I35ClNa requires M+Na, 342.8998); γmax (KBr)/cm-1 1747 (C=O); 
δH (400 MHz; CDCl3) 4.35 (2H, s, CH2I), 7.29-7.48 (3H, series of multiplets, Ar-H) 
and 7.75 (1H, s, 4-H); δC (100 MHz; CDCl3) –2.3 (CH21), 118.2, 120.1, 126.9, 128.7, 
130.0, 131.7, 140.0, 151.9 and 159.1 (Ar-C and C=O); m/z 321 [M+(35Cl), 0.1%] and 
193 (100).    
 
6-Bromo-3-(iodomethyl)coumarin 155e 
 
The procedure (method 1) described for the synthesis of 3-(iodomethyl)coumarin 
155a was followed, using conc. HI (10ml) and methyl 3-(2-benzyloxy-5-
bromophenyl)-3-hydroxy-2-methylenepropanoate 140e (0.37g, 1.0mmol) in a mixture 
of AcOH (5ml) and Ac2O (5ml). Work-up afforded, as a grey solid, 6-bromo-3-
(iodomethyl)coumarin 155e (0.23g, 61%), m.p. 148-150oC (Found: M+, 364.86850. 
C10H702I79Br requires M, 364.86747); γmax (KBr)/cm-1 1722 (C=O); δH (400 MHz; 
CDCl3) 4.35 (2H, s, CH2I), 7.20-7.61 (3H, series of overlapping signals) and  7.74 
(1H, s, 4-H); δC (100 MHz; CDCl3) –2.4 (CH2I), 117.3, 118.5, 120.6, 128.6, 130.0, 
134.6, 138.9 and 152.3 (Ar-C) and 159.1 (C=O); m/z 365 [M+(35Cl), 0.3%] and 237 
(100).  
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6,8-Dibromo-3-iodomethylcoumarin  155f 
 
The procedure (method 1) described for the synthesis of 3-(iodomethyl)coumarin 
155a was followed, using conc. HI (10ml) and  methyl 3-(2-benzyloxy-3,5-
dibromophenyl)-3-hydroxy-2-methylenepropanoate 140f (0.47g, 1.0mmol) in a 
mixture of AcOH (5ml) and Ac2O (5ml). Work-up afforded, as a pink solid, 6,8-
dibromo-3-(iodomethyl)coumarin 155f (0.28g, 61%), m.p. 208-210oC (Found: M+, 
441.77080. C10H502I79Br2 requires M, 441.77010); γmax (KBr)/cm-1 1747 (C=O); δH 
(400 MHz; CDCl3) 4.36 (2H, s, CH2I), 7.56 (1H, d, J 2.0Hz, Ar-H), 7.70 (1H, s, Ar-
H) and  7.87 (1H, d, J 2.0Hz, Ar-H); δC (100 MHz; CDCl3) –3.1 (CH2I), 111.3, 117.2, 
121.4, 129.2, 129.5, 137.3, 138.5, 149.3 and 158.2 (Ar-C and C=O); m/z 441 
[M+(79Br2), 0.3%] and 305 (100).    
 
 
3-(Chloromethyl)coumarin 156a 
 
Method 1 
 
Conc. HCl (10ml) was added to a solution of methyl 3-(2-benzyloxyphenyl)-3-
hydroxy-2-methylenepropanoate 140a (0.31g, 1.03mmol) in AcOH (5ml) and Ac2O 
(5ml). The mixture was boiled under reflux for 2h, allowed to cool to room 
temperature and then poured into ice-cooled water (10ml). Stirring for 30min (or 
more) gave a precipitate, which was filtered off and washed with hexane to afford, as 
a purple solid, 3-(chloromethyl)coumarin 156a (0.16g, 80%), m.p. 108-110oC (Found: 
M+, 194.01346. C10H7O235Cl requires M, 194.01346); γmax (KBr)/cm-1 1713 (C=O); 
δH (400 MHz; CDCl3) 4.55 (2H, s, CH2Cl), 7.30-7.56 (4H, series of multiplets, ArH) 
and 7.88 (1H, s, 4-H); δC (100 MHz; CDCl3) 41.0 (CH2), 116.7, 118.8, 124.7, 125.0; 
128.1, 132.0, 141.1 and 153.5 (Ar-C) and 160.1 (C=O); m/z 194 (M+, 31.4%) and 159 
(100). 
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Method 2 
 
Conc. HCl (4ml) was added to a solution of tert-butyl 3-hydroxy-3-(2-
hydroxyphenyl)-2-methylenepropanoate 146a (0.51g, 2.1mmol) in AcOH (2ml). The 
mixture was boiled under reflux for 2h, allowed to cool to room temperature and then 
poured into ice-cooled water (10ml). Stirring for 30min (or more) gave a precipitate, 
which was filtered off and washed with hexane to afford, as a grey solid, 3-
(chloromethyl)coumarin 156a (0.39g, 98%). 
 
Method 3 
 
Conc. HCl (10ml) was added to a solution of 3-(2-benzyloxyphenyl)-3-hydroxy-2-
methylenepropanenitrile 144a (0.27g, 1.0mmol) in AcOH (5ml) and Ac2O (5ml). The 
mixture was boiled under reflux for ca 1h, allowed to cool to room temperature and 
then poured into ice-cooled water (10ml). Stirring for 30min (or more) gave a 
precipitate, which was filtered off and purified using preparative layer  
chromatography [elution CHCl3-hexane (3:1)] to afford the following two products:-  
i)    3-(chloromethyl)coumarin 156a (0.15g, 75%), as a pale yellow solid; and 
ii)  3-(acetoxymethyl)coumarin 157a (30mg, 14%), as a pale yellow solid, m.p. 106-
110oC (Found: M+, 218.05797. C12H10O4 requires M, 218.05791); δH (400 MHz; 
CDCl3) 2.15 (3H, s, CH3), 5.06 (2H, s, CH2OAc), 7.29 (1H, d, J 7.6Hz, Ar-H), 7.33 
(1H, d, J 8.4Hz, Ar-H), 7.54 (2H, series of multiplets, Ar-H) and 7.74 (1H, s, 4-H); δC 
(100 MHz; CDCl3) 20.9 (CH3), 61.2 (CH2), 116.7, 118.7, 123.6, 124.7, 128.0, 131.8, 
140.7 and 153.5 (Ar-C) and 160.3 and 170.5 (2x C=O); m/z 218 (M+, 2%) and 175 
(100). 
 
3-(Chloromethyl)-8-methoxycoumarin 156b 
 
Method 1 
 
The procedure (method 1) described for the synthesis of  3-(chloromethyl)coumarin 
156a was followed, using conc. HCl (10ml) and a the solution of 3-(2-benzyloxy-3-
methoxyphenyl)-3-hydroxy-2-methylenepropanoate 140b (0.34g, 1.03mmol), in 
AcOH (5ml) and Ac2O (5ml). Work-up afforded, as a pale pink solid,  
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3-(chloromethyl)-8-methoxycoumarin 156b (0.20g, 87%), m.p. 146-148oC (Found: 
M+, 224.02470. C11H9O335Cl  requires M, 224.02402); γmax (KBr)/cm-1 1720 (C=O); 
δH (400 MHz; CDCl3) 3.99 (3H, s, OCH3), 4.58 (2H, s, CH2Cl), 7.13 (2H, 2xd, J 
7.6Hz, Ar-H), 7.26 (1H, t, J 9.0Hz, Ar-H) and 7.89 (1H, s, 4-H); δC (100 MHz; 
CDCl3) 41.0 (CH2), 56.3 (OCH3), 113.8, 119.4, 119.43, 124.6, 125.2, 141.2, 143.2 
and 147.2  (Ar-C) and 159.6 (C=O); m/z 223 [(M-H)+,  33.4%] and 189 (100). 
 
Method 2 
 
Conc. HCl (4ml) was added to a solution of tert-butyl 3-hydroxy-3-(2-hydroxy-3-
methoxyphenyl)methylenepropanoate 146b (0.58g, 2.1mmol) in AcOH (2ml). The 
mixture was boiled under reflux for 2hr, allowed to cool to room temperature and then 
poured into ice-cooled water (10ml). Stirring for 30min (or more)  gave a precipitate, 
which was filtered off and washed with hexane to afford, as a grey solid, 3-
(chloromethyl)-8-methoxycoumarin 156b (0.45g, 97%). 
 
Method 3 
 
Conc. HCl (10ml) was added to a solution of 3-(2-benzyloxy-3-methoxyphenyl)-3-
hydroxy-2-methylenepropanenitrile 144b (0.30g, 1.0mmol) in AcOH (5ml) and Ac2O 
(5ml). The mixture was boiled under reflux for ca 1h, allowed to cool to room 
temperature and then poured into ice-cooled water (10ml). Stirring for 30min (or 
more) gave a precipitate, which was filtered off and washed with hexane to afford, as 
a purple solid, 3-(chloromethyl)-8-methoxycoumarin 156b (0.16g, 69%). 
 
3-(Chloromethyl)-8-ethoxycoumarin 156c 
 
Method 1 
 
The procedure (method 1) described for the synthesis of 3-(chloromethyl)coumarin 
156a was followed, using conc. HCl (10ml) and a solution of methyl 3-(2-benzyloxy-
3-ethoxyphenyl)-3-hydroxy-2-methylenepropanoate 140c (0.35g, 1.0mmol) in AcOH  
(5ml) and Ac2O (5ml). Work-up afforded, as a pale pink solid, 3-(chloromethyl)-8-
ethoxycoumarin 156c (0.23g, 94%), m.p. 122-124oC (Found: M+, 238.03967. 
C12H11O335Cl requires M, 238.03967); γmax (KBr)/cm-1 1709 (C=O); δH (400 MHz;  
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CDCl3) 1.49 (3H, t, J 7.0Hz, OCH2CH3), 4.18 (2H, q, J 7.0Hz, OCH2CH3), 4.55 (2H, 
d, J 0.8Hz, CH2Cl), 7.08 (2H, d, J 7,2Hz, Ar-H), 7.20 (1H, t, J 8.0Hz, Ar-H) and 7.85 
(1H, s, 4-H); δC (100 MHz; CDCl3) 14.7 (OCH2CH3), 41.0 (CH2), 55,1 (OCH2CH3), 
115.2, 119.4, 119.6, 124.6, 125.1, 141.3, 143.4 and 146.5 (Ar-C) and 159.8 (C=O); 
m/z 238 (M+, 28.5%) and 175 (100). 
 
Method 2 
 
Conc. HCl (4ml) was added to a solution of tert-butyl 3-hydroxy-3-(3-ethoxy-2-
hydroxyphenyl)-2-methylenepropanoate 146c (0.61g, 2.1mmol) in AcOH (2ml).The 
mixture was boiled under reflux for 2h, allowed to cool to room temperature and then 
poured into ice-cooled water (10ml). Stirring for 30min (or more) gave a precipitate, 
which was filtered off and washed with hexane to afford, as a grey solid, 3-
(chloromethyl)-8-methoxycoumarin 156c (0.45g, 90%). 
 
6-Chloro-3-(chloromethyl)coumarin 156d 
 
Method 1 
 
The procedure (method 1) described for the synthesis of 3-(chloromethyl)coumarin 
156a was followed, using conc. HCl (15ml) and a solution of methyl 3-(2-benzyloxy-
5-chlorophenyl)-3-hydroxy-2-methylenepropanoate 140d (0.51g, 1.6mmol) in AcOH 
(7.5ml) and Ac2O (7.5ml). Work-up afforded, as a pale pink solid, 6-chloro-3-
(chloromethyl)coumarin 156d (0.33g, 94%), m.p. 112-114oC (Found: M+, 227.97476. 
C10H6O235Cl2 requires M, 227.97448)); γmax (KBr)/cm-1 1729 (C=O); δH (400 MHz; 
CDCl3) 4.54 (2H, s, CH2Cl), 7.31 (1H, d, J 8.8Hz, Ar-H), 7.48 and 7.50 (2H, 2xd, J 
2.3Hz, Ar-H) and 7.81 (1H, s, 4-H); δC (100 MHz; CDCl3) 40.8 (CH2), 118.1, 119.8, 
126.3, 127.3, 130.0, 131.9, 139.7, 151.8 (Ar-C) and 159.5 (C=O); m/z 228 [M+(35Cl2), 
23.2%] and 193 (100). 
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Method 2 
 
Conc. HCl (20ml) was added to a solution of 3-(2-benzyloxy-5-chlorophenyl)-3-
hydroxy-2-methylenepropanenitrile 144d (0.93g, 3.1mmol) in AcOH (15ml) and 
Ac2O (15ml). The mixture was boiled under reflux for ca 1h, allowed to cool to room 
temperature and then poured into ice-cooled water (ca 15ml). Stirring for 30min (or 
more)  gave a precipitate, which was filtered off and washed with hexane to afford, as 
a purple solid, 6-chloro-3-(chloromethyl)coumarin 156d (0.61g, 87%). 
 
6-Bromo-3-(chloromethyl)coumarin 156e 
 
Method 1 
 
The procedure (method 1) described for the synthesis of 3-(chloromethyl)coumarin 
156a was followed, using conc. HCl (10ml) and a solution of methyl 3-(2-benzyloxy-
5-bromophenyl)-3-hydroxy-2-methylenepropanoate 140e (0.39g, 1.0mmol) in AcOH 
(5ml) and Ac2O (5ml). Work-up afforded, as a pale pink solid, 6-bromo-3-
(chloromethyl)coumarin 156e (0.22g, 81%), m.p. 116-118oC (Found: M+, 271.92412. 
C10H6O235Cl79Br requires M, 271.92397); γmax (KBr)/cm-1 1722 (C=O); δH (400 MHz; 
CDCl3) 4.53 (2H, s, CH2Cl), 7.24 (1H, d, J 8.8Hz, Ar-H), 7.62 (1H, dd, J 2.0Hz and J 
8.8Hz, Ar-H), 7.66 (1H, d, J 2.0Hz, Ar-H) and 7.80 (1H, s, 4-H); δC (100 MHz; 
CDCl3) 40.8 (CH2), 117.3, 118.4, 120.3, 126.3, 130.3, 134.7, 139.6, 142.3 and 159.4 
(ArC and C=O); m/z 271 [M+(35Cl79Br), 34.9%] and 237(100). 
 
Method 2 
 
Conc. HCl (4ml) was added to a solution of tert-butyl 3-(5-bromo-2-hydroxyphenyl)-
3-hydroxy-2-methylenepropanoate 146e (0.68g, 2.1mmol) in AcOH (2ml). The 
mixture was boiled under reflux for 2h, allowed to cool to room temperature and then 
poured into ice-cooled water (10ml). Stirring for 30min (or more) gave a precipitate, 
which was filtered off and washed with hexane to afford, as a grey solid, 6-bromo-3-
(chloromethyl)coumarin 156e (0.54g, 95%). 
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Method 3 
 
Conc. HCl (10ml) was added to a solution of 3-(2-benzyloxy-5-bromophenyl)-3-
hydroxy-2-methylenepropanenitrile 144e (0.35g, 1.0mmol) in AcOH (5ml) and Ac2O 
(5ml). The mixture was boiled under reflux for ca 1h, allowed to cool to room 
temperature and then poured into ice-cooled water (10ml). Stirring for 30min (or 
more) gave a precipitate, which was filtered off and washed with hexane to afford, as 
a purple solid, 6-bromo-3-(chloromethyl)coumarin 156e (0.21g, 75%). 
 
6,8-Dibromo-3-(chloromethyl)coumarin 156f 
 
Method 1 
 
The procedure (method 1) described for the synthesis of 3-(chloromethyl)coumarin 
156a was followed, using conc. HCl (15ml) and a solution of methyl 3-(2-benzyloxy-
3,5-dibromophenyl)-3-hydroxy-2-methylenepropanoate 140f (0.47g, 1.0mmol), in 
AcOH (7.5ml) and Ac2O (7.5ml). Work-up afforded, as a pale pink solid, 6,8-
dibromo-3-(chloromethyl)coumarin 156f (0.32g, 90%), m.p. 166-168oC (Found M+, 
349.83490. C10H15O235Cl79Br2 requires M, 349.83448); γmax (KBr)/cm-1 1727 (C=O); 
δH (400 MHz; CDCl3) 4.54 (2H, s, CH2Cl), 7.67 (1H, d, J 2.0Hz,  Ar-H), 7.78 (1H, s, 
Ar-H) and 7.88 (1H, d, J 2.0Hz, Ar-H); δC (100 MHz; CDCl3) 40.5 (CH2), 111.2, 
117.3, 121.1, 127.1, 129.6, 137.5, 139.2 and 149.3 (Ar-C) and 158.48 (C=O); m/z 349 
[M+ (35Cl79Br2), 51%) and 317 (100). 
  
Method 2 
 
Conc. HCl (4ml) was added to a solution of tert-butyl 3-(3,5-dibromo-2-
hydroxyphenyl)-3-hydroxy-2-methylenepropanoate 140f (0.84g, 2.1mmol) in AcOH 
(2ml). The mixture was boiled under reflux for 2h, allowed to cool to room 
temperature and then poured into ice-cooled water (10ml). Stirring for 30min (or 
more) gave a precipitate, which was filtered off and washed with hexane to afford, as 
a grey solid, 6,8-dibromo-3-(chloromethyl)coumarin 156f (0.70, 95%). 
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3-(Acetoxymethyl)coumarin 157 and tert-butyl 2H-1-chromene-3-carboxylate  
161 
 
A mixture of tert-butyl 3-hydroxy-3-(2-hydroxyphenyl)-2-methylenepropanoate 146a 
(0.14g, 0.57mmol) in AcOH (12ml) was boiled under reflux for 6h. Water (10ml) was 
added to the cooled solution and the resulting mixture was extracted with chloroform. 
The organic solution was dried over anhyd. Na2SO4, filtered and evaporated in vacuo 
to afford a yellow solid, which was purified using preparative layer chromatography 
[elution with CHCl3-hexane (3:1)] to afford the following two products:-  
i)   3-(acetoxymethyl)coumarin 157 (80mg, 40%), as a pale yellow solid; and 
 
ii)  3-tert-butyl 2H-1-chromene-3-carboxylate 161, as a pale yellow oil (50mg, 
24%), (Found: M+, 232.11056. C14H16O3 requires M, 232.10994); δH (400 MHz; 
CDCl3) 1.53 [9H, s, C(CH3)3], 4.94 (2H, d, J 0.8Hz, CH2), 6.82 (1H, d, J 8.0Hz, Ar-
H), 6.90-7.20 (3H, series of multiplets, Ar-H) and 7.32 (1H, s, 4-H);† δC (100 MHz; 
CDCl3) 28.1 [C(CH2)3], 64.6 (CH2), 81.2 [C(CH2)3], 116.0, 121.3, 121.6, 124.3, 
128.7, 131.6, 132.5 and  155.0 (Ar-C) and 163.9 (C=O); m/z 232 (M+, 48%) and 131 
(100). 
 
 
3.2.7.  Synthesis of coumarins via intramolecular Baylis-Hillman 
reactions 
 
3.2.7.1 Preparation of salicylaldehyde acrylate esters 
. 
2-Formylphenyl acrylate 163a 159 
 
To a suspension of NaH (50% dispersion in oil; 0.86g, 18mmol) in dry THF (15ml) 
under nitrogen was added salicylaldehyde (1.46ml, 13.7mmol) and the resulting 
mixture was boiled under reflux for 1h to generate the phenoxide ion. To the cooled 
solution, acryloyl chloride (1.45ml, 17.9mmol) in dry THF (15ml) was added 
dropwise, with stirring, and the reaction mixture was boiled under reflux for 3h. The 
reaction was quenched by the addition of water (20ml) and the resulting mixture 
extracted with diethyl ether. The organic layer was washed with satd. brine, dried over 
anhyd.  
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MgSO4, and concentrated in vacuo to afford, as a yellow oil, 2-formylphenyl acrylate 
(2.0g, 83%) (Found: M+, 176.04764. Calc. for C10H8O3 M, 176.04734); γmax 
(KBr)/cm-1 1747 (C=O); δH (400 MHz; CDCl3) 6.09 and 6.66 (2H, 2xd, J 10.2Hz and 
J 17.2Hz, CH=CH2), 6.37 (1H, dd, J 10.2Hz and 17.2Hz, CH=CH2), 7.22 (1H, d, J 
8.0Hz, ArH), 7.39 and 7.63 (2H, 2x t, J 7.4Hz and 7.6Hz, ArH), 7.90 (1H, d, J 7.6Hz, 
ArH) and 10.13 (1H, s, CHO); δC (100 MHz; CDCl3) 133.8 (CH=CH2), 123.4, 126.5, 
127.1, 128.1, 130.3, 135.3 and 151.8 (CH=CH2 and Ar-C), 164.2 (C=O) and 188.4 
(CHO); m/z 176 (M+, 2.1%) and 121 (100). 
 
2-Formyl-6-methoxyphenyl acrylate 163b 
 
The procedure described for the synthesis of 2-formylphenyl acrylate 163a was 
followed, using 3-methoxysalicylaldehyde (2.08g, 13.7mmol), NaH (50% dispersion 
in oil; 0.86g, 18mmol) in dry THF (15ml) and acryloyl chloride (1.45ml, 17.9mmol) 
in dry THF (15ml). Work-up afforded, as a yellow oil, 2-formyl-6-methoxyphenyl  
acrylate 163b (2.20g, 87%) (Found: M+, 206.05770. C11H10O4 requires M, 
206.05791); γmax(KBr)/ cm-1 1747 (C=O);  δH (400 MHz; CDCl3) 3.81 (3H, s, OCH3), 
6.06 and 6.64 (2H, 2xd, J 10.4 Hz and 17.2Hz, CH=CH2), 6.37 (1H, dd, J 10.4 Hz and 
17.2Hz, CH=CH2), 7.19 (1H, d, J 8.4Hz, Ar-H), 7.29 (1H, t, J 8.0Hz, ArH), 7.44 (1H, 
d, J 8.0Hz, ArH) and 10.11 (1H, s, CHO); δC (100 MHz; CDCl3) 56.2 (OCH3), 133.6 
(CH=CH2), 117.8, 120.5, 126.7, 126.8, 129.2, 141.6 and 151.6 (CH=CH2  and Ar-C), 
163.7 (C=O) and 188.4 (CHO); m/z  206 (M+, 5%) and 151 (100). 
 
6-Ethoxy-2-formylphenyl acrylate 163c 
 
The procedure described for the synthesis of 2-formylphenyl acrylate 163a was 
followed, using 3-ethoxysalicylaldehyde (2.78mmol, 13.7mmol), NaH (50% 
dispersion in oil; 0.86g, 18mmol) in dry THF (15ml) and acryloyl chloride (1.45ml, 
17.9mmol) in dry THF (15ml). Work-up afforded, as a yellow oil, 6-ethoxy-2-
formylphenyl acrylate 163c (2.67g, 89%) (Found: M+, 220.07389 C12H12O4 requires 
M, 220.07356); γmax(KBr) /cm-1 1751 (C=O); δH (400 MHz; CDCl3) 1.35 (3H, t, J  
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7.0Hz, OCH2CH3), 4.06 (2H, q, J 6.8Hz, OCH2CH3), 6.08 and 6.67 (2H, 2xd, J 8.0 
Hz and J 7.8Hz, CH=CH2), 6.39 (1H, dd, J 10.4 Hz and J 17.6Hz, CH=CH2), 7.20 
(1H, d, J 7.2Hz, Ar-H), 7.29 (1H, t, J 7.8Hz, ArH), 7.45 (1H, dd,  J 7.6Hz and J 
8.0Hz, ArH) and 10.14 (1H, s, CHO); δC (100 MHz; CDCl3) 14.6 (OCH2CH3), 64.9 
(OCH2CH3), 133.4 (CH=CH2), 118.9, 120.3, 126.7, 126.8, 129.3, 142.1 and 151.0 
(CH=CH2 and Ar-C), 163.7 (C=O) and 188.5 (CHO); m/z  220 (M+, 41%) and 165 
(100). 
 
4-Bromo-2-formylphenyl acrylate 163e 
 
The procedure described for the synthesis of 2-formylphenyl acrylate 163a was 
followed, using 5-bromosalicylaldehyde (2.75ml, 13.7mmol), NaH (50% dispersion in 
oil; 0.86g, 18mmol) in dry THF (15ml) and acryloyl chloride (1.45ml, 17.9mmol) in 
dry THF (15ml). Work-up afforded, as white crystals, 4-bromo-2-formylphenyl  
acrylate 163e (3.01g, 86%), m.p. 70-72oC (from CHCl3) (Found: M+, 253.95893 
C10H7O379Br requires M, 253.95786); γmax(KBr)/cm-1 1751 (C=O); δH (400 MHz; 
CDCl3) 6.12 (1H, dd, J 0.4Hz and J 10.4Hz, CH=CHA), 6.67 (1H, dd, J 0.4Hz and J 
17.2Hz, CH=CHB), 6.36 (1H, dd, J 10.4Hz and J 17.2Hz, CH=CH2), 7.14 (1H, d, J 
8.4Hz, ArH), 7.73 (1H, dd, J 8.4Hz and J 2.4Hz, ArH), 8.01 (1H, d, J 2.4Hz, ArH) 
and 10.07 (1H, s, CHO); δC (100 MHz; CDCl3) 134.3 (CH=CH2), 119.8, 125.2, 126.7, 
129.3, 132.6, 138.0 and 150.8 (CH=CH2 and Ar-C), 163.8 (C=O) and 186.9 (CHO); 
m/z  254 [M+(79Br), 7.2%] and 201 (100). 
 
2-Formyl-5-nitrophenyl acrylate 163g 
 
The procedure described for the synthesis of 2-formylphenyl acrylate 163a was 
followed, using 4-nitrosalicylaldehyde (2.29mmol, 13.7mmol), NaH (50% dispersion 
in oil; 0.86g, 18mmol) in dry THF (15ml) and acryloyl chloride (1.45ml, 17.9mmol) 
in dry THF (15ml). Work-up afforded, as white soild, 2-formyl-5-nitrophenyl acrylate 
163g (2.94g, 99%), m.p. 58-60oC (from CHCl3) (Found: M+, 221.03189. C10H7NO5 
requires M, 221.03242); γmax(KBr)/cm-1 1747 (C=O); δH (400 MHz;  
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CDCl3) 6.21 and 6.73 (2H, 2xd, J 10.8Hz, CH=CH2), 6.40 (1H, dd, J 10.4 Hz and J 
17.2Hz, CH=CH2), 7.50 (1H, d, J 8.8Hz, ArH), 8.49 (1H, dd, J 2.4Hz and J 8.8Hz, 
ArH), 8.78 (1H, d, J 2.4Hz, ArH) and 10.20 (1H, s, CHO); δC (100 MHz; CDCl3) 
135.3 (CH=CH2), 124.8, 125.5, 126.3, 128.5, 129.5, 145.8 and 155.9 (CH=CH2 and 
Ar-C), 163.1 (C=O) and 186.1 (CHO); m/z 221 (M+, 7.2%) and 55 (100). 
 
3.2.7.2.   Preparation of coumarin-derived quaternary DABCO salts  
 
Quaternary ammonium salt 164a159 
 
To a solution of 2-formylphenyl acrylate 163a (2g, 11mmol) dry dichloromethane 
(23ml) at –10oC was added DABCO (1.27g, 11mmol), and the stirred solution was 
allowed to warm to room temperature over several hours. The resulting precipitate  
was filtered off, washed with dichloromethane and recrystallized from methanol and 
dichloromethane to afford, as a pale yellow solid, the quaternary ammonium salt 164a 
(2.05g, 61%), m.p. <250oC (dec.) ( Found: M+-HCl, 270.13662. Calc. for 
C16H18O2N2: M-36, 270.13683); γmax (KBr)/cm-1 1711 (C=O); δH (400 MHz; CD3OD) 
3.27 [6H, t, J 7.6Hz, (CH2)3N], 3.59 [6H, t, J 7.4Hz, (CH2)3N+], 4.53 (2H, s, CH2N+), 
7.48-7.86 (4H, series of multiplets, Ar-H) and  8.49 (1H, s, 4-H); δC (400 MHz; 
CD3OD) 46.3 (NCH2CH2N+), 53.87 (+NCH2CH2N), 64.03 (CH2N+), 116.6, 117.7, 
120.0, 126.4, 130.6, 135.1, 152.7 and 156.0 (Ar-C) and 163.0 (C=O); m/z  270 [(M+-
HCl), 9.3%] and 159 (100). 
 
Quaternary ammonium salt 164b 
 
The procedure described for the synthesis of the quaternary ammonium salt 164a was 
followed, using DABCO (1.27g, 11mmol) and 2-formyl-6-methoxyphenyl acrylate 
163b (2.3g, 11mmol) in dry chloromethane (23ml) at –10oC. Work-up and 
recrystallization from methanol and dichloromethane afforded, as a pale cream solid, 
the quaternary ammonium salt 164b (2.01g, 54%), m.p. < 246oC (dec.) (Found: M+, 
336.12394. C17H21O3N235Cl requires M, 336.12407); γmax (KBr)/cm-1 1719 (C=O); δH  
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(400 MHz; DMSO-d6) 3.24 [6H, t, J 7.2Hz, (CH2)3N+], 3.56 [6H, t, J 7.2Hz, 
(CH2)3N+], 4.03 (3H, s, OCH3), 4.48 (2H, s, CH2N+), 7.42 (3H, series of overlapping 
signals, Ar-H) and 8.41 (1H, s, 4-H); δC (400 MHz; DMSO-d6) 44.7 (NCH2CH2N+), 
51.6 (+NCH2CH2N), 56.2 (OCH3), 61.3 (CH2N+), 115.5, 115.9, 118.9, 120.2, 124.7, 
143.2, 146.3 and 150.6 (Ar-C ) and 160.5 (C=O); m/z  301 [(M+-Cl), 2.1%] and 189 
(100). 
 
Quaternary ammonium salt 164c 
 
The procedure described for the synthesis of the quaternary ammonium salt 164a was 
followed, using DABCO (1.27g, 11mmol) and 6-ethoxy-2-formyphenyl acrylate 163c 
(2.4g, 11mmol) in dry dichloromethane (23ml) at –10oC. Work-up and 
recrystallization from methanol and dichloromethane afforded, as a pale yellow solid, 
the quaternary ammonium salt 164c (2.02g, 52%), m.p. <200oC (dec.) (Found: M+, 
350.13995. C18H23O3N235Cl requires M, 350.13972); γmax (KBr)/cm-1 1722 (C=O); δH 
(400 MHz; DMSO-d6) 1.38 (3H, t, J 7.6Hz, OCH2CH3), 2.98 [6H, t, J 6.6Hz, 
(CH2)3N+], 3.41 [6H, t, J 6.6Hz, (CH2)3N+], 4.19 (2H, q, J 7.6Hz, OCH2CH3), 4.40 
(2H, s, CH2N+), 7.30-7.36 (3H, series of overlapping signals, Ar-H) and 8.41 (1H, s, 
4-H); δC (400 MHz; DMSO-d6) 14.6 (OCH2CH3), 44.7 (NCH2CH2N+), 51.6 
(+NCH2CH2N), 61.3 (CH2N+), 64.5 (OCH2CH3), 115.8, 116.3, 119.1, 120.2, 124.7, 
143.3, 145.5 and 150.7 (Ar-C) and 160.6 (C=O); m/z  350 [M+, 0.2%] and 175 (100). 
 
Quaternary ammonium salt 164e 
 
The procedure described for the synthesis of the quaternary ammonium salt 164a was 
followed, using DABCO (1.27g, 11mmol) and 4-bromo-2-formylphenyl acrylate 163e 
(2.8g, 11mmol) in dry dichloromethane (23ml) at –10oC. Work-up and 
recrystallization from methanol and dichloromethane afforded, as a pale cream solid, 
the quaternary ammonium salt 164e (2.50g, 59%), m.p. < 252oC (dec.) (Found: M+, 
384.02357. C16H18O2N235Cl79Br requires M, 384.02402); γmax (KBr)/cm-1 1727 
(C=O); δH (400 MHz; DMSO-d6) 3.03 [6H, t, J 7.0Hz, (CH2)3N], 3.43 [6H, t, J  
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7.0Hz, (CH2)3N+], 4.42 (2H, s, CH2N+), 7.50 (1H, d, J 8.4Hz, Ar-H), 7.89 and 7.91 
(2H, 2xd, J 2.4Hz and J 8.8Hz, Ar-H), 8.09 (1H, d, J 2.4Hz, Ar-H) and 8.35 (1H, s, 4-
H); δC (400 MHz; DMSO-d6) 44.7 (NCH2CH2N+), 51.6 (+NCH2CH2N), 61.1 
(CH2N+), 116.2, 116.9, 118.4, 120.3, 131.2, 135.5, 149.0 and 152.9 (Ar-C) and 160.3 
(C=O); m/z  348 [(M+-HCl), 7.8%] and 237 (100). 
 
Quaternary ammonium salt 164g 
 
The procedure described for the synthesis of the quaternary ammonium salt 164a was 
followed, using DABCO (1.27g, 11mmol) and  2-formyl-5-nitrophenyl acrylate 163g 
(2.4g, 11mmol) in dry dichloromethane (23ml) at –10oC. Work-up and 
recrystallization from methanol and dichloromethane afforded, as a yellow solid, the 
quaternary ammonium salt 164g ( 2.71g, 70%), m.p. < 210oC (dec.) ( Found: M+, 
351.09698. C16H18O4N335Cl requires M, 351.09858); γmax (KBr)/cm-1 1726 (C=O); δH 
(400 MHz; DMSO-d6) 3.00 [6H, br s, (CH2)3N], 3.43 [6H, br s, (CH2)3N+], 4.43 (2H, 
s, CH2N+), 7.71 (1H, d, J 9.2Hz, Ar-H), 8.51 (1H, d, J 8.8Hz, Ar-H) and 8.76 (1H, s, 
4-H); δC (400 MHz; DMSO-d6) 44.7 (NCH2CH2N+), 51.6 (+NCH2CH2N), 61.0 
(CH2N+), 117.7, 117.8, 118.7, 125.0, 127.6, 143.6, 149.3 and 157.4 (Ar-C) and 160.0 
(C=O); m/z  316 [(M+-Cl), 0.8%] and 204 (100). 
 
 
3.3.      Nucleophilic substitution reactions of coumarin derivatives 
 
Reaction of 3-(iodomethyl)coumarin 155a with ethyl acetoacetate enolate 
             
To a solution of sodium ethoxide [generated from sodium metal (18mg, 0.80mmol)] 
in dry ethanol (5ml) under N2 was added ethyl acetoacetate (0.1ml), and the resulting 
mixture was heated to 50oC. 3-(Iodomethyl)coumarin 155a (0.21g, 0.74mmol) was 
added and the resulting mixture boiled under reflux for 5h to afford a brown oil, 
which was purified using preparative layer chromatography [elution with hexane-
EtOAc (3:1)] to afford, as a pale yellow solid, ethyl 2-[(2-oxo-2H-chromen-3-
yl)methyl]-3-oxobutanoate 174a (88mg, 41%), m.p. 62-66oC (Found: M+, 288.0996.  
 
 
 164 
 
 
 
Experimental 
 
 
C16H16O5 requires M, 288.09977); δH (400 MHz; CDCl3) 1.17 (3H, t, J 7.2Hz, 
OCH2CH3), 2.25 (3H, s, COCH3), 3.09 (2H, m, CH2CH), 4.16 (3H, overlapping 
signals, OCH2CH3 and CH2CH), 7.20-7.46 (4H, series of multiplets, Ar-H) and 7.59 
(1H, s, Ar-H); δC (100 MHz; CDCl3) 14.0 (OCH2CH3), 29.7 (CH2CH), 29.8 (COCH3), 
57.1 (CH2CH), 61.6 (OCH2CH3), 116.4, 119.2, 124.4, 125.5, 127.6, 131.1, 141.9 and  
153.4 (Ar-C), 161.4, 168.7 and 202.0 (3x C=O); m/z 288 (M+, 0.1%) and 221 (100). 
 
Reaction of 3-(chloromethyl)-8-methoxycoumarin 156b with ethyl acetoacetate 
enolate 
The procedure described for the synthesis of ethyl 2-[(2-oxo-2H-chromen-3 
yl)methyl]-3-oxobutanoate 174a was followed, using ethyl acetoacetate (0.2ml), 
sodium ethoxide (1.6mmol) in dry ethanol (10ml) and 3-(chloromethyl)-8-
methoxycoumarin 156b (0.33g, 1.5mmol). Work-up and chromatography afforded, as 
a yellow oil, ethyl 2-[(8-methoxy-2-oxo-2H-chromen-3-yl)methyl]-3-oxobutanoate 
174b (0.20g, 42%) (Found: M+, 318.11164. C17H18O6 requires M, 318.11034); δH 
(400 MHz; CDCl3) 1.18 (3H, t, J 7.0Hz, OCH2CH3), 2.26 (3H, s, COCH3), 3.06 (2H, 
m, CH2CH), 3.92 ( 3H, s, OCH3), 4.13 (3H, series of overlapping signals, CH2CH and 
OCH2CH3), 7.00 (2H, t, J 4.4Hz, Ar-H), 7.16 (1H, t, J 8.0Hz, Ar-H) and 7.58 (1H, s, 
4-H); δC (100 MHz; CDCl3) 14.0 (OCH2CH3), 29.7 (CH2CH), 29.8 (COCH3), 56.1 
(OCH3), 56.9 (CH2CH), 61.5 (OCH2CH3), 113.0, 119.0, 120.0, 124.3, 125.6, 142.1, 
142.9, and 146.9 (Ar-C), 160.9, 168.7 and 202.1 (3x C=O); m/z 318 (M+, 0.9%) and 
229 (100). 
 
Reaction of 3-(chloromethyl)-8-ethoxycoumarin 156c with ethyl acetoacetate 
enolate 
 
The procedure described for the synthesis of ethyl 2-[(2-oxo-2H-chromen-3 
yl)methyl]-3-oxobutanoate 174a was followed, using ethyl acetoacetate (0.2ml), 
sodium ethoxide (1.6mmol) in dry ethanol (10ml) and 3-(chloromethyl)-8-
ethoxycoumarin 156c (0.35g, 1.5mmol). Work-up and chromatography afforded, as a  
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pale yellow oil, ethyl 2-[(8-ethoxy-2-oxo-2H-chromen-3-yl)methyl]-3-oxobutanoate 
174c (0.21g, 42%) (Found: M+, 332.12539. C18H20O6 requires M, 332.12599); δH 
(400 MHz; CDCl3) 1.19 (3H, t, J 7.0Hz, OCH2CH3), 1.49 (3H, t, J 7.0Hz, OCH2CH3), 
2.27 (3H, s, COCH3), 3.04 (2H, m, CH CH), 4.14 (5H, series of overlapping signals, 
CH
2
2CH and 2xOCH2CH3), 7.00 (2H, m, Ar-H), 7.15 (1H, t, J 8.0Hz, Ar-H) and 7.59 
(1H, s, 4-H); δC (100 MHz; CDCl3) 14.0 and 14.7 (2xOCH2CH3), 29.8 (CH2CH), 29.9 
(COCH3), 56.9 (CH2CH), 61.6 and 64.8 (2xOCH2CH3), 114.2, 118.9, 119.9, 124.3, 
125.5, 142.2, 143.2 and 146.3 (Ar-C), 161.1, 168.7 and  202.2 (3x C=O); m/z 332 
(M+, 1.1%) and 243 (100). 
 
 
Reaction of  6-chloro-3-(chloromethyl)coumarin 156d with ethyl acetoacetate 
enolate 
 
The procedure described for the synthesis of ethyl 2-[(2-oxo-2H-chromen-3 
yl)methyl]-3-oxobutanoate 174a was followed, using ethyl acetoacetate (0.2ml), 
sodium exthoxide (1.6mmol) in dry ethanol (10ml) and 6-chloro-3-(chloromethyl)-
coumarin 156d (0.34g, 1.5mmol). Work-up and chromatography afforded, as light 
yellow crystals, ethyl 2-[(6-chloro-2-oxo-2H-chromen-3-yl)methyl]-3-oxobutanoate 
174d (0.20g, 41%), m.p. 72-76oC (Found: M+, 322.06132. C16H15O535Cl requires M, 
322.06080); δH (400 MHz; CDCl3) 1.19 (3H, t, J 7.0Hz, OCH2CH3), 2.23 (3H, s, 
COCH3), 3.03 (2H, m, CH2CH), 4.06 (1H, dd, J 6.8Hz and J 7.6Hz, CH2CH), 4.16 
(2H, m, OCH2CH3), 7.20-7.40 (3H, series of multiplets, Ar-H) and 7.54 (1H, s, 4-H); 
δC (100 MHz; CDCl3) 14.0 (OCH2CH3), 29.6 (CH2CH), 30.1 (COCH3), 56.8 
(CH2CH), 61.6 (OCH2CH3), 117.8, 120.2, 126.76, 126.80, 129.7, 131.0, 140.6 and 
151.6 (Ar-C), 160.8, 168.5 and 201.8 (3x C=O); m/z 322 (M+, 0.7%) and 233 (100). 
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Reaction of  6-bromo-3-(chloromethyl)coumarin 156e with ethyl acetoacetate 
enolate 
 
The procedure described for the synthesis of ethyl 2-[(2-oxo-2H-chromen-3 
yl)methyl]-3-oxobutanoate 174a was followed, using ethyl acetoacetate (0.2ml), 
sodium metal (36mg, 1.6mmol) in dry ethanol (10ml) and 6-bromo-3-
(chloromethyl)coumarin 156e (0.40g, 1.5mmol). Work-up and chromatography 
afforded, as light yellow crystals, ethyl 2-[(6-bromo-2-oxo-2H-chromen-3-yl)methyl]-
3-oxobutanoate 174e (0.23g, 42%), m.p. 108-110oC (Found: M+, 366.01084. 
C16H15O579Br requires M, 366.01028); δH (400 MHz; CDCl3) 1.18 (3H, t, J 7.0Hz, 
OCH2CH3), 2.25 (3H, s, COCH3), 3.01 (2H, m, CH2CH), 4.04 (1H, t, J 7.2Hz, 
CH2CH), 4.16 (2H, m, OCH2CH3), 7.14 (1H, d, J 8.4Hz, Ar-H) and 7.52 (3H, series 
of overlapping signals, Ar-H); δC (100 MHz; CDCl3) 14.0 (OCH2CH3), 29.6 
(CH2CH), 30.2 (COCH3), 56.8 (CH2CH), 61.6 (OCH2CH3), 116.9, 118.1, 120.6, 
126.7, 129.8, 133.8, 140.5 and 152.1 (Ar-C), 160.7, 168.5 and 201.7 (3x C=O); m/z 
366 (M+, 1.4%) and 279 (100). 
 
Reaction of  3-(iodomethyl)coumarin 155a with diethyl malonate enolate 
 
To a solution of sodium ethoxide [generated from sodium metal (18mg, 0.80mmol)] 
in dry ethanol (5ml) under N2 was added diethyl malonate (0.1ml), and the resulting 
mixture was heated to 50oC. 3-(Iodomethyl)coumarin 155a (0.21g, 0.74mmol) was 
added and the resulting mixture boiled under reflux for 5h to afford a brown oil, 
which was purified using preparative layer chromatography [elution with hexane-
EtOAc (3:1)] to afford, as a pale yellow solid, diethyl 2-[(2-oxo-2H-chromen-3-
yl)methyl]propane-1,3-dioate 176a (0.11g, 47%), m.p. 66-70oC (Found: M+, 
318.10974. C17H18O6 requires M, 318.11034); δH (400 MHz; CDCl3) 1.19 (6H, t, J 
7.0Hz, 2x OCH2CH3), 3.11 (2H, d, J 7.6Hz, CH2CH), 4.15 (4H, 2x q, J 2.8Hz, 2x 
OCH2CH3), 7.21-7.49 (4H, series of doublets, Ar-H) and 7.59 (1H, s, 4-H); δC (100 
MHz; CDCl3) 14.0 (2xOCH2CH3), 30.7 (CH2CH), 49.9 (CH2CH), 61.5 (2x 
OCH2CH3), 116.4, 119.1, 124.4, 125.3, 127.5, 131.2, 141.5 and 153.4 (Ar-C), 161.2 
and 168.6 (2x C=O); m/z (FAB) 288 (MH+, 22%) and 171 (100). 
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Reaction of  3-(chloromethyl)-8-ethoxycoumarin 156c with diethyl malonate 
enolate 
 
The procedure described for the synthesis of diethyl 2-[(2-oxo-2H-chromen-3-
yl)methyl]propane-1,3-dioate 176a was followed, using diethyl malonate (0.21ml), 
sodium metal (1.6mmol) in dry ethanol (10ml) and 3-(chloromethyl)-8-
ethoxycoumarin 156c (0.33g, 1.5mmol). Work-up and chromatography afforded, as a 
yellow oil, diethyl 2-[(8-ethoxy-2-oxo-2H-chromen-3-yl)methyl]propane-1,3-dioate 
176c (0.27g, 50%) (Found: M+, 362.13673. C19H22O7 requires M, 362.13655); δH 
(400 MHz; CDCl3) 1.18 (6H, t, J 7.2Hz, 2x OCH2CH3), 1.46 (3H, t, J 7.2Hz, 
OCH2CH3), 3.10 (2H, d, J 8.0Hz, CH2CH), 3.94 (1H, t, J 7.8Hz, CH2CH), 4.08-4.17 
(6H, series of overlapping signals, 3x OCH2CH3), 6.98 (2H, 2xd, J 7.8Hz, Ar-H), 7.13 
(1H, t, J 8.0Hz, Ar-H) and 7.56 (1H, s, 4-H); δC (100 MHz; CDCl3) 14.0 and 14.6 (2x 
OCH2CH3), 30.7 (CH2CH), 49.7 (CH2CH), 61.6 and 64.8 (2x OCH2CH3), 114.2, 
118.8, 119.8, 124.2, 125.3, 147.1, 143.2 and 146.3 (Ar-C), 160.8 and 168.6 (2x C=O); 
m/z (FAB) 362 (M+, 63%) and 270 (100). 
 
Reaction of  6-chloro-3-(chloromethyl)coumarin 156d with diethyl malonate 
enolate 
 
The procedure described for the synthesis of 2-[(2-oxo-2H-chromen-3-yl)methyl]-
propane-1,3-dioate 176a was followed, using diethyl malonate (0.2ml), sodium 
ethoxide (1.6mmol) in dry ethanol (10ml) and 6-chloro-3-(chloromethyl)coumarin 
156d (0.34g, 1.5mmol). Work-up and chromatography afforded, as light yellow 
crystals, diethyl 2-[(6-chloro-2-oxo-2H-chromen-3-yl)methyl]propane-1,3-dioate 
176d (0.32g, 61%), m.p. 100-104oC (Found: M+, 352.07230. C17H17O635Cl  requires 
M, 352.07137); δH (400 MHz; CDCl3) 1.19 (6H, t, J 7.2Hz, 2x OCH2CH3), 3.10 (2H, 
d, J 7.6Hz, CH2CH), 3.91 (1H, t, J 7.6Hz, CH2CH), 4.15 (4H, 2x q, J 6.0Hz, 2x 
OCH2CH3), 7.21-7.42 (3H, series of multiplets, Ar-H) and 7.53 (1H, s, 4-H); δC (100 
MHz; CDCl3) 14.0 (2x OCH2CH3), 30.6 (CH2CH), 49.7 (CH2CH), 61.6 (2x  
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OCH2CH3), 117.9, 120.1, 126.6, 126.7, 129.6, 131.1, 140.2 and 151.7 (Ar-C), 160.6 
and 168.4 (C=O); m/z (FAB) 352 (M+, 29%) and 260 (100). 
 
Reaction of  6-bromo-3-(chloromethyl)coumarin 156e with diethyl malonate 
enolate 
 
The procedure described for the synthesis of 2-[(2-oxo-2H-chromen-3-
yl)methyl]propane-1,3-dioate 174a was followed, using diethyl malonate (0.2ml), 
sodium ethoxide (36mg, 1.6mmol) in dry ethanol (10ml) and 6-bromo-3-
(chloromethyl)coumarin 156e (0.40g, 1.5mmol). Work-up and chromatography 
afforded, as a pale yellow solid, diethyl 2-[(6-bromo-2-oxo-2H-chromen-3-yl)methyl]- 
propane-1,3-dioate 176e (0.27g, 45%), m.p. 104-106oC (Found: M+, 396.02156. 
C17H17O679Br  requires M, 396.02085); δH (400 MHz; CDCl3) 1.19 (6H, t, J 7.2Hz, 2x 
OCH2CH3), 3.10 (2H, d, J 7.6Hz, CH2CH), 3.90 (1H, t, J 7.6Hz, CH2CH), 4.13 (4H, 
2x q, J 6.8Hz, 2x OCH2CH3), 7.16 (1H, d, J 9.2Hz, Ar-H) and 7.53 (3H, overlapping 
signals, Ar-H); δC (100 MHz; CDCl3) 14.0 (2x OCH2CH3), 30.6 (CH2CH), 49.6 
(CH2CH), 61.6 (2x OCH2CH3), 116.9, 118.1, 120.6, 126.5, 129.7, 133.9, 140.1 and 
152.1 (Ar-C), 160.5 and 168.4 (C=O); m/z 396 [M+(79Br), 8.3%] and 307 (100). 
 
Reaction of  6,8-dibromo-3-(chloromethyl)coumarin 156f with diethyl malonate 
enolate 
 
The procedure described for the synthesis of 2-[(2-oxo-2H-chromen-3-
yl)methyl]propane-1,3-dioate 174a was followed, using diethyl malonate (0.2ml), 
sodium ethoxide (1.6mmol) in dry ethanol (10ml) and 6,8-dibromo-3-
(chloromethyl)coumarin 156f (0.65g, 1.5mmol). Work-up and chromatography 
afforded, as a pale yellow solid, diethyl 2-[(6,8-dibromo-2-oxo-2H-chromen-3-
yl)methyl]propane-1,3-dioate 176f (0.30g, 42%), m.p. 126-130oC (Found: M+, 
473.93159. C17H16O679Br2 requires M, 473.93136); δH (400 MHz; CDCl3) 1.21 (6H, t, 
J 7.0Hz, 2x OCH2CH3), 3.12 (2H, d, J 7.6Hz, CH2CH), 3.90 (1H, t, J 7.8Hz, CH2CH),  
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4.16 (4H, 2x q, J 7.2Hz, 2x OCH2CH3), 7.50-7.53 (2H, series of overlapping signals, 
Ar-H) and 7.81 (1H, d, J 1.6Hz, Ar-H); δC (100 MHz; CDCl3) 14.0 (2x OCH2CH3), 
30.4 (CH2CH), 49.6 (CH2CH), 61.7 (2x OCH2CH3), 110.9, 116.9, 112.3, 127.4, 
129.1, 136.7, 139.9 and 149.2 (Ar-C), 159.6 and 168.4 (C=O); m/z 473 [M+(79Br2), 
0.4%] and 329 (100). 
 
Reaction of  3-(iodomethyl)coumarin 155a with piperidine 
 
Method 1 
 
To a solution of 3-(iodomethyl)coumarin 155a (0.11g, 0.40mmol) in THF (ca 2ml) 
was added piperidine (0.1ml), and the mixture was stirred at room temperature in a 
stoppered round-bottomed flask for 3d. The solvent was evaporated in vacuo to  
afford the crude product, which was purified using preparative layer chromatography 
[elution with CHCl3-EtOAc (3:1)] to afford, as a brown solid, 3-
(piperidinomethyl)coumarin 150a (80mg, 82%).   
 
Method 2 
 
To a solution of the quaternary salt 164a (0.11g, 0.40mmol) in THF (ca 2ml) was 
added piperidine (0.1ml), and the mixture was stirred at room temperature in a 
stoppered round-bottomed flask for 3d. The solvent was evaporated in vacuo to afford 
the crude product, which was purified using preparative layer chromatography 
[elution with CHCl3-EtOAc (3:1)] to afford, as a brown solid, 3-
(piperidinomethyl)coumarin 150a (40mg, 42%).   
 
Reaction of  6-bromo-3-(iodomethyl)coumarin 155e with piperidine 
 
The procedure (method 1, above) described for the synthesis of 3-(piperidino- 
methyl)coumarin 150a was followed, using piperidine (0.1ml) and 6-bromo-3-
(iodomethyl)coumarin 155e (0.15g, 0.40mmol) in THF (ca 2ml), and stirring the 
mixture at room temperature  for 4h. Work-up and chromatography afforded, as a pale 
yellow solid, 6-bromo-3-(piperidinomethyl)coumarin 150e (70mg, 55%), m.p. 116- 
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118oC (Found: M+, 321.03675. C15H16NO279Br requires M, 321.03644); δH (400 
MHz; CDCl3) 1.46 (2H, m, CH2CH2CH2N), 1.60 (4H, m, CH2CH2N), 2.46 (4H, br s, 
CH2CH2N), 3.40 (2H, s, CH2N), 7.17 (1H, d, J 8.8Hz, ArH), 7.52 (1H, dd, J 8.8Hz 
and J 1.6Hz, Ar-H), 7.61 ( 1H, d, J 1.6Hz, Ar-H) and 7.70 (1H, s, Ar-H); δC (100 
MHz; CDCl3) 24.0, 26.0 and 54.7 (CH2CH2CH2N), 56.9 (CH2N), 116.7, 118.1, 121.0, 
127.6, 129.8, 133.4, 137.9 and 151.7 (Ar-C) and 160.8 (C=O); m/z 321 [M+(79Br) 
42%] and 85 (100). 
 
Reaction of  3-(iodomethyl)coumarin 155a with benzylamine 
    
The procedure (method 1, p.170) described for the synthesis of 3-(piperidino- 
methyl)coumarin 150a was followed, using benzylamine (0.11ml) and 3-
(iodomethyl)coumarin 155a (0.11g, 0.40mmol) in THF (ca 2ml), and stirring the 
mixture at room temperature for 4h. Work-up and chromatography afforded, as a 
yellow solid, 3-(benzylaminomethyl)coumarin 149a (60mg, 57%). 
 
Reaction of 6-bromo- 3-(iodomethyl)coumarin 155e with benzylamine 
 
The procedure (method 1, p.170) described for the synthesis of 3-(piperidino- 
methyl)coumarin 150a was followed, using benzylamine (0.11ml) and 6-bromo-3-
(iodomethy)lcoumarin 155e (0.15g, 0.40mmol) in THF (ca 2ml), and stirring the 
mixture for 4h. Work-up and chromatography afforded, as a yellow solid, 3-
(benzylaminomethyl)-6-bromocoumarin 149e (120mg, 88%), m.p. 106-110oC (Found: 
M+, 342.01166. C17H13O3N79Br requires M, 342.01296); δH (400 MHz; CDCl3) 2.0 
(1H, br s, NH), 3.74 (2H, s, CH2NHCH2Ph), 3.84 (2H, s, CH2NCH2Ph), 7.21 (1H, d, J 
8.8Hz, Ar-H), 7.25-7.6 (7H, series of overlapping signals, Ar-H) and 7.65 (1H, s, Ar-
H); δC (100 MHz; CDCl3) 48.2 and 53.2 (CH2NCH2), 116.9, 118.2, 120.8, 127.2, 
128.1, 128.5, 128.9, 129.8, 133.7, 137.6, 139.6 and 152.2 (Ar-C) and 160.7 (C=O); 
m/z 342 [M+( 79Br), 7.6%) and 252 (100). 
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Reaction of  3-(chloromethyl)coumarin 156a with methylmagnesium bromide 
 
To a solution of 3-(chloromethyl)coumarin 156a (0.16g, 0.80mmol) in THF (2ml) 
was added methyl magnesium bromide ( 2M solution in THF; 1.0mmol, 0.15ml), and 
the mixture was boiled under reflux for 4h. Water was then added and the aqueous 
layer extracted with CHCl3. The combined extracts were washed with satd. brine and 
dried (anhyd. NaSO4), filtered and concentrated in vacuo to afford the crude product, 
which was purified using preparative layer chromatography [elution with CHCl3-
EtOAc (3:1)] to afford, as a brown solid,  3-ethylcoumarin 178 (40mg, 29%), m.p. 68-
70oC ; δH (400 MHz; CDCl3) 1.25 (3H, t, J 7.6Hz, CH2CH3), 2.60 (2H, q, J 7.0Hz, 
CH2CH3), 7.22-7.26 (1H, m Ar-H), 7.30 (1H, d, J 8.0Hz, Ar-H) and 7.45 (3H, 
overlapping signals, Ar-H); δC (100 MHz; CDCl3) 12.3 (CH2CH3), 23.9 (CH2CH3), 
116.4, 119.6, 124.2, 127.1, 130.4, 131.3, 137.5 and 153.0 (Ar-C) and 161.8 (C=O); 
m/z 174 (M+, 0.5%) and 159 (100). 
 
Reaction of  3-(iodomethyl)coumarin 155a with methylmagnesium bromide 
 
To a solution of 3-(iodomethyl)coumarin 155a (0.23g, 0.8mmol) in THF (2ml) under 
N2 was added methylmagnesium bromide (3M solution in diethyl ether; 0.12ml, 
1.0mmol) at –10oC, and the resulting mixture was stirred for 24h at room temperature 
to give a pale-yellow precipitate, which was filtered off, washed with hexane and 
dried in vacuo to afford, as a pale yellow solid, 1,2-bis(2-oxo-2H-chromen-3-
yl)ethane 177 (0.18g, 94%), m.p. 90oC (Found: M+, 318.09055. C20H14O4 requires M, 
318.08921); δH (400 MHz; CDCl3) 2.96 (4H, s, CH2), 7.24 (2H, s, Ar-H), 7.31 (2H, d, 
J 10.0Hz, Ar-H), 7.41-7.48 (4H, series of overlapping signals, Ar-H) and 7.57 (2H, s, 
Ar-H); δC (100 MHz; CDCl3) 30.1 (CH2), 116.9, 119.8, 124.8, 127.8, 128.6, 131.2, 
140.2 and 153.3(Ar-C) and 162.1 (C=O); m/z 318 [M+, 88%) and 159 (100). 
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3.4.    Potential HIV-1 protease inhibitors 
 
3.4.1.   Preparation of the hydroxyethylene dipeptide isostere 
 
(L)-N,N-Dibenzylphenylalanine benzyl ester 190 211 
 
To a homogeneous solution of L-phenylalanine 189 (30g, 182mmol), K2CO3 (80g, 
0.58mmol) and water (120ml) was added benzyl chloride (66ml, 0.58mmol). The 
solution was heated under reflux for 16h. Heptane (80ml) and water (60ml) were 
added to the cooled reaction mixture. The organic solution was separated, washed 
with water-methanol (2:1; 2x30ml) and concentrated in vacuo to afford, as a pale 
yellow oil (L)-N,N-dibenzylphenylalanine benzyl ester 190 (60.9g, 77%); γmax (nujol 
mull/ cm-1) 1732 (C=O); δH (400 MHz; CDCl3) 3.04 and 3.17 (2H, 2xdd, J 8.0Hz and 
J 8.0Hz, CH2), 3.57 (2H, d, J 14Hz, CH2), 3.75 (1H, t, J 7.6Hz, CH), 3.96 (2H, d, J 
14Hz, CH2), 5.23 (2H, 2 xd, J 12.0Hz, CH2), 7.03-7.42 (20H, m, ArH); δC (100 MHz; 
CDCl3) 35.6 (CH2), 54.3 (2x CH2), 62.3 (CH), 66.0 (CH2), 126.2, 126.9, 128.10, 
128.13, 128.25, 128.34, 128.4, 128.5, 128.7, 129.3, 135.9, 138.0 and 139.2 (Ar-C) and 
172.1 (C=O). 
 
(4S)-4-Dibenzylamino-3-oxo-5-phenylpentanonitrile 191211 
 
A solution of the crude benzyl ester 190 (60g, 138mmol) in dry THF (162ml) was 
cooled to –45oC under N2. A separate flask was charged with sodium amide (95%; 
12g, 297mmol) under N2 followed by THF (134ml); the slurry was cooled to –45oC 
and CH3CN (16.5ml, 330mmol) was added over 15min, and the resulting solution was 
then added to the ester solution over 15min. After stirring the mixture at –45oC for 2h, 
the reaction was quenched with 25% aqueous citric acid (285ml). The organic layer 
was separated, washed with 20% brine (285ml), filtered and concentrated in vacuo. 
The residue was crystallized from ethanol (denatured with toluene; 150ml) to afford 
(4S)-4-dibenzylamino-3-oxo-5-phenylpentanonitrile 191 as white crystals (33g, 65%), 
m.p. 132-134oC (lit.211 84-85oC) (Found: M+, 368.18799. Calc. for C25H24N2O: M, 
368.18886); δH (400 MHz, CDCl3) 3.0 (1H, dd, J 3.2Hz and J 13.2Hz,  
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CH), 3.1 (1H, d, J 9.6Hz, CH), 3.21 (1H, dd, J 9.6Hz and J 13.5Hz, CH), 3.54 (1H, 
dd, J 3.2Hz and J 9.5Hz, CH), 3.59 (2H, d, J 13.2Hz, CH2), 3.81 (2H, d, J 4.8Hz, 
CH2), 3.89 (1H, d, J 11.2, CH) and 7.15-7.40 (15H, m , Ar-H); δC (100 MHz; CDCl3) 
28.5 (CH2), 30.0 (CH2), 54.8 (CH2), 68.5 (CH), 113.8, 126.4, 127.8, 128.6, 128.8, 
129.0, 129.5 and 138.1 (Ar-C) and 196.9 (C=O); m/z 368 (M+, 0.2%) and 300 (100) 
 
(5S)-2-Amino-5-dibenzylamino-4-oxo-1,6-diphenylhex-2-ene 192 211 
 
To a solution of nitrile 191 (35g, 95.3mmol) in dry THF (99ml) at 10oC was added a 
solution of benzylmagnesium chloride in dry THF (2.0M; 139ml, 278mmol). The 
solution was warmed to 25oC and stirred for 16h. The reaction mixture was cooled to 
5oC and quenched by slow addition of 10% aqueous citric acid (510ml). The organic 
layer was separated and washed with saturated brine (331ml), dried over Na2SO4 and 
concentrated in vacuo. The residue was crystallized from EtOH (denatured with 
toluene; 99ml) to afford (5S)-2-amino-5-dibenzylamino-4-oxo-1,6-diphenylhex-2-ene 
192 as a white crystals (39.6g, 90%), m.p. 100-102oC (lit.211 101-102oC) (Found: M+, 
460.25368. Calc. for C32H32N2O : M, 460.25146); γmax (nujol mull/ cm-1) 1597 (C=O); 
δH (400 MHz; CDCl3) 2.98 and 3.15 (2H, 2xdd, J 6.4Hz and J 8.0Hz, CH2), 3.48 (3H, 
m, CH2 and CH), 3.65 (2H, d, J 14Hz, CH2), 3.80 (2H, d, J 14Hz, CH2), 4.89 (1H, br 
s, NH), 5.10 (1H, s, CH), 7.11-7.41 (20H, m, Ar-H) and 9.81 (1H, br s, NH); δC (100 
MHz; CDCl3) 32.5 (CH2), 42.3 (CH2), 54.4 (CH2), 66.6 (CH), 96.9, 125.6, 126.7, 
127.3, 128.0, 128.1, 128.7, 128.9, 129.3, 129.5, 135.8, 140.1, 140.2 and 162.8 (Ar-C 
and CH=C) and 198.1 (C=O); m/z 460 (M+, 0.2%) and 300 (100). 
 
(2S, 3S, 5S)-5-Amino-2-(dibenzylamino)-3-hydroxy-1,6-diphenylhexane 194 211 
 
To a suspension of sodium borohydride (7.7g, 210mol) in dry THF (437ml) at –5oC, 
was added methanesulfonic acid (34ml, 525mmol), such that the temperature 
remained below 5oC. The reaction mixture was cooled to 0oC, and a solution of the 
enaminone 192 (39.6g,  86mmol) in THF (80ml) and iPrOH (46ml) was added, and 
the resulting mixture was stirred for 14h at 10oC. In a separate flask, a dispersion of 
sodium borohydride (13g, 343mmol) in THF (168ml) was cooled to 0oC, and  
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trifluoroacetic acid (33ml, 428mmol) was added slowly. The resulting mixture was 
stirred for 30min at 10oC and then added slowly to the enaminone solution 
maintaining the temperature below 15oC. The  resulting mixture was stirred for 4h, 
cooled to 10oC, and quenched with 3M-NaOH (273ml). tert-Butyl methyl ether 
(315ml) was added and the organic layer was separated and washed with NaOH 
(33ml), 20% aqueous NH4Cl (315ml) and 6% aqueous NaCl (2x 315ml). The organic 
solution was dried over Na2SO4 and concentrated in vacuo to afford a mixture of 
diastereomers 194 (40.3g). 
 
(2S, 3S, 5S)-2,5-Diamino-3-hydroxy-1,6-diphenylhexane dihydrochloride 195 211 
 
The diastereomeric mixture of the crude dibenzylamine 194 (40.3g, 86mmol), 
methanol (645ml), aqueous ammonium formate (27.4g in 46.3ml of water) and 5% 
palladium-on-carbon (50-60% water by weight; 8.0g) was heated under reflux for 6h. 
The cooled suspension was filtered through a bed of diatomaceous earth and the cake 
was washed with methanol (2x 300ml). The filtrate was concentrated in vacuo to 
afford an oil, which was dissolved in EtOAc (352ml) and washed  with 4% aq.NaOH 
(402ml), 20% aqueous NaCl (390ml) and water (195ml). The organic layer was 
concentrated in vacuo and, to the residue, was added iPrOH (240ml) and conc. HCl 
(34ml). The resulting suspension was heated under reflux for 1h, cooled to 25oC and 
then stirred for 12h. The slurry was filtered and the cake washed with iPrOH to afford, 
as white crystals, the diamine dihydrochloride 195 (20g, 82%), m.p. 302-304oC (lit.211 
>300oC) (Found: M+-2Cl, 285.19812. Calc. for C18H25N2O: M-70, 285.19669); δH 
(400 MHz; CDCl3) 1.76 and 1.85 (2H, 2xm, CH2), 2.91 (4H, m, 2xCH2), 3.30 (1H, m, 
CH), 3.61 (1H, m, CH), 3.79 (1H, m, CH), 7.18-7.34 (10H, m, Ar-H); δC (100 MHz; 
CDCl3) 36.8 (CH2), 37.0 (CH2), 40.0 (CH2), 53.2 (CH), 58.6 (CH), 69.0 (CH), 128.60, 
128.64, 130.20, 130.22, 130.5, 130.6, 136.7 and 136.9 (Ar-C). 
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(2S, 3S, 5S)-2,5-Diamino-3-hydroxy-1,6-diphenylhexane 188211 
 
A solution of the dihydrochloride salt 195 (0.50g, 1.4mmol) in water (2.0ml) was 
basified with a aqueous NaHCO3 (monitored by pH indicator paper). The resulting 
solution was extracted with EtOAc. The combined extracts were dried over Na2SO4 
and the solvent was evaporated in vacuo to afford (2S,3S,5S)-2,5-diamino-3-hydroxy-
1,6-diphenylhexane 188 as a yellow oil (0.30g, 77%) (Found: M+-2Cl, 285.19599. 
Calc. for C18H25N2O: M-70, 285.19669); δH (400 MHz; CDCl3) 1.53 and 1.66 (2H, m, 
CH2), 2.55-2.86 (5H, m, CH and 2x CH2), 3.12 (1H, m, CH), 3.72 (1H, m, CH) and  
7.12-7.32 ( 10H, m, Ar-H); δC (100 MHz; CDCl3) 39.1 (CH2), 41.2 (CH2), 47.2 
(CH2), 54.0 (CH), 57.5 (CH), 74.4 (CH), 126.1, 126.5, 128.4, 128.6, 129.29, 129.30, 
138.3 and 139.6 (ArC). 
 
3.4.2. Preparation of coumarin containing ritonavir analogues 
 
(2S,3S,5S)-3-Hydroxy-2,5-bis[(2-oxo-2H-chromen-3-yl)methylamino]-1,6-
diphenylhexane 186a 
 
Method 1 
 
A mixture of 3-(iodomethyl)coumarin 155a (0.11g, 0.4mmol) and (2S,3S,5S)-2,5-
diamino-3-hydroxy-1,6-diphenylhexane 188 (0.14g, 0.50mmol) in THF (2ml) was 
stirred under N2 at –45oC for 8h. Evaporation of the solvent from the resulting mixture 
afforded a crude product (0.34g), which was purified by preparative layer  
chromatography [elution with EtOAc-MeOH (2.5:0.5)] to afford as a yellow oil,  (2S, 
3S,5S)-3-hydroxy-2,5-bis[(2-oxo-2H-chromen-3-yl)methylamino]-1,6-diphenyl-
hexane 186a (30mg,  25%). 
 
Method 2 
 
A mixture of 3-(iodomethyl)coumarin 155a (0.11g, 0.4mmol), (2S,3S,5S)-2,5-
diamino-3-hydroxy-1,6-diphenylhexane 188 (0.14g, 0.50mmol) and NaHCO3 (0.2g) 
in acetone (5ml) was boiled under reflux for  2h. The resulting mixture was allowed to  
 
 
 176 
 
 
 
Experimental 
 
 
cool and then filtered through a layer of silica. Evaporation of the filtrate in vacuo 
afforded a crude product (0.25g), which was purified by preparative layer 
chromatography [elution with hexane-EtOAc (2:3)] to afford, as a yellow oil,  (2S,3S, 
5S)-3-hydroxy-2,5-bis[(2-oxo-2H-chromen-3-yl)methylamino]-1,6-diphenylhexane 
186a (30mg, 13%) 
 
Method 3 
 
A mixture of 3-(chloromethyl)coumarin 156a (0.16g, 0.8mmol), (2S,3S,5S)-2,5-
diamino-3-hydroxy-1,6-diphenylhexane 188 (0.11g, 0.40mmol) and Na2CO3 (0.2g) in 
ethanol (3ml) was stirred for ca. 76h. The resulting mixture was filtered through a 
layer of silica and evaporation of the filtrate in vacuo afforded a crude product 
(0.18g), which was purified by preparative layer chromatography [elution with 
hexane-EtOAc (2:3)] to afford as a yellow oil, (2S,3S,5S)-3-hydroxy-2,5-bis[(2-oxo-
2H-chromen-3-yl)methylamino]-1,6-diphenylhexane 186a (60mg, 50%); (Found: M+, 
600.26343. C38H36N2O5  require M, 600.26242); δH (400 MHz; CDCl3) 1.68 (2H, m, 
CH2), 2.65- 2.91 (4H, m, 2x CH2), 3.01 (1H, dd, J 4.8Hz and J 13.2Hz, CH), 3.14 
(1H, m, CH), 3.71 (4H, m, 2x CH2), 4.01 (1H, d, J 14.8Hz, CH), 7.13-7.68 (20H, m, 
Ar-H ); δC (100 MHz; CDCl3) 36.0 (CH2), 37.1(CH2), 40.8(CH2), 45.8 (CH2), 46.8 
(CH2), 59.7 (CH), 63.5 (CH), 72.9 (CH), 117.8, 117.9, 120.1, 120.3, 126.2, 126.6, 
126.9, 127.1, 128.1, 128.4, 128.6 129.0, 129.2, 129.3, 1295, 129.8, 130.8, 131.2, 
137.5 137.8, 138.2, 139.2, 151.4 and 151.6 (Ar-C), 160.3 and 160.8 (C=O); m/z  597 
[(M+-2H), 0.8%] and 131 (100).  
 
Method 4 
 
A mixture of the quaternary salt 164a (0.22g, 0.8mmol), (2S,3S,5S)-2,5-diamino-3-
hydroxy-1,6-diphenylhexane 188 (0.11g, 0.40mmol) in ethanol (3ml) was stirred for 
ca. 76h. The resulting mixture was filtered through a layer of silica and evaporation of 
the filtrate in vacuo afforded, as a yellow oil, (2S,3S,5S)-3-hydroxy-2,5-bis[(2-oxo-
2H-chromen-3-yl)methylamino]-3-hydroxy-1,6-diphenylhexane 186a (0.10g, 85%). 
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(2S,3S,5S)-3-Hydroxy-2,5-bis[(8-methoxy-2-oxo-2H-chromen-3-yl)methylamino]- 
1,6-diphenylhexane 186b 
 
A mixture of 8-methoxy-3-(chloromethyl)coumarin 156b (0.18g, 0.8mmol), (2S,3S, 
5S)-2,5-diamino-3-hydroxy-1,6-diphenylhexane 188 (0.11g, 0.40mmol) and Na2CO3 
(0.2g) in ethanol (3ml) was stirred for ca 76h. The resulting mixture was filtered 
through a layer of silica, and evaporation of the filtrate in vacuo afforded a crude 
product (0.18g), which was purified by preparative layer chromatography [elution 
with EtOAc] to afford, as a yellow oil, (2S,3S,5S)-3-hydroxy-2,5-bis[(8-methoxy-2-
oxo-2H-chromen-3-yl)methylamino]-1,6-diphenylhexane 186b (70mg, 53%) (Found: 
M+, 660.28558. C40H40N2O7 require M, 660.28355); δH (400 MHz; CDCl3) 1.67 (2H, 
m, CH2), 2.66-2.89 (4H, m, 2x CH2), 2.98 (1H, m, CH), 3.13 (1H, m, CH), 3.71 (4H, 
m, 2x CH2), 3.97 (7H, overlapping signals, CH and 2x CH3), 6.96-7.66 (18H, m, Ar-
H); δC (100 MHz; CDCl3) 36.4 (CH2), 37.0(CH2), 40.6 (CH2), 45.7 (CH2), 46.8 (CH2), 
56.17 and 56.20 (2x CH3), 59.7 (CH ), 63.4 (CH), 72.9 (CH), 112.8, 113.2, 119.1, 
119.2, 119.7, 120.0, 124.1, 124.3, 126.0, 126.5, 127.8, 126.9, 128.3, 128.6, 129.3, 
129.4, 138.0, 138.8, 139.3, 139.6, 142.7, 142.8, 147.01 and 147.10 (Ar-C), 160.8 and 
160.7 (C=O).  
 
(2S,3S,5S)-3-Hydroxy-2,5-bis[(6-chloro-2-oxo-2H-chromen-3-yl)methylamino]-
1,6-diphenylhexane 186d 
 
A mixture of 6-chloro-3-(chloromethyl)coumarin 156d (0.18g, 0.8mmol), (2S,3S,5S)-
2,5-diamino-3-hydroxy-1,6-diphenylhexane 188 (0.11g, 0.40mmol) and Na2CO3 
(0.2g) in ethanol (3ml) was stirred for ca 76h. The resulting mixture was filtered 
through a layer of silica, and evaporation of the filtrate in vacuo afforded a crude 
product (0.23g), which was purified by preparative layer chromatography [elution 
with EtOAc] to afford, as a yellow oil  (2S,3S,5S)-3-hydroxy-2,5-bis[(6-chloro-2-oxo-
2H-chromen-3-yl)methylamino]-1,6-diphenylhexane 186d (95mg, 71%) (Found: 
MH+, 669.19281. C38H3535Cl2N2O5 requires M+1, 669.19230); δH (400 MHz; CDCl3) 
1.63 (2H, m, CH2), 2.76- 2.90 (3H, m, CH and CH2), 2.94 and 2.97 (1H, dd, J 13.3 
and J 4.8Hz, CH), 3.10 (1H, m, CH), 3.68 (4H, m, 2x CH2), 3.96 (1H, d, J 15.2Hz, 
CH), 7.10-7.57 (19H, m, Ar-H); δC (100 MHz; CDCl3) 36.5 (CH2), 37.1  
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(CH2), 40.7 (CH2), 45.8 (CH2), 46.8 (CH2), 59.7 (CH), 63.5 (CH), 72.9 (CH), 117.8, 
117.9, 120.1, 120.3, 126.2, 126.6, 126.9, 127.1, 128.1, 128.4, 128.7, 129.0, 129.2, 
129.3, 1295, 129.8, 130.8, 131.2, 137.5, 137.8, 138.2, 139.2, 151.4 and 151.5 (Ar-C), 
160.3 and 160.8 (C=O); m/z  668 (M+, 1.1%) and 193 (100).  
 
(2S,3S,5S)-3-Hydroxy-2,5-bis[(6-bromo-2-oxo-2H-chromen-3-yl)methylamino]-
1,6-diphenylhexane 188e 
 
A mixture of 6-bromo-3-(chloromethyl)coumarin 156e (0.22g, 0.8mmol), (2S,3S,5S)-
2,5-diamino-3-hydroxy-1,6-diphenylhexane 188 (0.11g, 0.40mmol) and Na2CO3 
(0.2g) in ethanol (3ml) was stirred for ca 76h. The resulting mixture was filtered  
through a layer of silica, and evaporation of the filtrate in vacuo afforded a crude 
product (0.23g), which was purified by preparative layer chromatography [elution 
with EtOAc] to afford, as a yellow oil, (2S,3S,5S)-3-hydroxy-2,5-bis[(6-bromo-2-oxo-
2H-chromen-3-yl)methylamino]-1,6-diphenylhexane 186e (95mg, 63%) (Found: 
(M+H), 757.0903. C38H3579Br2N2O5  require M, 757.09127); δH (400 MHz; CDCl3) 
1.64 (2H, m, CH2), 2.74-2.89 (4H, m, 2x CH2), 2.95 (1H, dd, J 8.4Hz and J 13.2Hz, 
CH), 3.10 (1H, m, CH), 3.68 (4H, m, 2x CH2), 3.95 (1H, d, J 15.2Hz, CH), 7.07-7.53 
(18H, m, Ar-H); δC (100 MHz; CDCl3) 36.6 (CH2), 37.1 (CH2), 40.7 (CH2), 45.8 
(CH2), 46.7 (CH2), 59.7 (CH), 63.5 (CH), 72.9 (CH), 116.8, 117.0, 118.1, 118.2, 
120.6, 120.8, 126.2, 126.6, 128.3, 128.4, 128.6, 129.1, 129.3, 129.4, 129.9, 130.0, 
133.5, 134.0, 137.2, 137.89, 137.92, 139.3, 151.8 and 152.0 (Ar-H), 160.56 and 
160.57 (2x C=O).  
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3.5.     High-resolution mass spectrometric data 
 
 
3-(Benzylaminomethyl)coumarin 149a 
 
 
 
     Formula 
 
     Observed Mass 
 
    Calculated Mass 
     C17H15NO2         265.10800         265.11028 
     C17H14NO2         264.10378         264.10245 
     C10H8NO2         174.05556         174.05550 
     C10H8O2         160.05253         160.05243 
     C10H7O2         159.04557         159.04460 
     C9H8O         132.05585         132.05751 
     C9H7O         131.04967         131.04969 
     C9H7         115.05437         115.05478 
     C7H8N         106.06646         106.06567 
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3-(Benzylaminomethyl)-8-methoxycoumarin 149b 
 
 
 
     Formula 
 
     Observed Mass 
 
    Calculated Mass 
     C18H17NO3         295.11889         295.12084 
     C18H16NO3         294.11201         294.11302 
     C11H10NO3         204.06667         204.06607 
     C11H10O3         190.06200         190.06299 
     C11H9O3         189.05356         189.05517 
     C10H9O2         161.05823         161.06025 
     C7H8N         106.06572         106.06567 
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3-(Benzylaminomethyl)-8-ethoxycoumarin 149c 
 
 
 
     Formula 
 
     Observed Mass 
 
    Calculated Mass 
     C19H19NO3         309.13550         309.13649 
     C19H18NO3         308.12906         308.12867 
     C17H13NO3         279.09096         279.08954 
     C12H12NO3         218,08219         218,08172 
     C12H12O3         204.07760         204.07864 
     C12H11O3         203.07136         203.07082 
     C10H8NO3         190.05053         190.05042 
     C10H8O3         176.04727         176.04734 
     C10H7O3         175.04101         175.04220 
     C7H8N         106.06585         106.66567 
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3-(Benzylaminomethyl)-6-chlorocoumarin 149d 
 
 
 
     Formula 
 
     Observed Mass 
 
    Calculated Mass 
     C17H13NO235Cl         298.06312         298.06348 
     C10H7NO235Cl         208.01637         208.01653 
     C10H8NO2         174.05320         174.05550 
     C9H7O35Cl         166.01672         166.01854 
     C9H6O35Cl         165.01057         165.01072 
     C10H7O2         159.04289         159.04460 
     C9H635Cl         149.01514         149.01580 
     C9H7O         131.04915         131.04969 
     C7H8N         106.06494         106.06567 
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3-(Benzylaminomethyl)-6-bromocoumarin 149e 
 
 
 
     Formula 
 
     Observed Mass 
 
    Calculated Mass 
     C17H14NO279Br         343.02410         343.02357 
     C11H9O279Br         251.97943         251.07859 
     C10H7O279Br         237.96097         237.96294 
     C10H6O279Br         236.95387         236.95512 
     C9H6O79Br         208.95883         208.96020 
     C10H7NO2         173.04734         173.04768 
     C9H7NO         145.05268         145.05276 
     C9H7O         131.04870         131.04969 
     C7H8N         106.06559         106.06567 
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3-(Piperidinomethyl)coumarin 150a 
 
 
 
     Formula 
 
     Observed Mass 
 
    Calculated Mass 
     C15H17NO2         243.12507         243.12593 
     C13H12NO2         214.08792         214.08680 
     C12H10NO2         200.07173         200.07115 
     C11H9NO2         187.06395         187.06333 
     C10H8O2         160.05259         160.05243 
     C10H7O2         159.04461         159.04460 
     C9H8O         132.05676         132.05751 
     C9H7O         131.04978         131.04969 
     C9H7         115.05417         115.05478 
     C5H10N         84.08238         84.08132 
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8-Methoxy-3-(piperidinomethyl)coumarin 150b 
 
 
 
     Formula 
 
     Observed Mass 
 
    Calculated Mass 
     C16H19NO3         273.13683         273.13649 
     C14H14NO3         244.09818         244.09737 
     C13H12NO3         230.08249         230.08172 
     C12H11NO3         217.07386         217.07389 
     C11H10O3         190.06355         190.06299 
     C11H9O3         189.05593         189.05517 
     C10H10O2         162.06678         162.06808 
     C9H7O         131.04899         131.04969 
     C5H10N         84.08116         84.08132 
 
 
 
 
 186 
 
 
 
Experimental 
 
 
 
8-Ethoxy-3-(piperidinomethyl)coumarin 150c 
 
 
 
     Formula 
 
     Observed Mass 
 
    Calculated Mass 
     C17H21NO3         287.15264         287.15214 
     C15H16NO3         258.11412         258.11302 
     C14H14NO3         244.09787         244.09737 
     C13H13NO3         231.08994         231.08954 
     C12H12O3         204.07961         204.07864 
     C12H11O3         203.07209         203.07082 
     C10H18O3         176.04760         176.04734 
     C9H7O2         147.04439         147.04460 
     C9H7O          131.04944         131.04969 
     C5H10N         84.08152         84.08132 
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Experimental 
 
 
 
6-Chloro-3-(piperidinomethyl)coumarin 150d 
 
 
 
     Formula 
 
     Observed Mass 
 
    Calculated Mass 
     C15H16NO235Cl         277.08701         277.08696 
     C13H11NO235Cl         248.04834         248.04783 
     C12H9NO235Cl         234.03262         234.03218 
     C11H8NO235Cl         221.02359         221.02436 
     C9H5NO235Cl         193.99831         194.00088 
     C9H6O35Cl         165.01029         165.01072 
     C5H10N         84.08143         84.08132 
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6-Bromo-3-(piperidinomethyl)coumarin 150e 
 
 
 
     Formula 
 
     Observed Mass 
 
    Calculated Mass 
     C15H16NO279Br         321.03543         321.03644 
     C13H11NO279Br         291.99576         291.99731 
     C12H9NO279Br         277.98160         277.98166 
     C11H8NO279Br         264.97443         264.97384 
     C11H7NO279Br         237.96336         237.96294 
     C11H6NO279Br         236.955589         236.95512 
     C9H6O79Br         208.95896         208.96020 
     C5H10N         84.08143         84.08132 
 
 
 
Experimental 
3.5. High-resolution mass spectrometric data 
,~ 
3-(Benzylaminomethyl)coumarin 149a 
SCAN GRAPH. FJ8ggillll"Hlllh Resolution M.!z. FIHal""jlntO.2%. El(eI: RellEx.).HighllgIlUng"Baie Peak. .• 
100 Scan 29#3:16 SUb><12#1:24. 15!O!1;43. Entri9ll"52. e_ WPll»06646. 100% Int,=8.573S~, EI. POS, 
I 1~:{l6646 
I 
.. , 
., 
i " 
" 
60 
;; 
3 
f~ 
" 
114 ~5!i56 
91 '?548 
3C , 
I I 
" 
131 fl4e46 159~557 
264 ',0378 
n<!391 \160.q5253 
li055B~ \ .. , \265.108 
" 
65,0381 115.q5437 
il "'~ .. " II \ ! .i L i 
, 
, , .1. : 
;J.I 
" " 
~ 
'" '" '" 
;J, ;J, 
'" '" '" '" . -".- High Resolulioll MIz 
Formula Observed Mass Calculated Mass 
C17HlSN02 265.10800 265.11028 
C17Hl-tN0 2 264.10378 264.10245 
ClOHsN02 174.05556 174.05550 
CioHs02 160.05253 160.05243 
ClOH70 2 159.04557 159.04460 
C9HsO 132.05585 132.05751 
C9H70 131.04967 131.04969 
C9H7 115.05437 115.05478 
C7HsN 106.06646 -c 106.06567 
180 
Experimental 
~, 
3-(Benzylaminomethy1)-8-methoxycoumarin 149b 
S~PH, Flegglng"i-6gtl R\O$OII/Iioo wz. FlIterw(intO.22%. ~:o.3OO.-&d. ReflEx.~Hlghligt<tlnIFBase Peal(. 
100" Seen 391<1.21 Sub"26#'2:55 - 31#3:28. EnIIie$=l04. &1$ .. M/z=I.l06.Q6m. 100% 11'II,,.g,U(l3. EI. POS 
106.~ 2 
" 
80 
70 
'" l 
.~ " i ] 91',~548 
" 
204.~7 
" 
'" 
100:062 
-189,~3~ " 
65-r2EI3 1e1.p5823 243. ~2S55 205.\'689 10 136'~'tl7 '. ; , 
1. "'\' 1 , " .i .J ,~I, j 255.1254 294.1.t~1 0 ' I, I ;i: 
" 
,J, ,Jo 200 
'" 
-,." 300 
HlQh R/J$Olutlon Mlz 
-
Formula Observed Mass Calculated Mass 
ClsH17N03 295,11889 295.12084 
ClsH16N03 294.11201 294.11302 
CIIHlON03 204.06667 204.06607 
Cl1HlOO3 190.06200 190.06299 
Cl1H~3 189.05356 189.05517 
CIOH~2 161.05823 161.06025 
C7HSN 106.06572 106.06567 
181 
3-(Benzylaminomethyl)-8-ethoxycoumarin 149c 
SCAN GRAPH, flllI\jgif>g"HIQII Resoltllion Mh Fm."'II!!I:O.2~ &xcI: RefJE>LI.HlgII!Iehtlng .. B8&; Peal<. 
100 6il8n 29#3:1ti.31#3:28.33#3:41 5ntn88"114 Base MIz=106.06S81 100% Inl'<8.Dn65 E! POS. Saturated 
106,~~1 
" 
" 
176.04127 203 O~l36 
20 e:5.r~3903 , 
79.f)?452 
" 
" '" 
'50 200 
HI RQOlutlOll_MIz: 
Formula Observed Mass 
C19H19N03 309.13550 
C19H1SN03 308.12906 
C17H13N03 279.09096 
C12H12NO) 218,08219 
C12H1203 204.07760 
C12Hl103 203.07136 
ClOHsN03 190.05053 
ClOHsO) 176.04727 
ClOH703 175.04101 
C7HsN 106.06585 
182 
Experimental 
,. 
232.09461 
257.1,4009 
,so 
Calculated Mass 
309.13649 
308.12867 
279.08954 
218,08172 
204.07864 
203.07082 
190.05042 
176.04734 
175.04220 
106.66567 
I 308.1.~ 
300 
3-(Benzylaminomethyl)-6-chlorocoumarin 149d 
SCAN GRAPH, Flegglngctflgh Resolution MIl. Fdler:(lnt.O.16%, ExeI: ReliEx.).HlghnghtiI'lgCSau PMk 
10a Scan 57#6:18. EIlIn..,,=98. ea$e Mlz=106,06411l4. 100% Inl.=9.9814<1. EI. poe. . 
loe.~~ 4 
" 
" 
70 
" 
" 
165,.0'051 
100.?98 3 
131.~491S \ 195.~14 
Experimental 
..... 
\ 174.~32 ! "+-j4-~~~~~~44~~~'~~?~'''~''r~'i ~i~'~,.~,ooroL'~~~'-~~~~~~~\·300"" ,I ,( III.iii 
150 20t) 2M 
Hlph R$SOIl/fioo Mk 
65.0~922 
t. -125.01482 : 
,j n.~ , J. •. 1.1 \i. . ... 
" 
,Ix, 
Formula Observed Mass Calculated Mass 
C17H13N02"CI 298.06312 298.06348 
ClOH7NO/'CI 208.01637 208.01653 
ClOHSN02 174.05320 174.05550 
C9H?0"C1 166.01672 166.01854 
~H,;O"C1 165.01057 165.01072 
Cl~H702 159.04289 159.04460 
~H6"CI 149.01514 149.01580 
~H70 131.04915 131.04969 
C7HsN 106.06494 106.06567 
183 
Ii 
~. Experimental 
1 
'1. ~: 
,\~ 
~;, 
3-(Benzylaminomethy1)-6-bromocoumarin 14ge :: 
t 
f' 
.~' SCAN GRAPH. Flagglnll=Hlgll Ra'lOlUllon MIz. FIIlet"'!lntO. 1%. !<xcI: RellEx.~Hlghkg,lItIlg=Baa Peall (0\,< ... ..1 !.<+'3.0).ot-ftJ , ~oo &:an 84#7:04.67#7:24 Sub=44#4:53 -51#5:39 Eo\l'ies"'183. Base ~.05438 100% Inlc2.0304 Et. POS 
',.J1 .D,,(', c,;H'."1 
" 
91_0~~ 1 6.96569 
eo 
251_~7961 
eo 
;, 
" 
" j 
• 
., ,
J ~ , '< 
:;:50 
ii \,,~ 
" i .. :l 
" 
231.~j2a 
c , 
~:: 
, ,- , ~''''' , ., 102.0 
" 
~t 
tl5.~939 2S6.~04 ' , , 206.~5a85 ;' '<1, 
: '" " 
',: ,,~ 
130.?421 4:: J'; 
, 77.~a54 118.Q4414/ ~> 
• 
" ,~J .. ,1 ~,J, Ir 173.~4757 
22<1.95567 
! 
,I, j 
.I" ./.1 
~ 
, 
, I, "II, 
< 
: 
" '" 
,;, ,:", ,,, 
'" 
'50 i Hiah RHOIIItIoo Miz 
1----. -.'- --" .. - . - - - - "" .- .--'. .- ' - -... -
Formula Observed Mass Calculated Mass 
C17Hl..N02"Br 343.02410 343.02357 { CllH90 2"Br 251.97943 251.07859 
C IOH 702 "Br 237.96097 237.96294 
CIOH60 Z"Br 236.95387 236.95512 
C9H60"Br 208.95883 208.96020 
ClOH7N02 173.04734 173.04768 
~H7NO 145.05268 145.05276 
~H70 131.04870 131.04969 
C7HsN 106.06559 106.06567 
184 
3-(Piperidinomethy1)coumarin 150a 
SCAN gftAPH. FIa\I9111guHigh Resolubon MIz. FIIter=[lntO.25%, CxeI: ReflEx.P·llghllghtlt'(J=6ase Peak. 
100 6¢81! 221/:2:29, Sub=tl#O:44 - 8#0:9. Entna.=58. Base M/Z"84,06238 100% Inl"8.679n. 101, POS 
" 
eo 
'" 
eo 
f 
r 
., 
30 
20 
'" 
" 
II 
., 60 
Formula 
ClsHI7N(h 
C!3H12N02 
CI2HION02 
CIIH9N02 
CWHg02 
CWH70 2 
CgHsO 
C9H70 
C9H7 
CsHION 
77.~957 
96.~ 
J I 
eo 
180.1?5259 
115.q5417 
i 
"" 
~!o I 160 
High Resolution MIz 
Observed Mass 
243.12507 
214.08792 
200.07173 
187.06395 
160.05259 
159.04461 
132.05676 
131.04978 
115.05417 
84.08238 
185 
Experimental 
2OO.0?173 
243. ;2607 j 
I, 
214.pe71l2 
J " ,I, , I I , , I 2O" m "" 
187.qs396 
I i 
"" 
Calculated Mass 
243.12593 
214.08680 
200.07115 
187.06333 
160.05243 
159.04460 
132.05751 
131.04969 
. 
115.05478 
84.08132 
Experimental 
8-Methoxy-3-(piperidinomethyl)coumarin 150b 
: SCAN GRAPH. Ftaagins=H"ogI! Resolution MIX: Fllter'=(tntO.3%. Exct R«1E.x-J~RQ..aase Peek. _ .. 
100 Scan 34#3:48 - S513:5'1,37;f4:07. En1rieoP76. Sa" MIz>o84.08116. 100% Int"6.B7648. EI PeS. 
84.~1.16 
" 
., 
" 
" J 
i SO j 
" 
1911.q63M 
" 
" 
189~ 
230.~49 273",3683 
" 20 
" 
'61,O5~ 
96.1?S688 
118.~143 217 ~386 
" 
n.oaeo4 
! "I L l 
~ 146;rm'i?6678 , 244.09819 286.1?407 I 56.05063 202.0,&605 
Ii ; I:, i i 0 7; ~ '~i"h ReKIMion ~ 200 250 
I 
Formula Observed Mass Calculated Mass 
C16H 19N03 273.13683 273.13649 
C14H14N03 244.09818 244.09737 
C13HIZN03 230.08249 230.08172 
C12H llNO) 217.07386 217.07389 
CllHlOO3 190.06355 190.06299 
CllH90) 189.05593 189.05517 
CIOHIOOZ 162,06678 162.06808 
C9H70 131.04899 131.04969 
CSHION 84.08116 84.08132 
186 
r···.·.·
··'····'······ J 
-::; 
.~.,: .•.
f~' 
/\ 
Experimental 
8-Ethoxy-3-(piperidinomethy1)coumann 150c 
.:f 
SCAN GRAPH. Flaggm9"Hlgn ReSDlutlon MIz. Futer={lntD.2%. Exct. RotlEx.j.Hlg/IIi!jhtiRtl .. SatePeak. 
100 &an 41#4:3<1,63#6:58, SUb-""26#2"SS· 31#3:26, Entriu=lI3, Base Mrr-84.06162. 100"" Int=8.29367. EJ. POS. 
64_~152 
., 
" 
" 
'" } 
i''' 
• 
• 
" 
30 
176',9476 204·r961 24<1,~9781 287.:6264 
.. .. 
'" 
21)3.07209:' 
n.~856 118.09,723 147,;9 231.~944 
" 
,.I i 
218.1~954 i 272.1~784 11a,?"14 j 188,\333 / ! 256. \1412 j I Ii .I,. l, 
. f i . .~ , 50 ,0, '" ,0, ,., . ______ J::!iIl!lB.~~~ .. _-
Formula Observed Mass Calculated Mass 
C17HZIN03 287.15264 287.15214 
ClsH16N03 258.11412 258.11302 
C14HI~03 244.09787 244.09737 
CI3H13N03 231.08994 231.08954 
C12Hl203 204.07961 204.07864 
CUHuO) 203.07209 203.07082 
ClOH180) 176.04760 176.04734 
C9H70z 147.04439 147.04460 
~H70 131.04944 131.04969 
CSHION 84.08152 84.08132 
187 
Experimental 
6-Chloro-3 -(piperidinomethyl)coumarin 150d 
"CAN=."'",_,,"."',_=· "'"..,"".",,=.,,_= ... ii:". """,,,,,=.,,co,;;,,,n. ""';;;r;""'_='Hi@ •• ""_;;;;;;lij;;; ....."P"" .. ------------·-1 100 sdili eoI6:38 - 65#7:11. SUb><,.,..,;56 ·2'~'23. Entries"'()S. Bate M/r-<SII,OS14'3. 100'l4 fnt"',65451. EI. POS. 
i 
" 
" 
" 
.. 
'" 
; 
" , 
'02.().W4.4 , 77,O~~18 
I 
" 
'. 
%.q971~ 
I .. 
I ' I 
II ,:: "II III, , , , , " , , , , , 
,;" 
" 
Formula 
ClsHI6N02"CI 
CllHllN02"CI 
CI2H9N02"CI • 
CIIHsN02"CI 
C9HsN02"CI 
C9HeO"Cl 
CSHION 
165_0~029 
1~e,p"4 131.~92 
.. 
, 
, I 
, , , I , 'I \II, , 
'" Hlah Resolution MIz 
Observed Mass 
277.08701 
248.Q4834 
234.03262 
221.02359 
193.99831 
• 
165.01029 
84.08143 
188 
I 
Iroa·q~2fi 
,1111 'j", 
221 O?359 
243.1~ 262.05341 
II. ,1jI. ,j 'I 
'" 
Calculated Mass 
277.08696 
248.04783 
234.03218 
221.02436 
194.00088 
165.01072 
84.08132 
277 °.8701 
Experimental 
6-Bromo-3-(piperidinomethyl)coumarin 1 50e 
" ~AN GRAPH. F1899in9*iigh R8iOMkin MIz. FlHllfE[fnt:O.2% 6Ci, RellEx.~ffi9h1o; htlng=6ese Peak. I : --"-;:--._-_. 143. l00%lntatl.8983S. Et. POS 
I eo 
! 
. " 
20 
'" 
" 
Formula 
ClsH16N02 
C13HllN02 
Cl~9N02 
CllHsNOz 
CllH7N02 
Cll~N02 
C9~O Br 
CSHlON 
102_~4683 
SS.09729/ 
>D' 
Br 
Br 
Br 
Br 
Br 
Br 
208_~896 
II~ 
'" 
200 
H~fI RellO!uUOO'> MIz 
Observed Mass 
321.035 43 
291.995 76 
277.981 60 
264.974 43 
237.963 36 
.236.955 589 
208.958 96 
84.0814 3 
1 89 
Z37~ 
277:9616 
236 9.5589i 321 <!3543 
: 29199576 
249.95837 :' 
. 
j 2~'~'" II 3OO~\'~8 11. 
i ;, 
25' 200 
-. " .... ,,--
Calculated Mass 
321.03644 
291.99731 
277.98166 
264.97384 
237.96294 
236.95512 
208.96020 
84.08132 
'. 
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